0001104659-16-120481.txt : 20160512 0001104659-16-120481.hdr.sgml : 20160512 20160512160254 ACCESSION NUMBER: 0001104659-16-120481 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 55 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160512 DATE AS OF CHANGE: 20160512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Marathon Patent Group, Inc. CENTRAL INDEX KEY: 0001507605 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 010949984 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36555 FILM NUMBER: 161643679 BUSINESS ADDRESS: STREET 1: 11100 SANTA MONICA BLVD., STE. 380 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: (800) 804-1690 MAIL ADDRESS: STREET 1: 11100 SANTA MONICA BLVD., STE. 380 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: American Strategic Minerals Corp DATE OF NAME CHANGE: 20111213 FORMER COMPANY: FORMER CONFORMED NAME: VERVE VENTURES INC DATE OF NAME CHANGE: 20101210 10-Q 1 a16-6690_110q.htm 10-Q

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

[x] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2016

 

or

 

[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

MARATHON PATENT GROUP, INC.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

 

001-36555

 

01-0949984

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

 

 

 

11100 Santa Monica Blvd., Ste. 380
Los Angeles, CA

 

 

 

90025

(Address of principal executive offices)

 

 

 

(Zip Code)

 

Registrant’s telephone number, including area code: 703-232-1701

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  [x]  No  [_]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  [x] No  [_]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

[_]

Accelerated filer

[_]

 

 

 

 

Non-accelerated filer
(Do not check if smaller reporting company)

[_]

Smaller reporting company

[x]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [_] No [x]

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 14,967,141 shares of common stock are issued and outstanding as of May 6, 2016.

 



Table of Contents

 

TABLE OF CONTENTS

 

 

 

Page No.

PART I. - FINANCIAL INFORMATION

Item 1.

Financial Statements

 

 

Consolidated Balance Sheets

3

 

Consolidated Statements of Operations and Comprehensive Income (unaudited)

4

 

Consolidated Statements of Cash Flows (unaudited)

5

 

Notes to Unaudited Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

35

Item 4.

Controls and Procedures

35

 

 

 

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

36

Item 1A

Risk Factors

36

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

36

Item 3.

Defaults upon Senior Securities

36

Item 4.

Mine Safety Disclosures

36

Item 5.

Other Information

36

Item 6.

Exhibits

37

 

OTHER PERTINENT INFORMATION

 

Unless specifically set forth to the contrary, “Marathon Patent Group, Inc.,” “we,” “us,” “our” and similar terms refer to Marathon Patent Group, Inc., a Nevada corporation, and subsidiaries.

 

2



Table of Contents

 

Item 1. Financial Statements

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

 

 

March 31, 2016

 

December 31, 2015

 

 

(Unaudited)

 

 

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash

$

 

1,420,390

$

 

2,555,151

Accounts receivable - net of allowance for bad debt of $375,750 and $375,750 for March 31, 2016 and December 31, 2015

 

153,112

 

136,842

Bonds posted with courts

 

1,443,457

 

1,748,311

Prepaid expenses and other current assets, net of discounts of $3,414 and $3,414 for March 31, 2016 and December 31, 2015

 

146,336

 

338,598

Total current assets

 

3,163,295

 

4,778,902

 

 

 

 

 

Other assets:

 

 

 

 

Property and equipment, net of accumulated depreciation of $77,653 and $67,052 for March 31, 2016 and December 31, 2015

 

52,793

 

61,297

Intangible assets, net of accumulated amortization of $16,423,203 and $15,557,353 for March 31, 2016 and December 31, 2015

 

23,208,298

 

25,457,639

Deferred tax assets

 

14,385,393

 

12,437,741

Other non current assets, net of discounts of $3,900 and $4,831 for March 31, 2016 and December 31, 2015

 

207,100

 

9,169

Goodwill

 

4,605,733

 

4,482,845

Total other assets

 

42,459,317

 

42,448,691

 

 

 

 

 

Total Assets

$

 

45,622,612

$

 

47,227,593

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

$

 

8,832,010

$

 

6,534,825

Clouding IP earn out - current portion

 

103,049

 

33,646

Notes payable, net of discounts of $754,421 and $730,945 for March 31, 2016 and December 31, 2015

 

11,379,212

 

10,383,177

 

 

20,314,271

 

16,951,648

 

 

 

 

 

Long-term liabilities

 

 

 

 

Notes payable, net of discount of $1,224,817 and $1,425,167 for March 31, 2016 and December 31, 2015

 

10,493,877

 

12,223,884

Clouding IP earn out

 

3,213,177

 

3,281,238

Deferred tax liability

 

964,998

 

1,044,997

Revenue share liability

 

1,000,000

 

1,000,000

Other long term liability

 

49,075

 

50,084

Total long-term liabilities

 

15,721,127

 

17,600,203

 

 

 

 

 

Total liabilities

 

36,035,398

 

34,551,851

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

Preferred stock Series B, $.0001 par value, 50,000,000 shares  authorized: 782,004 and 782,004 issued and outstanding at March 31, 2016 and December 31, 2015

 

78

 

78

Common stock, $.0001 par value; 200,000,000 shares authorized;  14,967,141 and 14,867,141 at March 31, 2016 and December 31, 2015

 

1,497

 

1,487

Additional paid-in capital

 

43,774,961

 

43,217,513

Accumulated other comprehensive income (loss)

 

(1,018,385)

 

(1,265,812)

Accumulated deficit

 

(33,170,937)

 

(29,277,524)

 

 

 

 

 

Total Marathon Patent Group stockholders’ equity

 

9,587,214

 

12,675,742

 

 

 

 

 

Total liabilities and stockholders’ equity

$

 

45,622,612

$

 

47,227,593

 

The accompanying notes are an integral part to these unaudited consolidated financial statements.

 

3



Table of Contents

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

 

 

 

For The Three

 

For The Three

 

 

Months Ended

 

Months Ended

 

 

March 31, 2016

 

March 31, 2015

 

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

Revenues

 

 

$

2,059,676

 

 

$

4,093,869

 

 

 

 

 

Expenses

 

 

 

 

Cost of revenues

 

2,639,976

 

4,328,165

Amortization of patents and website

 

2,025,899

 

2,598,461

Compensation and related taxes

 

1,033,346

 

1,581,074

Consulting fees

 

280,776

 

896,543

Professional fees

 

405,493

 

769,615

General and administrative

 

217,010

 

219,481

Patent impairment

 

373,195

 

-

Total operarating expenses

 

6,975,695

 

10,393,339

 

 

 

 

 

Operating loss

 

(4,916,019)

 

(6,299,470)

 

 

 

 

 

Other income (expenses)

 

 

 

 

Other income (expense)

 

(2,159)

 

(39,402)

Foreign exchange gain (loss)

 

6,978

 

-

Change in fair value adjustment of Clouding IP earn out

 

(1,342)

 

-

Interest income

 

931

 

2

Interest expense

 

(1,006,850)

 

(931,541)

Total other income (expenses)

 

(1,002,442)

 

(970,941)

 

 

 

 

 

Loss before benefit for income taxes

 

(5,918,461)

 

(7,270,411)

 

 

 

 

 

Income tax benefit

 

2,025,048

 

2,488,840

 

 

 

 

 

Net loss

 

(3,893,413)

 

(4,781,571)

 

 

 

 

 

 

 

 

 

 

Loss per common share, basic and diluted:

 

 

$

(0.26)

 

 

$

(0.34)

 

 

 

 

 

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and Diluted

 

14,967,141

 

13,868,811

 

 

 

 

 

Other comprehensive income (loss)

 

 

 

 

Foreign currency translation adjustments

 

 

$

247,427

 

 

$

(950,239)

 

The accompanying notes are an integral part to these unaudited consolidated financial statements.

 

4



Table of Contents

 

MARATHON PATENT GROUP, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

 

 

For The Three

 

For The Three

 

 

Months Ended

 

Months Ended

 

 

March 31, 2016

 

March 31, 2015

 

 

(Unaudited)

 

(Unaudited)

Cash flows from operating activities:

 

 

 

 

Net loss

 

$

(3,893,413)

 

$

(4,781,571)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

 

 

 

 

Depreciation

 

1,652

 

1,869

Amortization of patents and website

 

2,025,899

 

2,598,461

Deferred tax asset

 

(1,934,419)

 

(2,335,116)

Deferred tax liability

 

(76,463)

 

(161,984)

Impairment of intangible assets

 

373,195

 

-

Stock based compensation

 

550,436

 

685,753

Stock issued for services

 

-

 

750,334

Non-cash interest, discount, and financing costs

 

605,690

 

613,719

Change in fair value of Clouding earnout

 

1,342

 

-

Other non-cash adjustments

 

(33,607)

 

83,148

Changes in operating assets and liabilities

 

 

 

 

Accounts receivable

 

(15,275)

 

(546,101)

Bonds posted with courts

 

359,960

 

 

Prepaid expenses and other current assets

 

192,352

 

26,248

Other non current assets

 

2,069

 

 

Accounts payable and accrued expenses

 

1,953,751

 

1,920,185

 

 

 

 

 

Net cash provided by (used in) operating activities

 

113,169

 

(1,145,055)

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

Purchase of property, equipment, and other intangible assets

 

(2,097)

 

(37,147)

Net cash used in investing activities

 

(2,097)

 

(37,147)

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

Payment on note payable in connection with the acquisition of Medtech and Orthophoenix

 

-

 

(3,000,000)

Payment on note payable in connection with the acquisition of Orthophoenix

 

-

 

(3,750,000)

Payment on note payable in connection with the acquisition of Sarif

 

-

 

(276,250)

Payment on note payable in connection with the acquisition of IP Liquidity

 

-

 

(1,068,750)

Payment on note payable in connection with the acquisition of Dynamic Advances

 

-

 

(905,000)

Payment on convertible debt

 

-

 

(5,050,000)

Payment on Fortress note payable

 

(1,184,600)

 

-

Cash received upon issuance of note payable, net of $400,000 loan fee

 

-

 

19,600,000

Cash received upon exercise of warrant

 

-

 

18,750

Payments of notes payable to vendors

 

(63,840)

 

-

Net cash provided (used in) by financing activities

 

(1,248,440)

 

5,568,750

 

 

 

 

 

Effect of exchange rate changes on cash

 

2,607

 

8,852

 

 

 

 

 

Net  increase (decrease) in cash

 

(1,134,761)

 

4,395,400

 

 

 

 

 

Cash at beginning of period

 

2,555,151

 

5,082,569

 

 

 

 

 

Cash at end of period

 

$

1,420,390

 

$

9,477,969

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW  INFORMATION:

 

 

 

 

Cash paid for:

 

 

 

 

Interest expense

 

$

401,159

 

$

317,821

Taxes paid

 

$

7,999

 

$

8,260

Loan fees

 

$

-

 

$

400,000

Cash invested in 3DNano

 

$

115,000

 

$

-

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

Common stock issued in conjunction with note payable

 

$

-

 

$

1,000,000

Warrant issued in conjunction with note payable

 

$

-

 

$

318,679

Revenue share liability incurred in conjunction with note payable

 

$

-

 

$

1,000,000

Convertible debt warrant repricing

 

$

6,425

 

$

-

 

The accompanying notes are an integral part to these unaudited consolidated financial statements.

 

5



Table of Contents

 

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Our business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company.  We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies.  Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets.  Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights.  We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances.  Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.

 

Marathon Patent Group, Inc. (the “Company”) was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company’s name was changed to Marathon Patent Group, Inc.

 

On December 7, 2011, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada in order to change its name to “American Strategic Minerals Corporation” from “Verve Ventures, Inc.”, and increase the Company’s authorized capital to 200,000,000 shares of common stock, par value $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. During June 2012, the Company decided to discontinue its exploration and potential development of uranium and vanadium minerals business.

 

On August 1, 2012, the shareholders holding a majority of the Company’s voting capital voted in favor of (i) changing the name of the Company to “Fidelity Property Group, Inc.” and (ii) the adoption the 2012 Equity Incentive Plan and reserving 10,000,000 shares of common stock for issuance thereunder (the “2012 Plan”).  The board of directors of the Company (the “Board of Directors”) approved the name change and the adoption of the 2012 Plan on August 1, 2012. The Company did not file an amendment to its Articles of Incorporation with the Secretary of State of Nevada and subsequently abandoned the decision to adopt the “Fidelity Property Group, Inc.” name and discontinue its real estate business.

 

On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to (i) change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”) and (ii) effectuate a reverse stock split of the Company’s common stock by a ratio of 3-for-2 (the “Reverse Split”) within one year from the date of approval of the stockholders of the Company.  The Board of Directors approved the Name Change and the Reverse Split on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of

 

6



Table of Contents

 

State of the State of Nevada in order to effectuate the Name Change. On May 31, 2013, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-five and not more than one-for-fifteen at any time prior to April 30, 2014, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion. On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

 

On September 16, 2014, the Board of Directors of the Company approved and adopted, subject to shareholder approval on or prior to September 16, 2015, the Company’s 2014 Equity Incentive Plan. The Company’s 2014 Equity Incentive Plan was approved by the shareholders of the Company at the annual meeting held on July 31, 2015.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 received one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

 

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company’s consolidated financial position as of March 31, 2016, and the results of operations and cash flows for the three months ended March 31, 2016 have been included. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December 31, 2015, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2016. The consolidated balance sheet as of December 31, 2015 was derived from those financial statements.

 

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of March 31, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote.  At March 31, 2016 and December 31, 2015, the Company had recorded an allowance for bad debts in the amounts of $375,750 and $375,750, respectively.  Accounts receivable-net at March 31, 2016 and December 31, 2015, amounted to $153,112 and $136,842, respectively. As of March 31, 2016, accounts receivable related to one license accounted for approximately 41% of the Company’s total accounts receivable, accounts receivable related to recurring royalties represented approximately 42% of total accounts receivable and the remainder of the accounts receivable is primarily related to a trade receivable associated with the terminated Uniloc merger. As of December 31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company’s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable. As of March 31, 2016, accounts receivable represented 7% of revenues for the three months ended March 31, 2016 and as of December 31, 2015, accounts receivable represented 2% of revenues for the three months ended December 31, 2015.

 

7



Table of Contents

 

Concentration of Revenue and Geographic Area

 

Patent license revenue from enforcement activities originates in either the United States or Germany. Revenue attributable to the United States involves US patents, revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.

 

Revenues from two licenses accounted for approximately 93% of the Company’s operating revenues for the three months ended March 31, 2016 and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended March 31, 2015 as set forth below.

 

For the Three Months Ended March 31, 2016

 

For the Three Months Ended March 31, 2015

Licensor

 

License
Amount

 

% of Revenue

 

Licensor

 

License
Amount

 

% of Revenue

Signal IP, Inc.

 

$

 1,900,000

 

92%

 

Vantage Point Technology, Inc.

 

$

 

2,750,000

 

67%

Signal IP, Inc.

 

$

 15,000

 

1%

 

Signal IP, Inc.

 

$

 

275,000

 

7%

 

 

 

 

 

 

Sarif Biomedical, LLC

 

$

 

225,000

 

6%

 

 

 

 

 

 

TLIF, LLC

 

$

 

220,000

 

5%

 

 

 

 

 

 

Vantage Point Technology, Inc.

 

$

 

80,000

 

2%

% of Total Revenues

 

93%

 

% of Total Revenues

87%

 

The remainder of the revenue is attributable to running royalties in the Company’s Medtech portfolio.

 

While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

 

The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 93% of its revenues for the three months ended March 31, 2016 from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties.

 

The Company’s subsidiaries entered into two license agreements during the three months ended March 31, 2016.

 

8



Table of Contents

 

Cost of Revenue

 

Cost of revenues mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.

 

Prepaid Expenses, Bonds Posted and Other Current Assets

 

Prepaid expenses and other current assets of $146,336 and $338,598 at March 31, 2016 and December 31, 2015, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

In addition, the Company had outstanding litigation bonds in the amount of $1,443,457 and $1,748,311 at March 31, 2016 and December 31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to some of the Company’s patents in German courts. The difference in the balance of the litigation bonds at March 31, 2016 compared to December 31, 2015 is attributable to $55,106 in currency translation impact and the return of $359,960 in bonds related to the litigation against Schrader and TRW, which were resolved in the fourth quarter of 2015.

 

Fair Value of Financial Instruments

 

The Company adopted FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of March 31, 2016, the Company determined that there was no change to the Clouding IP earn out liability or the carrying value of the Clouding IP intangible assets.

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of March 31, 2016 and December 31, 2015, the Company had outstanding bonds in the amount of $1,443,457 and $1,748,311, respectively. The Company adjusted the value as of March 31, 2016 of the bonds to reflect changes to the exchange rate between the Euro and the US Dollar.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.  With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.  The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

9



Table of Contents

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2015 tax returns. After review of the 2015 financial statements and the results of operations through March 31, 2016, the Company has recorded a deferred tax asset in the amount of $14,385,393, from which the Company expects to realize benefits in the future, and a deferred tax liability of $964,998.

 

The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.

 

Basic and Diluted Net Earnings (Loss) per Share

 

Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,339,100 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at March 31, 2016, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

 

 

For the Three Months
Ended March 31, 2016

 

For the Three Months
Ended March 31, 2015

 

 

 

 

 

 

 

Net loss

 

(3,893,413)

 

(4,781,571)

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

Weighted Average Common Shares - Basic

 

14,967,141

 

13,868,811

 

Weighted Average Common Shares - Diluted

 

14,967,141

 

13,868,811

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

Income (Loss) - Basic

 

$

(0.26)

 

$

(0.34)

 

Income (Loss) - Diluted

 

$

(0.26)

 

$

(0.34)

 

 

10



Table of Contents

 

Intangible Assets

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

 

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

 

1.                   Significant underperformance relative to expected historical or projected future operating results;

2.                   Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.                   Significant negative industry or economic trends; and

4.                   Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three months ended March 31, 2016 and March 31, 2015, the Company recorded no impairment charge to its goodwill.

 

Other Intangible Assets

 

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”.  The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

11



Table of Contents

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March 31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Reclassification

 

Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.

 

Recent Accounting Pronouncements

 

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

 

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

 

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

 

12



Table of Contents

 

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

 

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

 

NOTE 3 — ACQUISITIONS

 

Dynamic Advances, IP Liquidity and Sarif Biomedical

 

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus IP, LLC (“Granicus”) and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev,  SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company (the “DA Agreement,” the “IP Liquidity Agreement” and the “Sarif Agreement,” respectively and the collective transactions, the “Acquisitions”).

 

Dynamic Advances

 

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock.  Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Dynamic Advances, LLC holds exclusive license to monetize certain patents owned by a third party.

 

On May 2, 2014, the Company issued TechDev and SFF a promissory note in order to evidence the second cash payment due under the terms of the DA Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the DA Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock, that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for Dynamic Advances, including capitalized costs associated with the purchase, was $6,653,078.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

13



Table of Contents

 

IP Liquidity

 

Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock.  Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.  IP Liquidity Ventures, LLC holds contract rights to the proceeds from the monetization of certain patents owned by a number of third parties.

 

On May 2, 2014, the Company issued Granicus and SFF a promissory note in order to evidence the second cash payment due under the terms of the IP Liquidity Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the IP Liquidity Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, Granicus and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for IP Liquidity the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for IP Liquidity, including capitalized costs associated with the purchase, was $6,653,078.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

Sarif Biomedical

 

Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014.  Under the terms of the Sarif Agreement, TechDev is entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Sarif Biomedical, LLC holds ownership rights to certain patents.

 

On May 2, 2014, the Company issued TechDev a promissory note in order to evidence the second cash payment due under the terms of the Sarif Agreement in the amount of $250,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $300,000 if the Company’s payment pursuant to the terms of the Sarif Agreement were not made on or before September 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev extended the maturity to March 31, 2015 in return for a payment of $26,250, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on February 24, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the higher principal amount of the promissory note. The total amount of consideration paid by the Company for Sarif Biomedical, including capitalized costs associated with the purchase, was $552,024.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

14



Table of Contents

 

Dynamic Advances, IP Liquidity and Sarif Biomedical

 

Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement (the “IP Assets”).  Under the terms of the Pay Proceeds Agreement, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $10,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the net proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the net proceeds of such recoveries to the sellers.  In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

 

Pursuant to a Registration Rights Agreement with the sellers (the “Acquisition Registration Rights Agreement”), the Company agreed to file a “resale” registration statement with the SEC covering at least 10% of the registrable shares of the Company’s Series B Convertible Preferred Stock issued to the sellers under the terms of the DA Agreement and the IP Liquidity Agreement, at any time on or after November 2, 2014 upon receipt of a written demand from the sellers which describes the amount and type of securities to be included in the registration and the intended method of distribution thereof.  The Company shall not be required to file more than three such registration statements not more than 60 days after the receipt of each such written demand from the sellers.

 

TechDev and Mr. Erich Spangenberg (the founder of IP Nav) and his spouse Audrey Spangenberg have jointly filed a Schedule 13G and are deemed to be affiliates of the Company.

 

Selene Communication Technologies

 

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”).

 

Selene owns a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries.  IP Nav provides patent monetization and support services under an existing agreement with Selene.

 

Pursuant to the terms of the Selene Interests Sale Agreement, Selene merged with and into Acquisition LLC with Selene surviving the merger as the wholly owned subsidiary of the Company.  The Company (i) issued 100,000 shares of common stock to the Selene Sellers and (ii) paid the Selene Sellers $50,000 cash.  The Company valued these common shares at the fair market value on the date of grant at $9.80 per share or $980,000. The transaction resulted in a business combination and caused Selene to become a wholly-owned subsidiary of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations” in which the Company is the acquirer for accounting purposes and Selene is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

990,000

 

Net working capital

 

37,000

 

Goodwill

 

3,000

 

Net purchase price

 

$

1,030,000

 

 

15



Table of Contents

 

Clouding Corp.

 

On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. Clouding owns patents related to network and data management technology.

 

The Company paid Clouding IP (i) $1.4 million in cash, (ii) $1.0 million in the form of a promissory note issued by the Company that would have matured on October 31, 2014, (iii) 25,000 shares of its restricted common stock valued at $281,000 and (iv) fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses) in excess of $4.0 million in net revenues that the Company makes with respect to the patents purchased from Clouding IP. The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $11.24 per share or $281,000 and the promissory note was paid in full prior to October 31, 2014. The revenue share under item (iv) above was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value. The Company booked a payable to the sellers pursuant to the earn out liability in the amount of $2,148,000 at September 30, 2014, based on license agreements entered into during the quarter. No further amount is owed until the Company generates additional revenue, if any, from the Clouding patents.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

14,500,000

 

Goodwill

 

1,296,000

 

Net purchase price

 

$

15,796,000

 

 

Total consideration paid of the following:

 

Cash

 

$

1,400,000

 

Promissory Note

 

1,000,000

 

Common Stock

 

281,000

 

Earn Out Liability

 

13,115,000

 

Net purchase price

 

$

15,796,000

 

 

Historical financial statements of Clouding IP and the pro forma condensed combined consolidated financial statements (both carve-out of certain operations of Clouding IP) can be found on the Form 8-K/A filed with the SEC on November 12, 2014.  The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

 

TLI Communications LLC

 

On September 19, 2014, TLI Acquisition Corp (“TLIA”), a Virginia corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the membership interests of TLI Communications LLC (“TLIC”), a Delaware limited liability company. TLIC owns a patent in the telecommunications field.

 

Pursuant to the terms of the TLIC Interests Sale Agreement, TLIC merged with and into TLIA with TLIC surviving the merger as the wholly-owned subsidiary of the Company.  The Company (i) agreed to issue 60,000 shares of Common Stock to the sellers of TLIC (“TLIC Sellers”), (ii) paid the TLIC Sellers $350,000 cash and (iii) agreed to pay the TLIC Sellers a fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses and the cash portion of the acquisition consideration) that the Company makes with respect to the patent purchased pursuant to the acquisition of TLIC.  The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $13.63 per share or $818,000. The cash portion of the consideration was outstanding at September 30, 2014 and was subsequently paid in October 2014. The transaction resulted in a business combination and caused TIC to become a wholly-owned subsidiary of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

940,000

 

Goodwill

 

228,000

 

Net purchase price

 

$

1,168,000

 

 

16



Table of Contents

 

Medtech Entities

 

On October 13, 2014, Medtech Group Acquisition Corp (“Medtech Corp.”), a Texas corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the equity or membership interests of OrthoPhoenix, LLC (“OrthoPhoenix”), a Delaware limited liability company, TLIF, LLC (“TLIF”) and MedTech Development Deutschland GmbH (“MedTech GmbH” and along with OrthoPhoenix and TLIF, the “Medtech Entities”) from MedTech Development, LLC (“MedTech Development”). The Medtech Entities own patents in the medical technology field.

 

Pursuant to the terms of the Interest Sale Agreement between MedTech Development, Medtech Corp. and the Medtech Entities, the Company (i) paid MedTech Development $1,000,000 cash and (ii) issue a Promissory Note to MedTech Development in the amount of $9,000,000 and (iii) assumed existing debt payable to Medtronics, Inc.  The assumed debt payable to Medtronics was renegotiated, as a result of which, the outstanding amount was $6.25 million prior to any repayment by the Company. The debt was due in installments through July 20, 2015; in the event that the Company paid the total amount due by June 30, 2015, the Company would receive a reduction in the remaining principal owed by the Company in the amount of $750,000. The transaction resulted in a business combination and caused the Medtech Entities to become wholly-owned subsidiaries of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

12,800,000

 

Goodwill

 

2,700,000

 

Net purchase price

 

$

15,500,000

 

 

Historical financial statements of the Medtech Entities and the pro forma condensed combined consolidated financial statements can be found on the Form 8-K/A filed with the SEC on December 24, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

 

NOTE 4 – INTANGIBLE ASSETS

 

Intangible assets of the Company, including adjustments for currency translation adjustments, consisted of the following:

 

 

 

March 31, 2016

 

December 31, 2015

 

 

 

 

 

 

 

Intangible Assets

 

  $

39,631,501

 

  $

41,014,992

 

Accumulated Amortization & Impairment

 

(16,423,203)

 

(15,557,353)

 

 

Intangible assets, net

 

  $

23,208,298

 

  $

25,457,639

 

 

Other than the Company’s website as set forth in the table above, intangible assets are comprised of patents with estimated useful lives between approximately 1 to 15 years. The website was determined to have an estimated useful life of 3 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis.  Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included in operating expenses as reflected in the accompanying consolidated statements of operations. The Company recorded an impairment charge to its long-lived assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

 

17



Table of Contents

 

Patent and website amortization expense for the three months ended March 31, 2016 and March 31, 2015 was $2,025,899 and $2,598,461, respectively, net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

 

2016

 

  $

5,440,463

 

2017

 

5,251,025

 

2018

 

3,691,108

 

2019

 

2,846,570

 

2020

 

2,121,609

 

2021 and thereafter

 

3,857,523

 

Total

 

  $

23,208,298

 

 

The Company made the following patent purchases:

 

-      In April 2013, the Company through its subsidiary, Relay IP, Inc. acquired a US patent for $350,000;

-      In April 2013, the Company acquired 10 US patents, 27 foreign patents and 1 patent pending from CyberFone Systems valued at $1,135,512;

-      In June 2013, in connection with the closing of a licensing agreement with Siemens Technology, we acquired a patent portfolio from that company valued at $1,000,000;

-      In September 2013, the Company acquired 14 US patents for a total purchase price of $1,100,000;

-      In November 2013, the Company acquired four patents for 150,000 shares of the Company’s Common Stock, which the Company valued at $718,500 based on the fair market value of the stock issued;

-      In December 2013, the Company acquired certain patents from Delphi Technologies, Inc. for $1,700,000 pursuant to a Patent Purchase Agreement entered into on October 31, 2013 and Amended on December 16, 2013;

-      In December 2013, in connection with a licensing agreement with Zhone, the Company acquired a portfolio of patents from Zhone;

-      In December 2013, in connection with a settlement and license agreement, we agreed to settle and release another defendant for past and future use of our patents, whereby the defendant agreed to assign and transfer 2 U.S. patents and rights to the Company;

-      In May 2014, we acquired ownership rights of Dynamic Advances, LLC, a Texas limited liability company, IP Liquidity Ventures, LLC, a Delaware limited liability company, and Sarif Biomedical, LLC, a Delaware limited liability company, all of which hold patent portfolios or contract rights to the revenue generated from the patent portfolios;

-      In June 2014, we acquired Selene Communication Technologies, LLC, which holds multiple patents in the search and network intrusion field;

-      In August 2014, we acquired patents from Clouding IP LLC, with such patents related to network and data management technology;

-      In September 2014, we acquired TLI Communications, which owns a single patent in the telecommunication field;

-      In October 2014, we acquired three patent portfolios from MedTech Development, LLC, which owns medical technology patents.

 

As of March 31, 2016, the Company’s patent portfolios consist of 320 U.S. and foreign patents, 11 patent applications and contract rights to seven patents. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio is past (the patent is expired, but patent rules allow for six year look-back for royalties), the median expiration date for patents in the Company’s portfolio is June 17, 2017, and the latest expiration date for a patent in any of the Company’s patent portfolios is July 29, 2029.  A summary of the Company’s patent portfolios is as follows:

 

Subsidiary

 

Number of
Patents

 

Earliest
Expiration
Date

 

Median
Expiration
Date

 

Latest
Expiration
Date

 

Subject Matter

Bismarck IP Inc.

 

17

 

09/15/16

 

09/15/15

 

01/22/18

 

Communication and PBX equipment

Clouding Corp.

 

61

 

Expired

 

10/05/21

 

03/29/29

 

Network and data management

CRFD Research, Inc.

 

5

 

09/17/21

 

08/11/22

 

08/19/23

 

Web page content translator

Cyberfone Systems, LLC

 

35

 

Expired

 

01/31/17

 

06/07/20

 

Telephony and data transactions

Dynamic Advances, LLC

 

4

 

Expired

 

10/02/17

 

03/06/23

 

Natural language interface

E2E Processing, Inc.

 

4

 

04/27/20

 

11/17/23

 

07/18/24

 

Manufacturing schedules using adaptive learning

Hybrid Sequence IP, Inc.

 

2

 

11/14/15

 

09/09/16

 

07/17/17

 

Asynchronous communications

IP Liquidity Ventures, LLC

 

3

 

Expired

 

04/09/17

 

07/26/20

 

Pharmaceuticals / tire pressure systems

Loopback Technologies, Inc.

 

10

 

Expired

 

09/25/17

 

08/27/22

 

Automotive

Medtech Group Acquisition Corp.

 

131

 

Expired

 

06/01/18

 

07/29/29

 

Medical technology

Relay IP, Inc.

 

1

 

Expired

 

Expired

 

Expired

 

Multicasting

Sampo IP, LLC

 

3

 

03/13/18

 

03/13/18

 

11/16/23

 

Centrifugal communications

Sarif Biomedical LLC

 

4

 

Expired

 

Expired

 

Expired

 

Microsurgery equipment

Selene Communication Technologies, LLC

 

3

 

05/05/18

 

11/23/20

 

11/28/21

 

Communications

Signal IP, Inc.

 

7

 

03/10/14

 

12/01/15

 

08/06/22

 

Automotive

TLI Communications, LLC

 

6

 

06/17/17

 

06/17/17

 

06/17/17

 

Telecommunications

Vantage Point Technology, Inc.

 

31

 

Expired

 

12/21/16

 

03/09/18

 

Computer networking and operations

 

 

 

 

Median

 

09/25/17

 

 

 

 

 

18



Table of Contents

 

NOTE 5 - STOCKHOLDERS’ EQUITY

 

On December 7, 2011, the Company increased its authorized capital to 200,000,000 shares of Common Stock from 75,000,000 shares, changed the par value to $0.0001 per share from $.001 per share, and authorized 100,000,000 shares of preferred stock, par value $0.0001 per share.

 

On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split and stock dividend.

 

Series B Convertible Preferred Stock

 

On May 1, 2014, the Company filed with the Secretary of State of Nevada a Certificate of Designations of Series B Convertible Preferred Stock (the “Series B Certificate of Designations”) authorizing 500,000 shares of Series B Convertible Preferred Stock and establishing the designations, preferences, and other rights of the Series B Convertible Preferred Stock. The Series B Certificate of Designations became effective upon filing.

 

On May 2, 2014, the Company issued an aggregate of 782,000 shares of Series B Convertible Preferred Stock valued at $2,807,380 to acquire IP Liquidity Ventures, LLC, Dynamic Advances, LLC and Sarif Biomedical, LLC. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On September 17, 2014, the Company entered into a consulting agreement (the “GRQ Consulting Agreement”) with GRQ Consultants, Inc. (“GRQ”), pursuant to which GRQ shall provide certain consulting services including, but not limited to, advertising, marketing, business development, strategic and business planning, channel partner development and other functions intended to advance the business of the Company.  As consideration, GRQ was entitled to 200,000 shares of the Company’s Series B Convertible Preferred Stock, 50% of which vested upon execution of the GRQ Consulting Agreement, and 50% of which shall vest in six (6) equal monthly installments of commencing on October 17, 2014.  The first tranche of 100,000 shares of Series B Convertible Preferred Stock was issued to GRQ on October 6, 2014. In addition, the GRQ Consulting Agreement allows for GRQ to receive additional shares of Series B Convertible Preferred Stock upon the achievement of certain performance benchmarks. All shares of Series B Convertible Preferred Stock issuable to GRQ shall be pursuant to the 2014 Plan (as defined below) and shall be subject to shareholder approval of the 2014 Plan on or prior to September 16, 2015; the shareholders approved the 2014 Plan on July 31, 2015. The GRQ Consulting Agreement contains an acknowledgement that the conversion of the preferred stock into shares of the Company’s common stock is precluded by the equity blockers set forth in the certificate of designation and in Section 17 of the 2014 Plan to ensure compliance with NASDAQ Listing Rule 5635(d).

 

Common Stock

 

On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

 

On April 22, 2014, the Company issued 300,000 shares of restricted Common Stock to TT IP LLC pursuant to the acquisition of patents on November 13, 2013.

 

On June 2, 2014, the Company issued 48,078 shares of unrestricted Common Stock to an investor in the May 2013 PIPE, pursuant to the exercise of a warrant received in the May 2013 PIPE investment.

 

On June 30, 2014, the Company issued 200,000 shares of restricted Common Stock pursuant to the acquisition of Selene Communications Technologies, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the fair market value on the date of grant at $4.90 per share or $980,000.

 

19



Table of Contents

 

On July 18, 2014, the Company issues a total of 26,722 shares of Common Stock pursuant to the exercise of stock options held by a former member of the Company’s Board of Directors and the Company’s former Chief Financial Officer.

 

On September 16, 2014, the Company issued to two of its independent board members, in lieu of cash compensation, 6,178 shares of restricted Common Stock.  The shares shall vest quarterly over twelve (12) months commencing on the date of grant.

 

On September 30, 2014, the Company issued 50,000 shares of restricted Common Stock pursuant to the acquisition of the assets of Clouding IP, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $5.62 per share or $281,000.

 

For the three months ended September 30, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 84,652 shares of the Company’s Common Stock.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

 

For the three months ended December 31, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 29,230 shares of the Company’s Common Stock.

 

On January 29, 2015, the Company issued 134,409 shares of the Company’s Common Stock to DBD Credit Funding, LLC (“DBD”), an affiliate of Fortress Credit Corp. (“Fortress”), pursuant to the Fortress transaction as set forth in Note 6.

 

On March 13, 2015, the Company settled a dispute with a former consultant whereby the Company issued the consultant 60,000 shares of Common Stock for a full release of all claims.

 

For the three months ended March 31, 2015, certain holders of warrants exercised their warrants to purchase, in cash, 5,000 shares of the Company’s Common Stock.

 

For the three months ended June 30, 2015, certain holders of options exercised their options to purchase, on a net exercise basis, 33,968 (net) shares of the Company’s Common Stock.

 

In a series of transactions, the Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into shares of the Company’s Common Stock, with 183,330 shares of Series B Convertible Preferred Stock converted into Common Stock prior to September 30, 2015.

 

On September 21, 2015, the Company issued 150,000 shares of the Company’s Common Stock to Alex Partners, LLC and Del Mar Consulting Group, Inc., pursuant to a services agreement entered into on September 21, 2015. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $2.23 per share or $334,500. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On October 20, 2015, the remaining 16,666 shares of Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into 16,666 shares of the Company’s Common Stock.

 

On November 4, 2015, the Company issued 300,000 shares of the Company’s Common Stock to Dominion Harbor Group LLC (“Dominion”), pursuant to a settlement agreement entered into with Dominion on October 30, 2015.  In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.71 per share or $513,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On December 9, 2015, the Company entered into an agreement with Melechdavid, Inc. (“Melechdavid”), pursuant to which the Company agreed to issue 100,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.61 per share or $161,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

20



Table of Contents

 

Common Stock Warrants

 

On May 1, 2014, the Company issued warrants to purchase 511,790 shares of Common Stock, at a price of $3.75 per share of Common Stock, pursuant to the Private Placement described in detail below. The Company reviewed the issuance of warrants, done in conjunction with the financing closed on May 1, 2014, and determined that pursuant to ASC 480 and ASC 815, the warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.

 

In conjunction with the issuance of $5,550,000 in convertible debt on October 16, 2014, the Company issued two-year Warrants to purchase 258,998 shares of the Company’s Common Stock, par value $0.0001 per share pursuant to a securities purchase agreement. The warrants were valued at $164,020 and were recorded as a discount to the fair value of the convertible notes. The Warrants are initially convertible into shares of the Company’s Common Stock at an exercise price of $8.25 per share. The conversion and exercise prices are subject to adjustment in the event of certain events, including stock splits and dividends. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that there was no beneficial conversion feature and that the conversion feature should not be bifurcated.

 

On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement (“Fortress Purchase Securities Agreement”) with DBD, an affiliate of Fortress, under which the Company issued a five-year warrant (“Fortress Warrant”) to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment.  The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no beneficial conversion feature and that the convertible notes and warrants should not be bifurcated.

 

During the year ended December 31, 2015, warrants to purchase 5,000 shares of Common Stock were exercised and no warrants to purchase shares of Common Stock were forfeited.

 

During the three months ended March 31, 2015, the Company recorded stock based compensation expense of $3,465 in connection with the vested warrants associated with one warrant-based compensatory grant, compared to no compensation expenses for the three months ended March 31, 2016 associated with this warrant. The warrant was valued at the time of grant on January 26, 2012, based on the Black-Scholes model, using the strike and market prices of $3.25 per share, the term of 10 years, volatility of 191% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.96%. At December 31, 2015, there was a total of $0 of unrecognized compensation expense related to future recognition of warrant-based compensation arrangements.

 

A summary of the status of the Company’s outstanding stock warrants at March 31, 2016 is as follows:

 

 

 

Number of
Warrants

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

2,021,308

 

  $

4.27

 

0.87

Granted

 

-    

 

 

-    

 

-    

Cancelled

 

-    

 

-    

 

-    

Forfeited

 

-    

 

-    

 

-    

Exercised

 

-    

 

  $

-    

 

-    

Balance at March 31, 2016

 

2,021,308

 

4.27

 

0.63

 

 

 

 

 

 

 

Warrants exercisable at March 31, 2016

 

2,021,308

 

 

 

 

Weighted average fair value of warrants granted during the period

 

 

 

  $

-    

 

 

 

21



Table of Contents

 

Warrant Amendment Letter

 

On April 20, 2014, the Company sent a letter (the “Warrant Amendment Letter”) to all the holders of the warrants which were granted in connection with the sale of units pursuant to a securities purchase agreements which occurred between May 2013 and August 2013. The Warrant Amendment Letter offered to reduce the exercise price of the warrants from $6.50 per share to $5.75 per share, if the holders of the warrants accepted the Company’s offer to exercise the warrants in full for cash by April 22, 2014 (the “Expiration Date”).  The Company subsequently extended the Expiration Date to April 24, 2014. On April 24, 2014, one holder of warrants, who is an accredited investor, accepted the Company’s offer and thereby exercised his warrants, for gross proceeds to the Company of approximately $138,222. After analyzing the circumstances relative to the Warrant Amendment Letter – the extremely short period of time to exercise pursuant to the Amendment Letter, the relatively small change in the exercise price and the limited response to the Amendment Letter – the Company deemed that the change was not a significant modification of the terms of the warrant and did not assess a new fair value and consequently did not make an entry for any adjustment in the value.

 

On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company’s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 23,334 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $4.125 to the lower of 1) $2.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company’s Common Stock.

 

Common Stock Options

 

On April 15, 2014, the Company issued a new board member a five (5) year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $3.295 per share, subject to adjustment, which shall vest in twelve (12) monthly installments commencing on the date of grant. The option was valued based on the Black-Scholes model, using the strike and market prices of $3.295 per share, life of three years, volatility of 51% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 0.84%.

 

On May 14, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

 

On May 14, 2014, the Company issued to consultants, five (5) year options to purchase an aggregate of 160,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 3.5 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.00%.

 

On May 15, 2014, the Company entered into an executive employment agreement with Francis Knuettel II (“Knuettel Agreement”) pursuant to which Mr. Knuettel would serve as the Company’s Chief Financial Officer. As part of the consideration, the Company agreed to grant Mr. Knuettel a ten (10) year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $4.165 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Knuettel Agreement. The option was valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

 

On June 15, 2014, the Company issued to a consultant a five (5) year stock option to purchase an aggregate of 40,000 shares of the Company’s Common Stock with an exercise price of $5.05 per share, subject to adjustment, which shall vest in twenty-four (24) each monthly installments on each monthly anniversary date of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $5.05 per share, life of 3.25 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.05%.

 

22



Table of Contents

 

On August 29, 2014, the Company entered into an executive employment agreement with Daniel Gelbtuch (“Gelbtuch Agreement”) pursuant to which Mr. Gelbtuch would serve as the Company’s Chief Marketing Officer. As part of the consideration, the Company agreed to grant Mr. Gelbtuch ten (10) year stock options to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $5.62 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Gelbtuch Agreement. Mr. Gelbtuch’s employment with the Company was terminated as of January 20, 2015 and the vested shares at that time remained available for Mr. Gelbtuch to exercise until January 20, 2016.  The option was valued based on the Black-Scholes model, using the strike and market prices of $5.62 per share, life of 6.5 years, volatility of 62% based on the average volatility of comparable companies over the prior 10-year period and a discount rate as published by the Federal Reserve of 1.95%.

 

On September 16, 2014, the Company issued its independent board members five (5) year options to purchase an aggregate of 60,000 shares of the Company’s Common Stock with an exercise price of $7.445 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.445 per share, life of three years, volatility of 49% based on the average volatility of comparable companies over the prior 5-year period and a discount rate as published by the Federal Reserve of 1.04%.

 

On October 31, 2014, the Company entered into an executive employment agreement with Enrique Sanchez (“Sanchez Agreement”) pursuant to which Mr. Sanchez would serve as the Company’s Senior Vice President of Licensing. As part of the consideration, the Company agreed to grant Mr. Sanchez ten (10) year stock options to purchase an aggregate of 160,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Sanchez Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company entered into an executive employment agreement with Umesh Jani (“Jani Agreement”) pursuant to which Mr. Jani would serve as the Company’s Chief Technology Officer and SVP of Licensing. As part of the consideration, the Company agreed to grant Mr. Jani ten (10) year stock options to purchase an aggregate of 100,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Jani Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 680,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company issued to a consultant, a five (5) year options to purchase an aggregate of 30,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 3.25 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.03%.

 

On February 5, 2015 the Company issued to a consultant, a five (5) year options to purchase an aggregate of 25,000 shares of the Company’s Common Stock with an exercise price of $6.80 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.80 per share, an expected term of 3.25 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

 

On March 6, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $7.37 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.37 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.16%.

 

On March 18, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $6.61 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.61 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

 

23



Table of Contents

 

On April 7, 2015 (the “Effective Date”), the Company entered into a consulting agreement (the “Consulting Agreement”) with Richard Chernicoff, a member of the Company’s Board of Directors, pursuant to which Mr. Chernicoff shall provide certain services to the Company, including serving as the interim General Counsel and interim General Manager of commercial product commercialization development. Pursuant to the terms of the Consulting Agreement, Mr. Chernicoff shall receive a monthly retainer of $27,000 and a ten-year stock option to purchase 280,000 shares of the Company’s Common Stock pursuant to the Company’s 2014 Plan. The stock options shall have an exercise price of $6.76 per share, the closing price of the Company’s common stock on the date immediately prior to the Board of Directors approval of such stock options and the options shall vest as follows: 25% of the option shall vest on the 12 month anniversary of the Effective Date and thereafter 2.083% on the 21st day of each succeeding calendar month for the following twelve months, provided Mr. Chernicoff continues to provide services (in addition to as a member of the Company’s Board of Directors) at the time of vesting. The option shall be subject in all respects to the terms of the 2014 Plan. Notwithstanding anything herein to the contrary, the remainder of the option shall be subject to the following as an additional condition of vesting: (A) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $8.99 and (B) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $10.14. For valuation purposes, the options were divided into two parts – the time-based vesting component and the performance-based vesting component. The time-based vesting component was valued based on the Black-Scholes model, using the strike and market prices of $6.76 per share, an expected term of 6.25 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.53%. The performance-based vesting component was valued based on the Monte Carlo Simulation model, using the strike and market prices of $6.76 per share, an expected term of 10.0 years, volatility of 61% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.89%.

 

On September 16, 2015, the Company issued its independent board members ten-year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $2.03 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.03 per share, an expected term of 5.5 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%.

 

On October 14, 2015, the Company issued certain of its employees ten-year options to purchase an aggregate of 385,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

 

On October 14, 2015, the Company issued certain of its consultants ten (10) year options to purchase an aggregate of 70,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

 

For the three months ended March 31, 2016 the Company recorded option-based compensation expenses of $550,436. A summary of the stock options as of March 31, 2016 is as follows:

 

 

 

Number of
Options

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

3,383,267

 

  $

4.25

 

7.11

Granted

 

-    

 

  $

-    

 

-    

Cancelled

 

-    

 

  $

-    

 

-    

Forfeited

 

44,167

 

  $

6.45

 

6.31

Exercised

 

-    

 

  $

-    

 

-    

Balance at March 31, 2016

 

3,339,100

 

  $

4.22

 

6.93

 

 

 

 

 

 

 

Options Exercisable at March 31, 2016

 

2,122,560

 

 

 

 

Options expected to vest

 

1,216,541

 

 

 

 

Weighted average fair value of options granted during the period

 

 

 

  $

-    

 

 

 

24



Table of Contents

 

Stock options outstanding at March 31, 2016 as disclosed in the above table have approximately $59,150 in intrinsic value at March 31, 2016.

 

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

Fortress Transaction

 

On January 29, 2015, the Company and certain of its subsidiaries (each a “Subsidiary”) entered into a series of Agreements including a Fortress Securities Agreement and a Subscription Agreement with DBD, an affiliate of Fortress, under which the Company sold to the purchasers: (i) $15,000,000 original principal amount of Senior Secured Notes (“Fortress Notes”), (ii) a right to receive a portion of certain proceeds from monetization net revenues received by the Company (after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes),  (the “Revenue Stream”), (iii) a five-year Fortress Warrant to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment; and (iv) 134,409 shares of the Company’s Common Stock.  Under the Fortress Purchase Agreement, the Company has the right to require the purchasers to purchase an additional $5,000,000 of Notes (which will increase proportionately the Revenue Stream), subject to the achievement of certain milestones, and further contemplates that Fortress may, but is not obligated to, fund up to an additional $30,000,000, on equivalent economic terms.   The Company may use the proceeds to finance the monetization of its existing assets, provide further expansion capital for new acquisitions, to repay existing debt (including without limitation, the Company’s 11% convertible notes issued October 9, 2013 and for general working capital and corporate purposes.

 

Pursuant to the Purchase Agreement entered into on January 29, 2015, the Company issued to Fortress a Note in the original principal amount of $15,000,000 (the “Initial Note”). The Initial Note matures on July 29, 2018. If any additional Notes are issued pursuant to the Fortress Securities Purchase Agreement, the maturity date of such additional Fortress Notes shall be 42 months after issuance. The unpaid principal amount of the Initial Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement), the interest rate shall increase by an additional 2% per annum.  As of March 31, 2016, the twelve-month LIBOR USD rate was 1.21040%. Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2015.  Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”).  PIK Interest shall be treated as added principal of the Initial Note for all purposes, including interest accrual and the calculation of any prepayment premium.

 

The Fortress Securities Purchase Agreement contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,000,000 in unrestricted cash and cash equivalents and that the Company shall have Monetization Revenues (as defined in the Fortress Purchase Agreement) for each of the four fiscal quarters commencing December 31, 2014 of at least $15,000,000.

 

The terms of the Fortress Warrant provide that until January 29, 2020, the Fortress Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock.

 

As part of the transaction, DBD entered into a lock-up agreement (the “Lock-Up Agreement”) pursuant to which the parties and certain related holders agreed until the earlier of 12 months or acceleration of an Event of Default (as defined in the Fortress Securities Purchase Agreement), that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), the Lock-Up Shares (as defined in the Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by such Holder and his/her Related Group (as such terms are defined in the Lock-Up Agreement) on the date of the Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares.  The Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.

 

25



Table of Contents

 

In connection with the transactions described above, TechDev, Audrey Spangenberg, Erich Spangenberg, and Granicus (the “Spangenberg Holders”) entered into a lock-up agreement (the “Spangenberg Lockup”) with respect to 1,626,924 shares of Common Stock, 48,078 shares of Common Stock underlying warrants, and 782,000 shares of Common Stock underlying preferred stock, pursuant to which the Spangenberg Holders agreed that until payment in full of the Note Obligations (as defined in the Fortress Notes), which shall include but not be limited to all principal and interest on outstanding Notes pursuant to the Purchase Agreement, the Spangenberg Holders and certain related parties agreed that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), more than 5% of the Spangenberg Lockup shares (as defined in the Spangenberg Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by such Holder and his/her Related Group (as such terms are defined in the Spangenberg Lock-Up Agreement) on the date of the Spangenberg Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of more than 5% of the Spangenberg Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares. The Spangenberg Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Spangenberg Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.

 

Pursuant to the Fortress Securities Purchase Agreement, as security for the payment and performance in full of the Secured Obligations (as defined in the Fortress Securities Purchase Agreement) in favor of DBD, the Company and certain subsidiaries executed and delivered in favor of DBD a Security Agreement (“Security Agreement”) and a Patent Security Agreement (“Patent Security Agreement”), including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations is secured by a first priority lien and security interest in all of the assets of the Company, subject to permitted liens on permitted indebtedness that existed as of January 29, 2015. The security interest does not include a lien on the assets held by Orthophoenix, LLC. Certain subsidiaries of the Company (excluding Orthophoenix) also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations.  As required by the terms of certain notes issued by the Company in October 2014 (“October Notes”), the October Note holders consented to the transactions described herein.

 

Within thirty days, the Company was required to open a cash collateral account into which all Company revenue shall be deposited and which shall be subject to a control agreement outlining the disbursement in accordance with the terms of the Fortress Securities Purchase Agreement of all proceeds.

 

Pursuant to the Fortress Securities Purchase Agreement, the Company entered into the Fortress Patent License Agreement with DBD pursuant to which the Company agreed to grant to the Licensee certain rights, including right to license certain patents and patent applications, which licensing rights to be available solely upon an acceleration of the Note Obligations, as provided in the Fortress Securities Purchase Agreement.

 

Office Lease

 

In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California.  The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease.  In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes.  Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit.  In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease.  Minimum future lease payments under this lease at March 31, 2016, for the next five years and thereafter are as follows:

 

2016 (Nine Months)

 

$

51,669

 

2017

 

 

71,288

 

 

2018

 

 

74,540

 

 

2019

 

 

77,872

 

 

2020

 

 

81,336

 

 

Thereafter

 

 

27,504

 

 

Total

 

$

384,209

 

 

NOTE 7 – SUBSEQUENT EVENTS

 

On April 18, 2016, a wholly-owned subsidiary of the Company entered into a settlement agreement under which the Company agreed to dismiss with prejudice certain pending litigation. Under the terms of the settlement the Company will book revenue on the amount of $24.9 million. A portion of the proceeds of the settlement will be paid to the original patent owner as well as contingent fees to counsel. In connection with the settlement, the parties have agreed to keep the additional terms of the settlement confidential. The Company believes that other voice recognition services also infringe patents involved in the settled action.

 

26



Table of Contents

 

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

This report on Form 10-Q (“Report”) and other written and oral statements made from time to time by us may contain so-called “forward-looking statements,” all of which are subject to risks and uncertainties.  Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “forecasts,” “projects,” “intends,” “estimates,” and other words of similar meaning.  One can identify them by the fact that they do not relate strictly to historical or current facts.  These statements are likely to address our growth strategy, financial results and product and development programs.  One must carefully consider any such statement and should understand that many factors could cause actual results to differ from our forward looking statements.  These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not.  No forward-looking statement can be guaranteed and actual future results may vary materially.

 

Information regarding market and industry statistics contained in this Report is included based on information available to us that we believe is accurate.  It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis.  We have not reviewed or included data from all sources, and cannot assure investors of the accuracy or completeness of the data included in this Report.  Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services.  We do not assume any obligation to update any forward-looking statement.  As a result, investors should not place undue reliance on these forward-looking statements.

 

Overview

 

We acquire patents and patent rights from owners or other ventures and seek to monetize the value of the patents through litigation and licensing strategies, alone or with others.  Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter which allows us to seek the benefits of a diversified portfolio of assets in differing industries and countries.  Generally, the patents and patent rights that we seek to acquire have large identifiable targets who are or have been using technology that we believe infringes our patents and patent rights.  We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into comprehensive settlement and license agreements that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms.  Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company. As of March 31, 2016, we owned 327 U.S. and foreign patents and patent rights and 11 patent applications.

 

Our principal office is located at 11100 Santa Monica Blvd., Suite 380, Los Angeles, CA 90225. Our telephone number is (703) 232-1701.

 

We were incorporated in the State of Nevada on February 23, 2010 under the name “Verve Ventures, Inc.” On December 7, 2011, we changed our name to “American Strategic Minerals Corporation” and were engaged in exploration and potential development of uranium and vanadium minerals business. During June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In November 2012, we discontinue our real estate business.

 

On July 18, 2013, we filed a certificate of amendment to our Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of our issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13) basis (the “Reverse Split”). The Reverse Split became effective with the FINRA at the open of business on July 22, 2013. As a result of the Reverse Stock Split, every thirteen shares of our pre-reverse split common stock was combined and reclassified into one share of our common stock. No fractional shares of common stock were issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share received the next highest number of whole shares.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 received one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this Report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

 

Throughout this Report, each instance in which we refer to a number of shares of our Common Stock, the number refers to the number of shares of Common Stock after giving effect to the Reverse Split and the Dividend, unless otherwise indicated.

 

27



Table of Contents

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Management believes the following critical accounting policies affect the significant judgments and estimates used in the preparation of the financial statements.

 

Principles of Consolidation

 

The consolidated financial statements are prepared in accordance with US GAAP and present the financial statements of the Company and our wholly-owned and majority owned subsidiaries.  In the preparation of our consolidated financial statements, intercompany transactions and balances are eliminated.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition.” Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

 

The Company considers the revenue generated from a settlement and licensing agreement as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the Company’s major central business, the Company presents these two elements as one revenue category in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.  With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 – Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.  The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Intangible Assets - Patents

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions.  The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value.  The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

 

28



Table of Contents

 

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

 

1.                                      Significant underperformance relative to expected historical or projected future operating results;

2.                                      Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.                                      Significant negative industry or economic trends; and

4.                                      Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three months ended March 31, 2016 and March 31, 2015, the Company recorded no impairment charge to its goodwill.

 

Other Intangible Assets

 

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”.  The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets, including mineral rights, may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to their estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

29



Table of Contents

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March 31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Liquidity and Capital Resources

 

At March 31, 2016, we had $1.4 million in cash and cash equivalents and a working capital deficit of $17.2 million.

 

Based on the Company’s current revenue and profit projections, management is uncertain that the Company’s existing cash and accounts receivables will be sufficient to fund its operations through at least the next twelve months. If we do not meet our revenue and profit projections or the business climate turns negative, then we will need to:

 

·                                          raise additional funds to support the Company’s operations. There is no assurance that the Company will be able to raise such additional funds on acceptable terms, if at all. If the Company raises additional funds by issuing securities, existing stockholders may be diluted; and

 

·                                          review strategic alternatives.

 

If adequate funds are not available, we may be required to curtail our operations or other business activities or obtain funds through arrangements with strategic partners or others that may require us to relinquish rights to certain technologies or potential markets.

 

Recent Accounting Pronouncements

 

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

 

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

 

30



Table of Contents

 

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

 

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

 

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in US GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

 

Results of Operations

 

For the Three Months Ended March 31, 2016 and 2015

 

We generated revenues of $2,059,676 during the three months ended March 31, 2016 as compared to $4,093,869 during the three months ended March 31, 2015. For the three months ended March 31, 2016, this represented a decrease of $2,034,193 or 50%. Revenue for the three months ended March 31, 2016 and the three months ended March 31, 2015 were derived primarily from the issuance of one-time patent licenses, with the balance of the revenue coming from recurring royalties.

 

For the three months ended March 31, 2016, revenues from two settlement and license agreements accounted for approximately 93% of the Company’s total revenues and 100% of license revenues, whereas revenues from the largest five settlement and license agreements accounted for 87% of the Company’s total revenue and 92% of license revenues for the period ending March 31, 2015.

 

The Company expects that a significant portion of its future revenues will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.

 

While the number of patents is not determinative of revenue, during the time that the Company’s merger with Uniloc was pending, the Company did not add to its patent portfolios and the Company determined that it had fully utilized some of its existing patent portfolios. As a result, the total number of patents declined. Following the termination of the merger, however, the Company aggressively began reviewing new portfolios with the intent to add to its patent holdings.

 

31



Table of Contents

 

Direct cost of revenues during the three months ended March 31, 2016 amounted to $2,639,976 and for the three months ended March 31, 2015, the direct cost of revenues amounted to $4,328,165. For the three months ended March 31, 2015, this represented a decrease of $1,688,189 or 39%. Direct costs of revenue include contingent payments to patent enforcement legal costs, patent enforcement advisors and inventors as well as various non-contingent costs associated with enforcing the Company’s patent rights and otherwise in developing and entering into settlement and licensing agreements that generate the Company’s revenue.  For the three months ended March 31, 2016, the decline in the direct cost of revenues was associated with lower contingent counsel expenses and the termination as of September 30, 2015 of a fixed-fee engagement agreement with litigation counsel for numerous enforcement actions with trials held during the second and third quarters of 2015, offset by increased activity in Germany and France.

 

We incurred other operating expenses of $4,335,719 for the three months March 31, 2016 and $6,065,174 for the three months March 31, 2015.  For the three months ended March 31, 2016, this represented a decrease of $1,729,455 or 29%. These expenses primarily consisted of amortization of patents, general expenses, compensation to our officers, directors and employees, professional fees and consulting incurred in connection with the day-to-day operation of our business. Total other operating expenses declined for the three months ended March 31, 2016 relative to the same period in the prior year in virtually every category of expenses, with the largest decreases resulting from declines in expenses associated with patent amortization, compensation and consulting costs, offset by a patent impairment charge in the amount of $373,195 for the three months ended March 31, 2016 compared to no impairment charge for the three months ended March 31, 2015.

 

The operating expenses consisted of the following:

 

 

 

Total Other Operating Expenses

 

 

 

 

 

For the Three
Months Ended
March 31, 2016

 

 

For the Three
Months Ended
March 31, 2015

 

 

 

 

 

 

 

 

Amortization of patents(1)

 

$

2,025,899

 

$

2,598,461

 

Compensation and related taxes (2)

 

1,033,346

 

1,581,074

 

Consulting fees (3)

 

280,776

 

896,543

 

Professional fees (4)

 

405,493

 

769,615

 

Other general and administrative (5)

 

217,010

 

219,481

 

Patent Impairment (6)

 

373,195

 

-    

 

Total

 

$

4,335,719

 

$

6,065,174

 

 

Operating expenses for the three months ended March 31, 2016 and March 31, 2015 include non-cash operating expenses totaling $2,952,492 and $4,067,802, respectively. Non-cash operating expenses consisted of the following:

 

 

 

Non-Cash Operating Expenses

 

 

 

 

 

For the Three
Months Ended
March 31, 2016

 

 

For the Three
Months Ended
March 31, 2015

 

 

 

 

 

 

 

 

Amortization of patents (1)

 

$

2,025,899

 

$

2,598,461

 

Compensation and related taxes (2)

 

424,807

 

637,308

 

Consulting fees (3)

 

117,691

 

813,248

 

Professional fees (4)

 

8,535

 

8,527

 

Other general and administrative (5)

 

1,652

 

10,258

 

Patent Impairment (6)

 

373,195

 

-    

 

Total

 

$

2,951,779

 

$

4,067,802

 

 

(1)         Amortization of patents: Amortization expenses were $2,025,899 and $2,598,461 during the three months ended March 31, 2016 and 2015, respectively, a decrease of $572,562 or 22%. The decrease results from the expiration of some of the Company’s patents and lower book value associated with remaining patent portfolios following impairment charges taken over the last twelve months to some of the Company’s portfolios. When the Company acquires patents and patent rights, the Company capitalizes the cost of those assets and amortizes those costs over the remaining useful lives of the assets. All patent amortization expenses are non-cash expenses.

 

32



Table of Contents

 

(2)         Compensation expense and related taxes: Compensation expense includes cash compensation and related payroll taxes and benefits, and non-cash equity compensation expenses. For the three months ended March 31, 2016 and 2015, respectively, compensation expense and related payroll taxes were $1,033,346 and $1,581,074, a decrease of $547,728 or 35%. The decrease in compensation primarily reflects bonuses earned and paid during the three months ended March 31, 2015, the termination of certain employees in 2015 and a decrease in non-cash equity-based compensation expenses. During the three months ended March 31, 2016 and 2015, we recognized non-cash employee and board equity-based compensation of $424,807 and $637,308, respectively.  The decline in non-cash equity-based compensation expenses during the three months ended March 31, 2016 compared to the same period in 2015 resulted from the termination of options in 2015 held by former employees and board members, completion of vesting of certain option grants issued when the Company’s stock was higher and smaller new grants to employees.

 

(3)         Consulting fees: For the three months ended March 31, 2016 and 2015, we incurred consulting fees of $280,776 and $896,543, respectively, a decrease of $615,767 or 69%. Consulting fees include both cash and non-cash related consulting fees primarily for investor relations and public relations services as well as other consulting services.  The decline in consulting fees for the three months ended March 31, 2016 compared to the same period in the prior year was primarily the result of higher non-cash equity-based compensation expenses provided to a consultant during the three months ended March 31, 2015.  During the three months ended March 31, 2016 and 2015, we recognized non-cash equity-based consulting fees of $117,691 and $813,248, respectively.  For the three months ended March 31, 2015, $750,328 of the non-cash equity based consulting expenses are non-recurring.

 

(4)         Professional fees:  For the three months ended March 31, 2016 and 2015, professional fees were $405,493 and $769,615, respectively, a decrease of $364,122 or 47%.  Professional fees primarily reflect the costs of professional outside accounting fees, legal fees and audit fees.  The decrease in professional fees for the three months ended March 31, 2016 compared to the three months ended March 31, 2015 related to professional outside legal, accounting and audit fees resulting from a lower level of patent acquisition efforts during the pendency of the Uniloc merger agreement during the three months ended March 31, 2016 and the higher costs associated with closing the Fortress transaction during the three months ended March 31, 2015.  During the three months ended March 31, 2016 and 2015, we recognized non-cash equity based consulting of $8,535 and $8,527, respectively.

 

(5)         Other general and administrative expenses: For the three months ended March 31, 2016 and 2015, other general and administrative expenses were $228,636 and $219,481, respectively, an increase of $9,155 or 4%. General and administrative expenses reflect the other non-categorized operating costs of the Company and include expenses related to being a public company, rent, insurance, technology and other expenses incurred to support the operations of the Company.  The increase in general and administrative costs in the three months ended March 31, 2016 compared to the three months ended March 31, 2015 resulted from an increase in these expenses, including opening an office in Germany, in support of the continued expansion of the operations of the Company.

 

(6)         Patent impairment: Based on the Company’s determination that the fair value of two of the Company’s portfolios were less than the carrying amounts, the Company took an impairment charge in the carrying value of the two portfolios in the amount of $373,195 for the three months ended March 31, 2016. There was no impairment charge during the comparable periods in 2015.

 

Operating Income (loss)

 

We reported operating income (loss) from continuing operations of $(4,916,019) for the three months ended March 31, 2016 and operating income (loss) of $(6,299,470), for the three months ended March 31, 2015. For the three months ended March 31, 2016, this represented a reduction in the operating loss in the amount of $1,383,451. The decreased loss from operations during the three months ended March 31, 2016 relative to the same period in 2015 was primarily decreases in expenses in almost all categories, offset by lower revenue.

 

Other Income (expenses)

 

Total other income (expenses) was $(1,002,445) for the three months ended March 31, 2016 and $(970,941) for the three months ended March 31, 2015. For the three months ended March 31, 2016, this represented a decrease in other income (expenses) of $31,504.  The principal component of the increase in the other income (loss) for the three months ended March 31, 2016 was an increase in interest expenses.

 

Income Tax Benefit

 

We recognized an income tax benefit in the amount of $2,025,048 for the three months ended March 31, 2016, compared to the recognition of an income tax benefit in the amount of $2,488,839 for the three months ended March 31, 2015.

 

33



Table of Contents

 

Net Income (Loss)

 

We reported net income (loss) of $(3,893,413) for the three months ended March 31, 2016 and net income (loss) of $(4,781,572) for the three months ended March 31, 2015. For the three months ended March 31, 2016, this represented a reduction in the net loss in the amount of $888,159.

 

Non-GAAP Reconciliation

 

The Company incurred total net non-cash expenses in the amount of $1,533,763 and $2,197,909 for the three months ended March 31, 2016 and March 31, 2015, respectively. The details of those expenses and non-GAAP reconciliation of these non-cash items are set forth below:

 

 

 

Non-GAAP Reconciliation

 

 

 

For the Three
Months Ended
March 31, 2016

 

For the Three
Months Ended
March 31, 2015

 

Net income (loss)

 

(3,893,413

)

(4,781,572

)

Non-GAAP

 

 

 

 

 

Amortization of intangible assets & depreciation

 

2,025,899

 

2,598,461

 

Equity-based compensation

 

551,033

 

1,459,083

 

Impairment of Intellectual Property

 

373,195

 

-    

 

Change in Earn Out Liability

 

1,342

 

-    

 

Non-cash interest expense

 

605,690

 

627,207

 

Deferred tax benefit

 

(2,025,048

)

(2,497,100

)

Other

 

1,652

 

10,258

 

Non-GAAP net income (loss)

 

(2,359,650

)

(2,583,663

)

 

The following table sets forth the computation of basic and diluted loss per share on a Non-GAAP basis:

 

 

 

For the Three Months
Ended March 31, 2016

 

For the Three Months
Ended March 31, 2015

 

Non-GAAP net income (loss)

 

$

(2,359,650

)

$

(2,583,663

)

 

 

 

 

 

 

Denominator

 

 

 

 

 

Weighted Average Common Shares - Basic

 

14,967,141

 

13,868,811

 

Weighted Average Common Shares - Diluted

 

14,967,141

 

13,868,811

 

 

 

 

 

 

 

Non-GAAP earnings (Loss) per common share:

 

 

 

 

 

Non-GAAP income (Loss) - Basic

 

$

(0.16

)

$

(0.19

)

Non-GAAP income (Loss) - Diluted

 

$

(0.16

)

$

(0.19

)

 

Liquidity and Capital Resources

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. At March 31, 2016, the Company’s cash and cash equivalents balances totaled $1,420,390 compared to $2,555,151 at December 31, 2015.  The decrease in the cash balances of $1,134,761 resulted primarily from repayment of principal of debt to Fortress, offset by net cash provided by operations.

 

Net working capital declined by $4,978,230 to $(17,150,976) at March 31, 2016 from $(12,172,746) at December 31, 2015.  The decline in net working capital resulted primarily from a decline in current assets related to cash used to repay debt and an increase in current liabilities associated with an increase in accounts payable and accrued expenses and an increase in short-term debt classified as long-term debt in the prior reporting period.

 

34



Table of Contents

 

Cash provided (used) in operating activities was $113,169 during the three months ended March 31, 2016 and cash provided (used) in operating activities of $(1,145,055) during the three months ended March 31, 2015.

 

Cash provided (used) in investing activities was $(2,097) for the three months ended March 31, 2016 compared to $(37,147) cash used in invested activities for the three months ended March 31, 2015. The use of cash during the three months ended March 31, 2016 and the three months ended March 31, 2015 was solely related to the purchases of property, equipment and other non-patent intangible assets.

 

Cash provided (used) in financing activities was $(1,248,440) during the three months ended March 31, 2016 compared to cash provided by financing activities in the amount of $5,568,750 during the three months ended March 31, 2015.  Cash used in financing activities for the three months ended March 31, 2016 resulted from the repayment of Fortress debt and cash provided by financing activities for the three months ended March 31, 2015 resulted from the transaction entered into with Fortress on January 29, 2015, less repayment of general and patent portfolio acquisition debt, of equal or shorter terms, incurred during 2014.

 

Management believes that the balance of cash and cash equivalents of $1,420,390 at March 31, 2016, combined with licensing activity during the three months ended June 30, 2016, is sufficient to continue to fund the Company’s current operations.  However, the Company’s operations are subject to various risks and there is no assurance that changes in the operations of the Company will not require the Company to raise additional cash sooner than planned in order to continue uninterrupted operations.  In that event, the Company would seek to raise additional capital from the sale of the Company’s securities, from borrowing or from other sources.  Should the Company seek to raise capital from the issuances of its securities, such transactions would be subject to the risks of the market for the Company’s securities at the time.

 

Off-balance Sheet Arrangements

 

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholder’s equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures.

 

We maintain “disclosure controls and procedures,” as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

We conducted an evaluation of the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”), as defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act, as of March 31, 2016, the end of the period covered by this Quarterly Report on Form 10-Q. The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, due to our limited internal audit function, our Disclosure Controls were not effective as of March 31, 2016, such that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and out Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure.

 

35



Table of Contents

 

Management is in the process of determining how best to change our current system and implement a more effective system to insure that information required to be disclosed in this Quarterly Report on Form 10-Q has been recorded, processed, summarized and reported accurately. Our management acknowledges the existence of this problem, and intends to develop procedures to address them to the extent possible given limitations in financial and manpower resources. While management is working on a plan, no assurance can be made at this point that the implementation of such controls and procedures will be completed in a timely manner or that they will be adequate once implemented.

 

Changes in Internal Controls.

 

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2016 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

In the ordinary course of business, we actively pursue legal remedies to enforce our intellectual property rights and to stop unauthorized use of our technology. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, are adverse to the Company or has a material interest adverse to us.

 

In the normal course of our business of patent monetization, it is generally necessary for us to initiate litigation in order to commence the process of protecting our patent rights. Such litigation is expected to lead to a monetization event. Accordingly, we are, and in the future expect to become, a party to ongoing patent enforcement related litigation alleging infringement by various third parties of certain patented technologies owned and/or controlled by us. Litigation is commenced by and managed through the subsidiary that owns the related portfolio of patents or patent rights. In connection with our enforcement activities, we are currently involved in multiple patent infringement cases. As of March 31, 2016, the Company is involved in a total of 28 lawsuits against defendants in the following jurisdictions:

 

United States

 

 

District of Delaware

 

8

Central District of California

 

5

Eastern District of Michigan

 

1

Northern District of New York

 

1

US Court of Appeals for the Federal Circuit

 

3

 

 

 

Foreign

 

 

Germany

 

9

France

 

1

 

Item 1A.  Risk Factors.

 

Not required for smaller reporting companies.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

Certain officers of the Company have received stock grants and / or options in 3D Nanocolor Corp. (“3D Nano”), a wholly-owned subsidiary of the Company, pursuant to 3D Nano’s 2016 Equity Incentive Plan.

 

36



Table of Contents

 

Item 6. Exhibits.

 

10.1

 

Termination Agreement dated February 22, 2016 of Business Combination Agreement dated August 14, 2015

 

31.1

 

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

31.2

 

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1

 

Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2

 

Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101.ins

 

XBRL Instance Document**

101.sch

 

XBRL Taxonomy Schema Document**

101.cal

 

XBRL Taxonomy Calculation Document**

101.def

 

XBRL Taxonomy Linkbase Document**

101.lab

 

XBRL Taxonomy Label Linkbase Document**

101.pre

 

XBRL Taxonomy Presentation Linkbase Document**

 

* Furnished herewith

** Filed herein

 

37



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 12, 2016

 

 

 

 

MARATHON PATENT GROUP, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Doug Croxall

 

 

Name: Doug Croxall

 

 

Title: Chief Executive Officer and Chairman

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 

 

By:

/s/ Francis Knuettel II

 

 

Name: Francis Knuettel II

 

 

Title: Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

 

38


EX-10.1 2 a16-6690_1ex10d1.htm EX-10.1

Exhibit 10.1

 

Per Section 6.1(a) of the Business Combination Agreement, dated as of 14 August 2015 (the “Agreement”), by and among Marathon Group SA, a Luxembourg société anonyme, Uniloc Luxembourg, S.A., a Luxembourg société anonyme, Uniloc Corporation Pty. Limited, an Australian company limited by shares ACN 058 043 744 (“Uniloc Australia”), and Marathon Patent Group, Inc., a Nevada corporation (“Marathon”), the undersigned agree to terminate the Agreement.

 

 

MARATHON GROUP SA

UNILOC LUXEMBOURG S.A.

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

 

By:

 

 

Name:

Richard S. Chernicoff

Name:

Craig Etchegoyen

Title:

Director

Title:

CEO

 

 

 

 

 

 

 

 

MARATHON PATENT GROUP, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Name:

Douglas B. Croxall

 

 

Title:

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

UNILOC CORPORATION PTY LIMITED

 

 

 

 

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Name:

Craig Etchegoyen

 

 

Title:

Chairman

 

 

 


EX-31.1 3 a16-6690_1ex31d1.htm EX-31.1

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Doug Croxall, certify that:

 

1.    I have reviewed this quarterly report on Form 10-Q of Marathon Patent Group, Inc.;

 

2.    Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.    Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to  adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

 

 

 

Dated: May 12, 2016

By:

/s/ Doug Croxall

 

 

Doug Croxall

Chief Executive Officer and Chairman (Principal Executive Officer)

 


 

EX-31.2 4 a16-6690_1ex31d2.htm EX-31.2

Exhibit 31.2

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER

PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, Francis Knuettel II, certify that:

 

1.    I have reviewed this quarterly report on Form 10-Q of Marathon Patent Group, Inc.;

 

2.    Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3.    Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;

b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

 

5.   The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to  adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

 

 

 

 

Dated: May 12, 2016

By:

/s/ Francis Knuettel II

 

 

Francis Knuettel II

Chief Financial Officer (Principal Financial and Accounting Officer)

 


EX-32.1 5 a16-6690_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Marathon Patent Group, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Doug Croxall, Chief Executive Officer and Chairman (Principal Executive Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date: May 12, 2016

 

By:

/s/ Doug Croxall

 

 

 

Doug Croxall

Chief Executive Officer and Chairman (Principal
Executive Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-32.2 6 a16-6690_1ex32d2.htm EX-32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Marathon Patent Group, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Francis Knuettel II, Chief Financial Officer, Secretary and Director (Principal Financial Officer) of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

 

Date: March 12, 2016

 

By:

/s/ Francis Knuettel II

 

 

 

Francis Knuettel II

Chief Financial Officer (Principal Financial and
Accounting Officer)

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.INS 7 mara-20160331.xml XBRL INSTANCE DOCUMENT 0001507605 mara:TLICommunicationsLLCMember mara:InterestsSaleAgreementMember 2014-09-01 2014-09-30 0001507605 mara:CloudingCorpMember mara:InterestsSaleAgreementMember 2014-08-29 2014-08-29 0001507605 us-gaap:CommonStockMember 2015-04-01 2015-06-30 0001507605 us-gaap:CommonStockMember 2014-10-01 2014-12-31 0001507605 us-gaap:CommonStockMember 2014-07-18 2014-07-18 0001507605 us-gaap:CommonStockMember 2014-07-01 2014-09-30 0001507605 us-gaap:SeriesBPreferredStockMember mara:GRQMember 2014-10-06 2014-10-06 0001507605 us-gaap:RestrictedStockMember 2014-09-16 2014-09-16 0001507605 us-gaap:RestrictedStockMember 2014-04-22 2014-04-22 0001507605 mara:MelechdavidIncMember us-gaap:CommonStockMember 2015-12-09 2015-12-09 0001507605 mara:DominionHarborGroupLlcMember us-gaap:CommonStockMember 2015-11-04 2015-11-04 0001507605 mara:AlexPartnersLlcAndDelMarConsultingGroupIncMember us-gaap:CommonStockMember 2015-09-21 2015-09-21 0001507605 us-gaap:CommonStockMember 2015-03-13 2015-03-13 0001507605 us-gaap:WarrantMember mara:SpangenbergLockupAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:PreferredStockMember mara:SpangenbergLockupAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:CommonStockMember mara:SpangenbergLockupAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:CommonStockMember 2015-01-29 2015-01-29 0001507605 us-gaap:CommonStockMember 2014-06-02 2014-06-02 0001507605 us-gaap:CommonStockMember 2013-06-24 2013-06-24 0001507605 2013-06-24 2013-06-24 0001507605 us-gaap:MinimumMember 2013-05-31 2013-05-31 0001507605 us-gaap:MaximumMember 2013-05-31 2013-05-31 0001507605 mara:MelechdavidIncMember us-gaap:CommonStockMember 2015-12-09 0001507605 mara:DominionHarborGroupLlcMember us-gaap:CommonStockMember 2015-11-04 0001507605 mara:AlexPartnersLlcAndDelMarConsultingGroupIncMember us-gaap:CommonStockMember 2015-09-21 0001507605 us-gaap:RestrictedStockMember 2014-09-30 0001507605 us-gaap:RestrictedStockMember 2014-06-30 0001507605 us-gaap:PerformanceSharesMember us-gaap:MinimumMember 2015-04-07 2015-04-07 0001507605 mara:TimeBasedSharesMember us-gaap:MinimumMember 2015-04-07 2015-04-07 0001507605 mara:CommonStockOptionMember 2016-03-31 0001507605 mara:CommonStockOptionMember 2015-12-31 0001507605 2015-09-16 2015-09-16 0001507605 us-gaap:StockOptionMember 2015-04-07 2015-04-07 0001507605 us-gaap:StockOptionMember 2014-08-29 2014-08-29 0001507605 2012-08-01 0001507605 mara:CloudingCorpMember mara:PatentPurchaseAgreementMember 2014-08-29 0001507605 us-gaap:WarrantMember 2015-01-01 2015-03-31 0001507605 2014-05-01 0001507605 mara:TLICommunicationsLLCMember 2016-01-01 2016-03-31 0001507605 mara:SeleneCommunicationTechnologiesMember 2016-01-01 2016-03-31 0001507605 mara:MedtechEntitiesMember 2016-01-01 2016-03-31 0001507605 mara:CloudingCorpMember 2016-01-01 2016-03-31 0001507605 us-gaap:RestrictedStockMember 2014-09-30 2014-09-30 0001507605 us-gaap:RestrictedStockMember 2014-06-30 2014-06-30 0001507605 mara:FortressMember 2016-01-01 2016-03-31 0001507605 mara:SarifBiomedical1Member 2015-01-01 2015-03-31 0001507605 mara:OrthophoenixLlcMember 2015-01-01 2015-03-31 0001507605 mara:MedtechAndOrthophoenixMember 2015-01-01 2015-03-31 0001507605 mara:IPLiquidityMember 2015-01-01 2015-03-31 0001507605 mara:DynamicAdvancesMember 2015-01-01 2015-03-31 0001507605 mara:RangeTwoMember mara:AcquisitionsAgreementMember us-gaap:MinimumMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:RangeTwoMember mara:AcquisitionsAgreementMember us-gaap:MaximumMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:RangeThreeMember mara:AcquisitionsAgreementMember us-gaap:MinimumMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:RangeOneMember mara:AcquisitionsAgreementMember us-gaap:MaximumMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:AcquisitionsAgreementMember us-gaap:MaximumMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 us-gaap:WarrantMember 2014-04-24 2014-04-24 0001507605 2014-10-16 2014-10-16 0001507605 mara:GRQMember us-gaap:SeriesBPreferredStockMember 2015-10-20 0001507605 mara:IPLiquidityMember us-gaap:ConvertiblePreferredStockMember 2014-05-02 0001507605 mara:DynamicAdvancesMember us-gaap:ConvertiblePreferredStockMember 2014-05-02 0001507605 us-gaap:SeriesBPreferredStockMember 2014-05-01 0001507605 us-gaap:SeriesBPreferredStockMember 2016-03-31 0001507605 us-gaap:SeriesBPreferredStockMember 2015-12-31 0001507605 mara:SarifBiomedical1Member 2016-01-01 2016-03-31 0001507605 mara:IPLiquidityMember 2015-04-01 2015-04-01 0001507605 mara:MedtechEntitiesMember 2014-10-13 2014-10-13 0001507605 mara:CloudingCorpMember mara:InterestsSaleAgreementMember 2014-09-30 2014-09-30 0001507605 mara:CommonStockWarrantMember 2014-05-01 2014-05-01 0001507605 us-gaap:SubsequentEventMember mara:SettlementAgreementMember 2016-04-18 2016-04-18 0001507605 mara:SignalIpIncMember 2016-01-01 2016-03-31 0001507605 mara:SignalIpInc1Member 2016-01-01 2016-03-31 0001507605 mara:VantagePointTechnologyIncMember 2015-01-01 2015-03-31 0001507605 mara:VantagePointTechnologyInc1Member 2015-01-01 2015-03-31 0001507605 mara:TlifMember 2015-01-01 2015-03-31 0001507605 mara:SignalIpIncMember 2015-01-01 2015-03-31 0001507605 mara:SarifBiomedicalLlcMember 2015-01-01 2015-03-31 0001507605 us-gaap:StockOptionMember 2015-01-20 2015-01-20 0001507605 us-gaap:StockOptionMember 2014-10-31 2014-10-31 0001507605 us-gaap:StockOptionMember mara:ExistingEmployeesMember 2015-10-14 2015-10-14 0001507605 us-gaap:StockOptionMember mara:ConsultantsMember 2015-10-14 2015-10-14 0001507605 us-gaap:StockOptionMember 2015-09-16 2015-09-16 0001507605 us-gaap:PerformanceSharesMember 2015-04-07 2015-04-07 0001507605 mara:TimeBasedSharesMember 2015-04-07 2015-04-07 0001507605 us-gaap:StockOptionMember 2015-03-18 2015-03-18 0001507605 us-gaap:StockOptionMember 2015-03-06 2015-03-06 0001507605 us-gaap:StockOptionMember 2015-02-05 2015-02-05 0001507605 2015-01-20 2015-01-20 0001507605 mara:StockOption4Member 2014-10-31 2014-10-31 0001507605 mara:StockOption3Member 2014-10-31 2014-10-31 0001507605 mara:StockOption2Member 2014-10-31 2014-10-31 0001507605 2014-10-31 2014-10-31 0001507605 us-gaap:StockOptionMember 2014-09-16 2014-09-16 0001507605 mara:StockOption3Member 2014-05-15 2014-05-15 0001507605 us-gaap:StockOptionMember 2014-04-15 2014-04-15 0001507605 us-gaap:WarrantMember 2015-12-31 0001507605 mara:DynamicAdvancesMember 2016-03-31 0001507605 mara:SarifBiomedical1Member 2014-09-30 0001507605 mara:IPLiquidityMember 2014-09-30 0001507605 mara:DynamicAdvancesMember 2016-01-01 2016-03-31 0001507605 mara:InitialNoteMember mara:FortressSecuritiesAgreementMember 2015-01-29 2015-01-29 0001507605 mara:SarifBiomedical1Member 2014-07-01 2014-09-30 0001507605 mara:IPLiquidityMember 2014-07-01 2014-09-30 0001507605 mara:InitialNoteMember mara:FortressSecuritiesAgreementMember mara:TwelveMonthsLondonInterbankOfferedRateMember 2016-03-31 0001507605 us-gaap:ConvertibleDebtMember 2013-10-09 0001507605 mara:AdditionalObligationUponMilestoneAchievementMember mara:SeniorSecuredNotesMember mara:FortressSecuritiesAgreementMember 2015-01-29 0001507605 mara:SeniorSecuredNotesMember mara:FortressSecuritiesAgreementMember 2015-01-29 0001507605 mara:InitialNoteMember mara:FortressSecuritiesAgreementMember 2015-01-29 0001507605 mara:InitialNoteMember mara:FortressSecuritiesAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-01-29 2015-01-29 0001507605 mara:GRQMember us-gaap:SeriesBPreferredStockMember 2015-10-20 2015-10-20 0001507605 us-gaap:SeriesBPreferredStockMember mara:GRQMember 2015-09-01 2015-09-30 0001507605 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2016-01-01 2016-03-31 0001507605 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2015-01-01 2015-12-31 0001507605 2013-07-18 0001507605 2011-12-07 0001507605 2011-12-06 0001507605 mara:FortressSecuritiesAgreementMember 2015-01-29 0001507605 us-gaap:WarrantMember 2014-04-20 0001507605 us-gaap:WarrantMember 2014-04-19 0001507605 2015-03-31 0001507605 2014-12-31 0001507605 mara:CloudingCorpMember 2014-08-31 0001507605 mara:DynamicAdvancesMember 2014-05-02 0001507605 mara:CloudingCorpMember 2014-08-29 2014-08-29 0001507605 mara:TLICommunicationsLLCMember mara:InterestsSaleAgreementMember 2014-09-30 0001507605 mara:CloudingCorpMember mara:InterestsSaleAgreementMember 2014-08-29 0001507605 mara:SeleneCommunicationTechnologies1Member 2014-06-17 0001507605 mara:CyberFoneMember 2015-01-01 2015-09-30 0001507605 mara:DelphiMember 2013-12-01 2013-12-31 0001507605 mara:FourPatentsMember 2013-11-01 2013-11-30 0001507605 mara:FourteenUsPatentsMember 2013-09-01 2013-09-30 0001507605 mara:SiemensTechnologyMember 2013-06-01 2013-06-30 0001507605 mara:RelayIPMember 2013-04-01 2013-04-30 0001507605 mara:CyberFoneMember 2013-04-01 2013-04-30 0001507605 us-gaap:SeriesBPreferredStockMember 2014-05-02 2014-05-02 0001507605 us-gaap:PatentsMember us-gaap:MinimumMember 2016-01-01 2016-03-31 0001507605 us-gaap:PatentsMember us-gaap:MaximumMember 2016-01-01 2016-03-31 0001507605 mara:WebsiteMember 2016-01-01 2016-03-31 0001507605 mara:CommonStockOptionMember 2015-01-01 2015-12-31 0001507605 mara:CommonStockWarrantMember 2015-01-01 2015-03-31 0001507605 mara:CommonStockWarrantMember 2016-03-10 2016-03-10 0001507605 mara:CommonStockWarrantMember 2016-03-11 2016-03-11 0001507605 mara:CommonStockWarrantMember 2015-01-01 2015-12-31 0001507605 mara:CommonStockWarrantMember 2016-01-01 2016-03-31 0001507605 us-gaap:CommonStockMember 2015-01-01 2015-03-31 0001507605 2014-11-19 0001507605 mara:AcquisitionsAgreementMember us-gaap:MinimumMember us-gaap:ConvertiblePreferredStockMember mara:RegistrationRightsAgreementMember 2014-11-02 0001507605 us-gaap:StockOptionMember mara:ExistingEmployeesMember 2015-10-14 0001507605 us-gaap:StockOptionMember mara:ConsultantsMember 2015-10-14 0001507605 us-gaap:SeriesBPreferredStockMember mara:GRQMember 2015-09-17 0001507605 us-gaap:StockOptionMember 2015-09-16 0001507605 2015-04-07 0001507605 us-gaap:StockOptionMember 2015-03-18 0001507605 us-gaap:StockOptionMember 2015-03-06 0001507605 us-gaap:StockOptionMember 2015-02-05 0001507605 mara:StockOption4Member 2014-10-31 0001507605 mara:StockOption3Member 2014-10-31 0001507605 us-gaap:StockOptionMember 2014-09-16 0001507605 us-gaap:StockOptionMember 2014-06-15 0001507605 us-gaap:StockOptionMember 2014-04-15 0001507605 us-gaap:StockOptionMember 2014-10-31 0001507605 mara:StockOption2Member 2014-10-31 0001507605 us-gaap:StockOptionMember 2014-08-29 0001507605 mara:StockOption3Member 2014-05-15 0001507605 us-gaap:StockOptionMember mara:ExistingEmployeesMember 2014-05-14 0001507605 mara:StockOption2Member 2014-05-14 0001507605 us-gaap:StockOptionMember 2015-04-07 0001507605 us-gaap:SeriesBPreferredStockMember mara:GRQMember 2014-09-17 0001507605 2012-10-01 2012-10-01 0001507605 mara:TLICommunicationsLLCMember mara:InterestsSaleAgreementMember 2014-09-19 2014-09-19 0001507605 mara:CloudingCorpMember mara:PatentPurchaseAgreementMember 2014-08-29 2014-08-29 0001507605 mara:RangeTwoMember mara:AcquisitionsAgreementMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:RangeThreeMember mara:AcquisitionsAgreementMember mara:PayProceedsAgreementMember 2014-05-02 2014-05-02 0001507605 mara:AcquisitionsAgreementMember 2014-05-02 2014-05-02 0001507605 us-gaap:WarrantMember mara:FortressSecuritiesAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:MinimumMember mara:SpangenbergLockupAgreementMember 2015-01-29 2015-01-29 0001507605 mara:MedtechEntitiesMember 2014-10-13 0001507605 mara:TLICommunicationsLLCMember 2014-09-19 0001507605 mara:SarifBiomedical1Member 2014-05-02 0001507605 mara:IPLiquidityMember 2014-05-02 0001507605 mara:DynamicAdvancesMember 2013-05-02 0001507605 mara:CommonStockOptionMember 2016-01-01 2016-03-31 0001507605 us-gaap:StockOptionMember 2014-06-15 2014-06-15 0001507605 us-gaap:StockOptionMember mara:ExistingEmployeesMember 2014-05-14 2014-05-14 0001507605 mara:StockOption2Member mara:ConsultantsMember 2014-05-14 2014-05-14 0001507605 mara:CommonStockWarrantMember 2012-01-26 2012-01-26 0001507605 mara:FortressSecuritiesAgreementMember 2014-01-01 2014-12-31 0001507605 mara:AcquisitionsAgreementMember us-gaap:MaximumMember mara:RegistrationRightsAgreementMember 2014-11-02 2014-11-02 0001507605 mara:SeleneCommunicationTechnologies1Member 2014-06-17 2014-06-17 0001507605 us-gaap:CustomerConcentrationRiskMember 2016-03-31 0001507605 us-gaap:CreditConcentrationRiskMember 2016-03-31 0001507605 us-gaap:CreditConcentrationRiskMember 2015-12-31 0001507605 us-gaap:CustomerConcentrationRiskMember 2015-03-31 0001507605 mara:SeniorSecuredNotesMember mara:FortressSecuritiesAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:MinimumMember mara:FortressSecuritiesAgreementMember 2014-01-01 2014-12-31 0001507605 mara:DBDCreditFundingLLCMember mara:FortressSecuritiesAgreementMember 2015-01-29 2015-01-29 0001507605 2014-05-01 2014-05-01 0001507605 mara:WebPageContentTranslatorAndDeviceToDeviceTransferSystemMember 2016-01-01 2016-03-31 0001507605 mara:TelephonyAndDataTransactionsMember 2016-01-01 2016-03-31 0001507605 mara:TelecommunicationsMember 2016-01-01 2016-03-31 0001507605 mara:PharmaceuticalsTirePressureSystemsMember 2016-01-01 2016-03-31 0001507605 mara:NetworkAndDataManagementMember 2016-01-01 2016-03-31 0001507605 mara:NaturalLanguageInterfaceMember 2016-01-01 2016-03-31 0001507605 mara:MulticastingMember 2016-01-01 2016-03-31 0001507605 mara:MicrosurgeryEquipmentMember 2016-01-01 2016-03-31 0001507605 mara:MedicalTechnologyMember 2016-01-01 2016-03-31 0001507605 mara:ManufacturingSchedulesUsingAdaptiveLearningMember 2016-01-01 2016-03-31 0001507605 mara:ComputerNetworkingAndOperationsMember 2016-01-01 2016-03-31 0001507605 mara:CommunicationsMember 2016-01-01 2016-03-31 0001507605 mara:CommunicationAndPBXEquipmentMember 2016-01-01 2016-03-31 0001507605 mara:CentrifugalCommunicationsMember 2016-01-01 2016-03-31 0001507605 mara:AutomotiveOneMember 2016-01-01 2016-03-31 0001507605 mara:AutomotiveMember 2016-01-01 2016-03-31 0001507605 mara:AsynchronousCommunicationsMember 2016-01-01 2016-03-31 0001507605 mara:InitialNoteMember mara:FortressSecuritiesAgreementMember 2015-01-31 2015-01-31 0001507605 mara:IPLiquidityMember 2016-01-01 2016-03-31 0001507605 mara:DynamicAdvancesMember 2014-05-02 2014-05-02 0001507605 mara:MedtechEntitiesMember mara:InterestsSaleAgreementMember 2014-10-13 2014-10-13 0001507605 2015-01-01 2015-03-31 0001507605 mara:CommonStockWarrantMember 2016-03-31 0001507605 mara:CommonStockWarrantMember 2015-03-31 0001507605 mara:SarifBiomedical1Member 2014-05-02 2014-05-02 0001507605 mara:IPLiquidityMember 2014-05-02 2014-05-02 0001507605 mara:DynamicAdvancesMember 2013-05-02 2013-05-02 0001507605 2016-03-31 0001507605 2015-12-31 0001507605 mara:FortressSecuritiesAgreementMember 2015-01-29 2015-01-29 0001507605 us-gaap:WarrantMember 2015-01-29 2015-01-29 0001507605 us-gaap:WarrantMember 2014-10-16 2014-10-16 0001507605 us-gaap:WarrantMember 2014-05-01 2014-05-01 0001507605 2016-05-06 0001507605 2016-01-01 2016-03-31 mara:installment mara:period mara:item mara:patent mara:agreement xbrli:pure mara:payment iso4217:USD iso4217:USD xbrli:shares xbrli:shares false --12-31 Q1 2016 2016-03-31 10-Q 0001507605 14967141 Yes Smaller Reporting Company Marathon Patent Group, Inc. 3.75 8.25 7.44 5000000 1748311 1443457 359960 2 2 2 4.27 4.27 0.42 0.54 0.41 1000000 750000 2850000 2850000 300000 $2,850,000 $300,000 $2,850,000 6425 1000000 0.0275 11/14/15 Expired 03/10/14 03/13/18 09/15/16 05/05/18 Expired 04/27/20 Expired Expired Expired Expired Expired Expired 06/17/17 Expired 09/17/21 0.11 -1342 2335116 1934419 -161984 -76463 07/17/17 08/27/22 08/06/22 11/16/23 01/22/18 11/28/21 03/09/18 07/18/24 07/29/29 Expired Expired 03/06/23 03/29/29 07/26/20 06/17/17 06/07/20 08/19/23 42th month of the lease 400000 P12M 1425167 1224817 09/09/16 09/25/17 12/01/15 03/13/18 09/15/15 11/23/20 12/21/16 11/17/23 06/01/18 Expired Expired 10/02/17 10/05/21 04/09/17 06/17/17 01/31/17 08/11/22 15000000 15000000 115000 730945 754421 5 1 1 2 2 3 320 2 10 7 3 17 3 31 4 131 4 1 4 61 3 6 35 5 3 4 50 50 50 50 2122560 1216541 3339100 4831 3900 1.00 1.00 1.00 1.00 1.00 -63840 0.46 0.05 0.0499 3414 3414 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Prepaid Expenses, Bonds Posted and Other Current Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses and other current assets of $146,336 and $338,598 at March&nbsp;31, 2016 and December&nbsp;31, 2015, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In addition, the Company had outstanding litigation bonds in the amount of $1,443,457 and $1,748,311 at March&nbsp;31, 2016 and December&nbsp;31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to some of the Company&#x2019;s patents in German courts. The difference in the balance of the litigation bonds at March&nbsp;31, 2016 compared to December&nbsp;31, 2015 is attributable to $55,106 in currency translation impact and the return of $359,960 in bonds related to the litigation against Schrader and TRW, which were resolved in the fourth quarter of 2015.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 6250000 3 0.50 0.40 0.50 0.50 P60D P5M 0.93 1000000 P1Y <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td colspan="6" valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:48.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:22.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:21.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,900,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92% </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,750,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>275,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sarif Biomedical, LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>225,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TLIF, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000&nbsp; </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2% </td> </tr> <tr> <td colspan="4" valign="top" style="width:35.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="6" valign="top" style="width:36.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87% </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.50 0.02083 0.50 0.25 3 3 36 36 36 36 12 24 12 24 24 24 12 12 12 12 -6 24 24 0.10 1 5000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:29.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Subsidiary</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Number&nbsp;of</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Patents</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Earliest</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Median</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Latest</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Subject&nbsp;Matter</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Bismarck IP Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/15/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/15/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">01/22/18</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Communication and PBX equipment</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Clouding Corp.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10/05/21</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/29/29</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Network and data management</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">CRFD Research,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/17/21</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/11/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/19/23</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Web page&nbsp;content translator </font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cyberfone Systems, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">01/31/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/07/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Telephony and data transactions</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Dynamic Advances, LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10/02/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/06/23</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Natural language interface</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">E2E Processing,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">04/27/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/17/23</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/18/24</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Manufacturing schedules using adaptive learning</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Hybrid Sequence IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/14/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/09/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/17/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Asynchronous communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">IP Liquidity Ventures, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">04/09/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/26/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pharmaceuticals / tire pressure systems</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Loopback Technologies,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/25/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/27/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Automotive</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Medtech Group Acquisition Corp.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/01/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/29/29</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Medical technology</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Relay IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Multicasting</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sampo IP, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/13/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/13/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/16/23</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Centrifugal communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sarif Biomedical LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Microsurgery equipment</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Selene Communication Technologies, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">05/05/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/23/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/28/21</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/10/14</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">12/01/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/06/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Automotive</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TLI Communications, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Telecommunications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">12/21/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/09/18</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer networking and operations</font></p> </td> </tr> <tr> <td valign="bottom" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Median</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/25/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 2021308 P5Y 318679 5000 0 23334 3.25 4.125 2.00 2021308 P10M13D P7Y1M10D P6Y11M5D P7M17D P6Y3M22D 6534825 8832010 136842 153112 136842 153112 67052 77653 -1265812 -1018385 P3Y P15Y P1Y 43217513 43774961 375750 375750 375750 375750 2598461 2025899 0 373195 47227593 45622612 4778902 3163295 42448691 42459317 782000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The unaudited consolidated&nbsp;financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#x201C;US GAAP&#x201D;) and present the consolidated financial statements of the Company&nbsp;and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company&#x2019;s consolidated financial position as of March&nbsp;31, 2016, and the results of operations and cash flows for the three months ended March&nbsp;31, 2016 have been included. The results of operations for the three months ended March&nbsp;31, 2016 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December&nbsp;31, 2015, which are contained in Form&nbsp;10-K as filed with the Securities and Exchange Commission (&#x201C;SEC&#x201D;) on March&nbsp;30, 2016. The consolidated balance sheet as of December&nbsp;31, 2015 was derived from those financial statements.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 2013-04-01 2013-04-01 2013-06-01 2013-09-01 2013-11-01 2013-12-01 2013-04-01 100000 60000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 3 &#x2014; ACQUISITIONS</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Dynamic Advances,&nbsp;IP Liquidity and Sarif Biomedical</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;2, 2014, the Company completed the acquisition of certain ownership rights (the &#x201C;Acquired Intellectual Property&#x201D;) from TechDev, Granicus IP, LLC (&#x201C;Granicus&#x201D;) and SFF pursuant to the terms of three purchase agreements between: (i)&nbsp;the Company, TechDev,&nbsp;SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii)&nbsp;the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii)&nbsp;the Company, TechDev,&nbsp;&nbsp;SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company (the &#x201C;DA Agreement,&#x201D; the &#x201C;IP Liquidity Agreement&#x201D; and the &#x201C;Sarif Agreement,&#x201D; respectively and the collective transactions, the &#x201C;Acquisitions&#x201D;).</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Dynamic Advances</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i)&nbsp;two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September&nbsp;30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June&nbsp;30, 2014; and (ii)&nbsp;195,500 shares of the Company&#x2019;s Series&nbsp;B Convertible Preferred Stock.&nbsp;&nbsp;Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Dynamic Advances, LLC holds exclusive license to monetize certain patents owned by a third party.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;2, 2014, the Company issued TechDev and SFF a promissory note in order to evidence the second cash payment due under the terms of the DA Agreement in the amount of $2,375,000 due on or before September&nbsp;30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company&#x2019;s payment pursuant to the terms of the DA Agreement were not made on or before June&nbsp;30, 2014. The promissory note matured on September&nbsp;30, 2014; effective September&nbsp;30, 2014, TechDev and SFF extended the maturity to March&nbsp;31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October&nbsp;10, 2014 and the promissory note was repaid on April&nbsp;1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June&nbsp;30, 2014, the Company included in the consideration paid for Dynamic Advances the promissory note balance of $2,850,000.&nbsp;&nbsp;Further, the Company had the Series&nbsp;B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series&nbsp;B Convertible Preferred Stock, that it was on par with the value of the Company&#x2019;s Common Stock. The total amount of consideration paid by the Company for Dynamic Advances, including capitalized costs associated with the purchase, was $6,653,078.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.&nbsp;&nbsp;Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">IP Liquidity</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i)&nbsp;two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September&nbsp;30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June&nbsp;30, 2014; and (ii)&nbsp;195,500 shares of the Company&#x2019;s Series&nbsp;B Convertible Preferred Stock.&nbsp;&nbsp;Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.&nbsp;&nbsp;IP Liquidity Ventures, LLC holds contract rights to the proceeds from the monetization of certain patents owned by a number of third parties.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;2, 2014, the Company issued Granicus and SFF a promissory note in order to evidence the second cash payment due under the terms of the IP Liquidity Agreement in the amount of $2,375,000 due on or before September&nbsp;30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company&#x2019;s payment pursuant to the terms of the IP Liquidity Agreement were not made on or before June&nbsp;30, 2014. The promissory note matured on September&nbsp;30, 2014; effective September&nbsp;30, 2014, Granicus and SFF extended the maturity to March&nbsp;31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October&nbsp;10, 2014 and the promissory note was repaid on April&nbsp;1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June&nbsp;30, 2014, the Company included in the consideration paid for IP Liquidity the promissory note balance of $2,850,000.&nbsp;&nbsp;Further, the Company had the Series&nbsp;B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series&nbsp;B Convertible Preferred Stock that it was on par with the value of the Company&#x2019;s Common Stock. The total amount of consideration paid by the Company for IP Liquidity, including capitalized costs associated with the purchase, was $6,653,078.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.&nbsp;&nbsp;Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Sarif Biomedical</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment due on or before September&nbsp;30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June&nbsp;30, 2014.&nbsp;&nbsp;Under the terms of the Sarif Agreement, TechDev is entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Sarif Biomedical, LLC holds ownership rights to certain patents.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;2, 2014, the Company issued TechDev a promissory note in order to evidence the second cash payment due under the terms of the Sarif Agreement in the amount of $250,000 due on or before September&nbsp;30, 2014, with such amount due under the terms of the promissory note being subject to increase to $300,000 if the Company&#x2019;s payment pursuant to the terms of the Sarif Agreement were not made on or before September&nbsp;30, 2014. The promissory note matured on September&nbsp;30, 2014; effective September&nbsp;30, 2014, TechDev extended the maturity to March&nbsp;31, 2015 in return for a payment of $26,250, payable within thirty days. The payment for this extension of the maturity date was made on October&nbsp;10, 2014 and the promissory note was repaid on February&nbsp;24, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June&nbsp;30, 2014, the Company included in the consideration paid for Dynamic Advances the higher principal amount of the promissory note. The total amount of consideration paid by the Company for Sarif Biomedical, including capitalized costs associated with the purchase, was $552,024.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Dynamic Advances,&nbsp;IP Liquidity and Sarif Biomedical</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement (the &#x201C;IP Assets&#x201D;).&nbsp;&nbsp;Under the terms of the Pay Proceeds Agreement, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $10,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the net proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the net proceeds of such recoveries to the sellers.&nbsp;&nbsp;In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to a Registration Rights Agreement with the&nbsp;sellers (the &#x201C;Acquisition Registration Rights Agreement&#x201D;), the Company agreed to file a &#x201C;resale&#x201D; registration statement with the SEC covering at least 10% of the registrable shares of the Company&#x2019;s Series&nbsp;B Convertible Preferred Stock issued to the sellers under the terms of the DA Agreement and the IP Liquidity Agreement, at any time on or after November&nbsp;2, 2014 upon receipt of a written demand from the sellers which describes the amount and type of securities to be included in the registration and the intended method of distribution thereof.&nbsp;&nbsp;The Company shall not be required to file more than three such registration statements not more than 60 days after the receipt of each such written demand from the sellers.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TechDev and Mr.&nbsp;Erich Spangenberg (the founder of IP Nav) and his spouse Audrey Spangenberg have jointly filed a Schedule 13G and are deemed to be affiliates of the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Selene Communication Technologies</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;17, 2014, Selene Communication Technologies Acquisition LLC (&#x201C;Acquisition LLC&#x201D;), a Delaware limited liability company and newly formed wholly owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (&#x201C;Selene&#x201D;).</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Selene owns a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries.&nbsp;&nbsp;IP Nav provides patent monetization and support services under an existing agreement with Selene.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the terms of the Selene Interests Sale Agreement, Selene merged with and into Acquisition LLC with Selene surviving the merger as the wholly owned subsidiary of the Company.&nbsp;&nbsp;The Company (i)&nbsp;issued 100,000 shares of common stock to the Selene Sellers and (ii)&nbsp;paid the Selene Sellers $50,000 cash.&nbsp;&nbsp;The Company valued these common shares at the fair market value on the date of grant at $9.80 per share or $980,000. The transaction resulted in a business combination and caused Selene to become a wholly-owned subsidiary of the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounted for the acquisition as a business combination in accordance with ASC 805 &#x201C;Business Combinations&#x201D; in which the Company is the acquirer for accounting purposes and Selene is the acquired company.&nbsp; The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>990,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net working capital</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,030,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Clouding Corp.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On August&nbsp;29, 2014, the Company entered into a patent purchase agreement (the &#x201C;Clouding Agreement&#x201D;) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201C;Clouding&#x201D;) and Clouding IP, LLC, a Delaware limited liability company (&#x201C;Clouding IP&#x201D;), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. Clouding owns patents related to network and data management technology.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company paid Clouding IP (i)&nbsp;$1.4 million in cash, (ii)&nbsp;$1.0 million in the form of a promissory note issued by the Company that would have matured on October&nbsp;31, 2014, (iii)&nbsp;25,000 shares of its restricted common stock valued at $281,000 and (iv)&nbsp;fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses) in excess of $4.0 million in net revenues that the Company makes with respect to the patents purchased from Clouding IP. The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $11.24 per share or $281,000 and the promissory note was paid in full prior to October&nbsp;31, 2014. The revenue share under item (iv)&nbsp;above was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value. The Company booked a payable to the sellers pursuant to the earn out liability in the amount of $2,148,000 at September&nbsp;30, 2014, based on license agreements entered into during the quarter. No further amount is owed until the Company generates additional revenue, if any, from the Clouding patents.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounted for the acquisition as a business combination in accordance with ASC 805 &#x201C;Business Combinations&#x201D;. The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,796,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total consideration paid of the following:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cash</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,400,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Promissory Note</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,000,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Common Stock</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Earn Out Liability</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,115,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,796,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Historical financial statements of Clouding IP and the pro forma condensed combined consolidated financial statements (both carve-out of certain operations of Clouding IP) can be found on the Form&nbsp;8-K/A filed with the SEC on November&nbsp;12, 2014.&nbsp;&nbsp;The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">TLI Communications LLC</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;19, 2014, TLI Acquisition Corp (&#x201C;TLIA&#x201D;), a Virginia corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the membership interests of TLI Communications LLC (&#x201C;TLIC&#x201D;), a Delaware limited liability company. TLIC owns a patent in the telecommunications field.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the terms of the TLIC Interests Sale Agreement, TLIC merged with and into TLIA with TLIC surviving the merger as the wholly-owned subsidiary of the Company.&nbsp;&nbsp;The Company (i)&nbsp;agreed to issue 60,000 shares of Common Stock to the sellers of TLIC (&#x201C;TLIC Sellers&#x201D;), (ii)&nbsp;paid the TLIC Sellers $350,000 cash and (iii)&nbsp;agreed to pay the TLIC Sellers a fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses and the cash portion of the acquisition consideration) that the Company makes with respect to the patent purchased pursuant to the acquisition of TLIC.&nbsp;&nbsp;The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $13.63 per share or $818,000. The cash portion of the consideration was outstanding at September&nbsp;30, 2014 and was subsequently paid in October 2014. The transaction resulted in a business combination and caused TIC to become a wholly-owned subsidiary of the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounted for the acquisition as a business combination in accordance with ASC 805 &#x201C;Business Combinations&#x201D;. The Company is the acquirer for accounting purposes and TLIC is the acquired company.&nbsp; The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>940,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>228,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,168,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Medtech Entities</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;13, 2014, Medtech Group Acquisition Corp (&#x201C;Medtech Corp.&#x201D;), a Texas corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the equity or membership interests of OrthoPhoenix, LLC (&#x201C;OrthoPhoenix&#x201D;), a Delaware limited liability company, TLIF, LLC (&#x201C;TLIF&#x201D;) and MedTech Development Deutschland GmbH (&#x201C;MedTech GmbH&#x201D; and along with OrthoPhoenix and TLIF, the &#x201C;Medtech Entities&#x201D;) from MedTech Development, LLC (&#x201C;MedTech Development&#x201D;). The Medtech Entities own patents in the medical technology field.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the terms of the Interest Sale Agreement between MedTech Development, Medtech Corp. and the Medtech Entities, the Company (i)&nbsp;paid MedTech Development $1,000,000 cash and (ii)&nbsp;issue a Promissory Note to MedTech Development in the amount of $9,000,000 and (iii)&nbsp;assumed existing debt payable to Medtronics,&nbsp;Inc.&nbsp;&nbsp;The assumed debt payable to Medtronics was renegotiated, as a result of which, the outstanding amount was $6.25 million prior to any repayment by the Company. The debt was due in installments through July&nbsp;20, 2015; in the event that the Company paid the total amount due by June&nbsp;30, 2015, the Company would receive a reduction in the remaining principal owed by the Company in the amount of $750,000. The transaction resulted in a business combination and caused the Medtech Entities to become wholly-owned subsidiaries of the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounted for the acquisition as a business combination in accordance with ASC 805 &#x201C;Business Combinations&#x201D;. The Company is the acquirer for accounting purposes and TLIC is the acquired company.&nbsp; The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,800,000&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,700,000&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,500,000&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Historical financial statements of the Medtech Entities and the pro forma condensed combined consolidated financial statements can be found on the Form&nbsp;8-K/A filed with the SEC on December&nbsp;24, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 9.80 11.24 13.63 15796000 6653078 281000 1000000 13115000 1342 250000000 250000000 250000000 33646 103049 3281238 3213177 37000 1030000 15796000 1168000 15500000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Accounting for Acquisitions</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.&nbsp;&nbsp;With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 &#x2014; Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.&nbsp;&nbsp;The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Organization</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Our business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company.&nbsp;&nbsp;We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies.&nbsp;&nbsp;Part&nbsp;of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets.&nbsp;&nbsp;Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights.&nbsp;&nbsp;We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances.&nbsp;&nbsp;Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Marathon Patent Group,&nbsp;Inc. (the &#x201C;Company&#x201D;) was incorporated in the State of Nevada on February&nbsp;23, 2010 under the name Verve Ventures,&nbsp;Inc. On December&nbsp;7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June&nbsp;2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October&nbsp;2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company&#x2019;s name was changed to Marathon Patent Group,&nbsp;Inc.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On December&nbsp;7, 2011, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada in order to change its name to &#x201C;American Strategic Minerals Corporation&#x201D; from &#x201C;Verve Ventures,&nbsp;Inc.&#x201D;,&nbsp;and increase the Company&#x2019;s authorized capital to 200,000,000 shares of common stock, par value $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. During June&nbsp;2012, the Company decided to discontinue its exploration and potential development of uranium and vanadium minerals business.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On August&nbsp;1, 2012, the shareholders holding a majority of the Company&#x2019;s voting capital voted in favor of (i)&nbsp;changing the name of the Company to &#x201C;Fidelity Property Group,&nbsp;Inc.&#x201D; and (ii)&nbsp;the adoption the 2012 Equity Incentive Plan and reserving 10,000,000 shares of common stock for issuance thereunder (the &#x201C;2012 Plan&#x201D;).&nbsp;&nbsp;The board of directors of the Company (the &#x201C;Board of Directors&#x201D;) approved the name change and the adoption of the 2012 Plan on August&nbsp;1, 2012.&nbsp;The Company did not file an amendment to its Articles of Incorporation with the Secretary of State of Nevada and subsequently abandoned the decision to adopt the &#x201C;Fidelity Property Group,&nbsp;Inc.&#x201D; name and discontinue its real estate business.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;1, 2012, the shareholders holding a majority of the Company&#x2019;s voting capital had voted and authorized the Company to (i)&nbsp;change the name of the Company to Marathon Patent Group,&nbsp;Inc. (the &#x201C;Name Change&#x201D;) and (ii)&nbsp;effectuate a reverse stock split of the Company&#x2019;s common stock by a ratio of 3-for-2 (the &#x201C;Reverse Split&#x201D;) within one year from the date of approval of the stockholders of the Company.&nbsp;&nbsp;The Board of Directors approved the Name Change and the Reverse Split on October&nbsp;1, 2012. The Board of Directors determined the name &#x201C;Marathon Patent Group,&nbsp;Inc.&#x201D; better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward.&nbsp;On February&nbsp;15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change. On May&nbsp;31, 2013, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company&#x2019;s issued and outstanding common stock by a ratio of not less than one-for-five and not more than one-for-fifteen at any time prior to April&nbsp;30, 2014, with such ratio to be determined by the Company&#x2019;s Board of Directors, in its sole discretion. On June&nbsp;24, 2013, the reverse stock split ratio of one (1)&nbsp;for thirteen (13) basis was approved by the Board of Directors. On July&nbsp;18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company&#x2019;s issued and outstanding common stock, par value $0.0001 per share on a one (1)&nbsp;for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;16, 2014, </font><font style="display:inline;">the Board of Directors of the Company </font><font style="display:inline;">approved and adopted, subject to shareholder approval on or prior to September&nbsp;16, 2015, the Company&#x2019;s 2014 Equity Incentive Plan. The Company&#x2019;s 2014 Equity Incentive Plan was approved by the shareholders of the Company at the annual meeting held on July&nbsp;31, 2015.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On November&nbsp;19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company&#x2019;s Common Stock as of the close of business of the record date of December&nbsp;15, 2014 received one additional share of Common Stock at the close of business on December&nbsp;22, 2014 for each share of Common Stock held by such holders. Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 384209 51669 81336 77872 74540 71288 27504 5082569 9477969 2555151 1420390 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Cash</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.&nbsp;&nbsp;The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company&#x2019;s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;). As of March&nbsp;31, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 250000 4395400 -1134761 6.50 5.75 7.44 100000 2021308 2021308 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 6 &#x2013; COMMITMENTS AND CONTINGENCIES</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Fortress Transaction</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On January&nbsp;29, 2015, the Company and certain of its subsidiaries (each a &#x201C;Subsidiary&#x201D;) entered into a series of Agreements including a Fortress Securities Agreement and a Subscription Agreement with DBD, an affiliate of Fortress, under which the Company sold to the purchasers: (i)&nbsp;$15,000,000 original principal amount of Senior Secured Notes (&#x201C;Fortress Notes&#x201D;), (ii)&nbsp;a right to receive a portion of certain proceeds from monetization net revenues received by the Company (after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes),&nbsp;&nbsp;(the &#x201C;Revenue Stream&#x201D;), (iii)&nbsp;a five-year Fortress Warrant to purchase 100,000 shares of the Company&#x2019;s Common Stock exercisable at $7.44 per share, subject to adjustment; and (iv)&nbsp;134,409 shares of the Company&#x2019;s Common Stock.&nbsp;&nbsp;Under the Fortress Purchase Agreement, the Company has the right to require the purchasers to purchase an additional $5,000,000 of Notes (which will increase proportionately the Revenue Stream), subject to the achievement of certain milestones, and further contemplates that Fortress may, but is not obligated to, fund up to an additional $30,000,000, on equivalent economic terms.&nbsp;&nbsp;&nbsp;The Company may use the proceeds to finance&nbsp;the monetization of its existing assets, provide further expansion capital for new acquisitions, to repay existing&nbsp;debt (including without limitation, the Company&#x2019;s 11% convertible notes issued October&nbsp;9, 2013 and for general working capital and corporate purposes.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the Purchase Agreement entered into on January&nbsp;29, 2015, the Company issued to Fortress a Note in the original principal amount of $15,000,000 (the &#x201C;Initial Note&#x201D;). The Initial Note matures on July&nbsp;29, 2018. If any additional Notes are issued pursuant to the Fortress Securities Purchase Agreement, the maturity date of such additional Fortress Notes shall be 42</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">months after issuance.&nbsp;The unpaid principal amount of the Initial Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum;</font><font style="display:inline;font-style:italic;">&nbsp;provided</font><font style="display:inline;"> that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement), the interest rate shall increase by an additional 2% per annum.&nbsp;&nbsp;As of March&nbsp;31, 2016, the twelve-month LIBOR USD rate was 1.21040%. Interest on the Initial Note shall be paid on the last business day of each calendar month (the &#x201C;Interest Payment Date&#x201D;), commencing January&nbsp;31, 2015.&nbsp;&nbsp;Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">effective as of the applicable Interest Payment Date (&#x201C;PIK Interest&#x201D;).&nbsp;&nbsp;PIK Interest shall be treated as added principal of the Initial Note for all purposes, including interest accrual and the calculation of any prepayment premium.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Fortress Securities Purchase Agreement contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,000,000 in unrestricted cash and cash equivalents and that the Company shall have Monetization Revenues (as defined in the Fortress Purchase Agreement) for each of the four fiscal quarters commencing December&nbsp;31, 2014 of at least $15,000,000.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The terms of the Fortress Warrant provide that until January&nbsp;29, 2020, the Fortress Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As part of the transaction, DBD entered into a lock-up agreement (the &#x201C;Lock-Up Agreement&#x201D;) pursuant to which the parties and certain related holders agreed until the earlier of 12 months or acceleration of an Event of Default (as defined in the Fortress Securities Purchase Agreement), that they will not, directly or indirectly, (i)&nbsp;offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), the Lock-Up Shares (as defined in the Lock-Up Agreement), beneficially owned, within the meaning of Rule&nbsp;13d-3 under the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), by such Holder and his/her Related Group (as such terms are defined in the Lock-Up Agreement) on the date of the Lock-Up Agreement or thereafter acquired or (ii)&nbsp;enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Shares, whether or not any such swap or transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of any Lock-Up Shares.&nbsp;&nbsp;The Holders may purchase additional shares of the Company&#x2019;s Common Stock during the Lock-Up Period (as defined in the Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In connection with the transactions described above, TechDev, Audrey Spangenberg, Erich Spangenberg, and Granicus (the &#x201C;Spangenberg Holders&#x201D;) entered into a lock-up agreement (the &#x201C;Spangenberg Lockup&#x201D;) with respect to 1,626,924 shares of Common Stock, 48,078 shares of Common Stock underlying warrants, and 782,000 shares of Common Stock underlying preferred stock, pursuant to which the Spangenberg Holders agreed that until payment in full of the Note Obligations (as defined in the Fortress Notes), which shall include but not be limited to all principal and interest on outstanding Notes pursuant to the Purchase Agreement, the Spangenberg Holders and certain related parties&nbsp;agreed that they will not, directly or indirectly, (i)&nbsp;offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), more than 5% of the Spangenberg Lockup shares (as defined in the Spangenberg Lock-Up Agreement), beneficially owned, within the meaning of Rule&nbsp;13d-3 under the Exchange Act, by such Holder and his/her Related Group (as such terms are defined in the Spangenberg Lock-Up Agreement) on the date of the Spangenberg Lock-Up Agreement or thereafter acquired or (ii)&nbsp;enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of more than 5% of the Spangenberg Lock-Up Shares, whether or not any such swap or transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of any Lock-Up Shares. The Spangenberg Holders may purchase additional shares of the Company&#x2019;s Common Stock during the Lock-Up Period (as defined in the Spangenberg Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the Fortress Securities Purchase Agreement, as security for the payment and performance in full of the Secured Obligations (as defined in the Fortress Securities Purchase Agreement) in favor of DBD, the Company and certain subsidiaries executed and delivered in favor of DBD a Security Agreement (&#x201C;Security Agreement&#x201D;) and a Patent Security Agreement (&#x201C;Patent Security Agreement&#x201D;), including a pledge of the Company&#x2019;s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations is secured by a first priority lien and security interest in all of the assets of the Company, subject to permitted liens on permitted indebtedness that existed as of January&nbsp;29, 2015. The security interest does not include a lien on the assets held by Orthophoenix, LLC. Certain subsidiaries of the Company (excluding Orthophoenix) also executed guarantees in favor of the purchasers (each, a &#x201C;Guaranty&#x201D;), guaranteeing the Note Obligations.&nbsp;&nbsp;As required by the terms of certain notes issued by the Company in October&nbsp;2014 (&#x201C;October&nbsp;Notes&#x201D;), the October&nbsp;Note holders consented to the transactions described herein.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Within thirty days, the Company was required to open a cash collateral account into which all Company revenue shall be deposited and which shall be subject to a control agreement outlining the disbursement in accordance with the terms of the Fortress Securities Purchase Agreement of all proceeds.</font><font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to the Fortress Securities Purchase Agreement, the Company entered into the Fortress Patent License Agreement with DBD pursuant to which the Company agreed to grant to the Licensee certain rights, including right to license certain patents and patent applications, which licensing rights to be available solely upon an acceleration of the Note Obligations, as provided in the Fortress Securities Purchase Agreement.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Office Lease</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In October&nbsp;2013, the Company entered into a net-lease for its current&nbsp;office space in Los Angeles, California.&nbsp;&nbsp;The lease will commence on May&nbsp;1, 2014 and runs for seven years through April&nbsp;30, 2021, with monthly lease payment escalating each year of the lease.&nbsp;&nbsp;In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes.&nbsp;&nbsp;Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit.&nbsp;&nbsp;In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease.&nbsp; Minimum future lease payments under this lease at March&nbsp;31, 2016, for the next five years and thereafter are as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2016 (Nine Months)</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,669&nbsp; </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2017</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,288&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2018</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,540&nbsp; </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2019</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,872&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2020</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,336&nbsp; </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,504&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>384,209&nbsp; </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.001 0.0001 0.0001 0.0001 0.0001 75000000 200000000 200000000 200000000 14867141 14967141 14867141 14967141 1487 1497 0.87 0.02 0.93 0.07 183330 16666 4328165 2639976 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Cost of Revenue</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cost of revenues mainly includes expenses incurred in connection with the Company&#x2019;s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses.&nbsp;Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 10393339 6975695 0.0975 LIBOR 15000000 15000000 30000000 0.11 0.012104 0.02 P30D P30D P42M P30D 964998 1000000 1000000 14385393 12437741 14385393 1044997 964998 1869 1652 2598461 2025899 249375 26250 249375 -0.34 -0.26 -0.34 -0.26 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Basic and Diluted Net Earnings (Loss) per Share</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (&#x201C;ASC 260&#x201D;). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,339,100 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at March&nbsp;31, 2016, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company&#x2019;s net loss.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following table sets forth the computation of basic and diluted loss per share:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 2pt;"> <font style="display:inline;font-size:2pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,893,413) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,781,571) </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Denominator</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Earnings (Loss) per common share:</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0.50 -6978 8852 2607 27000 0 P10Y P3Y P3Y6M P6Y6M P6Y6M P3Y3M P3Y P5Y9M P5Y9M P5Y9M P3Y3M P6Y6M P3Y3M P3Y P3Y P6Y3M P10Y P5Y6M P6Y6M P6Y6M 1.91 0.51 0.5 0.63 0.63 0.5 0.49 0.53 0.53 0.49 0.53 0.62 0.47 0.41 0.41 0.53 0.61 0.47 0.49 0.49 0.0196 0.0084 0.01 0.0197 0.0197 0.0105 0.0104 0.0178 0.0178 0.0103 0.0178 0.0195 0.0092 0.0116 0.0092 0.0153 0.0189 0.0172 0.0157 0.0157 0.87 0.06 0.07 0.05 0.02 0.67 0.93 0.01 0.92 1135512 350000 1000000 1100000 718500 1700000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Fair Value of Financial Instruments</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company adopted FASB ASC 820, &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC&nbsp;820 did not have an impact on the Company&#x2019;s financial position or operating results, but did expand certain disclosures. ASC&nbsp;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC&nbsp;820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;1:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</font></p> </td> </tr> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;2:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Observable market-based inputs or unobservable inputs that are corroborated by market data</font></p> </td> </tr> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;3:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity&#x2019;s own assumptions.</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of March&nbsp;31, 2016, the Company determined that there was no change to the Clouding IP earn out liability or the carrying value of the Clouding IP intangible assets.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of March&nbsp;31, 2016 and December&nbsp;31, 2015, the Company had outstanding bonds in the amount of $1,443,457 and $1,748,311, respectively. The Company adjusted the value as of March&nbsp;31, 2016 of the bonds to reflect changes to the exchange rate between the Euro and the US Dollar.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 15557353 16423203 3857523 5440463 2121609 2846570 3691108 5251025 41014992 39631501 25457639 23208298 -950239 247427 219481 217010 3000 1296000 228000 2700000 4482845 4605733 373195 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Goodwill</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, &#x201C;Intangibles - Goodwill and Others&#x201D;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 1.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant underperformance relative to expected historical or projected future operating results;</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 2.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant changes in the manner of use of the acquired assets or the strategy for the overall business;</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 3.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant negative industry or economic trends; and</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 4.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.</font></p></td></tr></table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company&#x2019;s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit&#x2019;s goodwill and if the carrying value of the reporting unit&#x2019;s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September&nbsp;30.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended March&nbsp;31, 2016 and March&nbsp;31, 2015, the Company recorded no impairment charge to its goodwill.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 0 0 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Other Intangible Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In accordance with ASC 350-30-65, &#x201C;Intangibles - Goodwill and Others&#x201D;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1)&nbsp;significant underperformance relative to expected historical or projected future operating results; (2)&nbsp;significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3)&nbsp;significant negative industry or economic trends.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Impairment of Long-lived Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 &#x201C;Property, Plant and Equipment&#x201D;.&nbsp;&nbsp;The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable.&nbsp; Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> -7270411 -5918461 -0.34 -0.26 8260 7999 -2488840 -2025048 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Income Taxes</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounts for income taxes pursuant to the provision of ASC 740-10, &#x201C;Accounting for Income Taxes&#x201D; which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.&nbsp;The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2015 tax returns. After review of the 2015 financial statements and the results of operations through March&nbsp;31, 2016, the Company has recorded a deferred tax asset in the amount of $14,385,393, from which the Company expects to realize benefits in the future, and a deferred tax liability of $964,998.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 1920185 1953751 546101 15275 -359960 -2069 -26248 -192352 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;color:#000000;"></font><font style="display:inline;color:#000000;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 3pt;"> <font style="display:inline;font-size:3pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible Assets</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,631,501 </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.22%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41,014,992 </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accumulated Amortization&nbsp;&amp; Impairment</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,423,203) </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(15,557,353) </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets, net</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,208,298 </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.22%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,457,639 </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 990000 14500000 940000 12800000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 4 &#x2013; INTANGIBLE ASSETS</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets of the Company, including adjustments for currency translation adjustments, consisted of the following:</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 3pt;"> <font style="display:inline;font-size:3pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible Assets</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,631,501 </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.22%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41,014,992 </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accumulated Amortization&nbsp;&amp; Impairment</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(16,423,203) </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:21.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(15,557,353) </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.46%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:21.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets, net</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,208,298 </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:18.22%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6.5pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,457,639 </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:46.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.46%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Other than the Company&#x2019;s website as set forth in the table above, intangible assets are comprised of patents with estimated useful lives between approximately 1 to 15 years. The website was determined to have an estimated useful life of 3 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis.&nbsp; Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included in operating expenses as reflected in the accompanying consolidated statements of operations. The Company recorded an impairment charge to its long-lived assets during the three months ended March&nbsp;31, 2016 in the amount of $373,195 associated with the end of life of two of the Company&#x2019;s portfolios, compared to no impairment charge during the three months ended March&nbsp;31, 2015.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Patent and website amortization expense for the three months ended March&nbsp;31, 2016 and March&nbsp;31, 2015 was $2,025,899 and $2,598,461, respectively, net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2016</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:04.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:15.92%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,440,463 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2017</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,251,025 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2018</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,691,108 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2019</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,846,570 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2020</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,121,609 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2021 and thereafter</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,857,523 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:04.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:15.92%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,208,298 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company made the following patent purchases:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2013, the Company through its subsidiary, Relay IP,&nbsp;Inc. acquired a US patent for $350,000;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April&nbsp;2013, the Company acquired 10 US patents, 27 foreign patents and 1 patent pending from CyberFone Systems valued at $1,135,512;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2013, in connection with the closing of a licensing agreement with Siemens Technology, we acquired a patent portfolio from that company valued at $1,000,000;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2013, the Company acquired 14 US patents for a total purchase price of $1,100,000;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November&nbsp;2013, the Company acquired four patents for 150,000 shares of the Company&#x2019;s Common Stock, which the Company valued at $718,500 based on the fair market value of the stock issued;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2013, the Company acquired certain patents from Delphi Technologies,&nbsp;Inc.&nbsp;for $1,700,000 pursuant to a Patent Purchase Agreement entered into on October&nbsp;31, 2013 and Amended on December&nbsp;16, 2013;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2013, in connection with a licensing agreement with Zhone, the Company acquired a portfolio of patents from Zhone;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2013, in connection with a settlement and license agreement, we agreed to settle and release another defendant for past and future use of our patents, whereby the defendant agreed to assign and transfer 2 U.S. patents and rights to the Company;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2014, we acquired ownership rights of Dynamic Advances, LLC, a Texas limited liability company,&nbsp;IP Liquidity Ventures, LLC, a Delaware limited liability company, and Sarif Biomedical, LLC, a Delaware limited liability company, all of which hold patent portfolios or contract rights to the revenue generated from the patent portfolios;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June&nbsp;2014, we acquired Selene Communication Technologies, LLC, which holds multiple patents in the search and network intrusion field;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August&nbsp;2014, we acquired patents from Clouding IP LLC, with such patents related to network and data management technology;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In September&nbsp;2014, we acquired TLI Communications, which owns a single patent in the telecommunication field;</font> </p> <p style="margin:0pt 0pt 0pt 36pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October&nbsp;2014, we acquired three patent portfolios from MedTech Development, LLC, which owns medical technology patents.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of March&nbsp;31, 2016, the Company&#x2019;s patent portfolios consist of 320 U.S. and foreign patents, 11 patent applications and contract rights to seven patents.&nbsp;In the aggregate, the earliest date for expiration of a patent in the Company&#x2019;s patent portfolio is past (the patent is expired, but patent rules&nbsp;allow for six year look-back for royalties), the median expiration date for patents in the Company&#x2019;s portfolio is June&nbsp;17, 2017, and the latest expiration date for a patent in any of the Company&#x2019;s patent portfolios is July&nbsp;29, 2029.&nbsp;&nbsp;A summary of the Company&#x2019;s patent portfolios is as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:29.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Subsidiary</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Number&nbsp;of</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Patents</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Earliest</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Median</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Latest</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Expiration</font><br /><font style="display:inline;font-weight:bold;font-size:9pt;">Date</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 9pt;"> <font style="display:inline;font-weight:bold;font-size:9pt;">Subject&nbsp;Matter</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Bismarck IP Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/15/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/15/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">01/22/18</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Communication and PBX equipment</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Clouding Corp.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10/05/21</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/29/29</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Network and data management</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">CRFD Research,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/17/21</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/11/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/19/23</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Web page&nbsp;content translator </font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cyberfone Systems, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">01/31/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/07/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Telephony and data transactions</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Dynamic Advances, LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">10/02/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/06/23</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Natural language interface</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">E2E Processing,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">04/27/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/17/23</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/18/24</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Manufacturing schedules using adaptive learning</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Hybrid Sequence IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/14/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/09/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/17/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Asynchronous communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">IP Liquidity Ventures, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">04/09/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/26/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pharmaceuticals / tire pressure systems</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Loopback Technologies,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/25/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/27/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Automotive</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Medtech Group Acquisition Corp.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/01/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">07/29/29</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Medical technology</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Relay IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Multicasting</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sampo IP, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/13/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/13/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/16/23</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Centrifugal communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sarif Biomedical LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Microsurgery equipment</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Selene Communication Technologies, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">05/05/18</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/23/20</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">11/28/21</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Communications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/10/14</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">12/01/15</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">08/06/22</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Automotive</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TLI Communications, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">06/17/17</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Telecommunications</font></p> </td> </tr> <tr> <td valign="top" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Expired</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">12/21/16</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">03/09/18</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Computer networking and operations</font></p> </td> </tr> <tr> <td valign="bottom" style="width:29.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Median</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">09/25/17</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:2pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Intangible Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March&nbsp;31, 2016 in the amount of $373,195 associated with the end of life of two of the Company&#x2019;s portfolios, compared to no impairment charge during the three months ended March&nbsp;31, 2015.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 23208298 931541 1006850 317821 401159 2 931 750334 1581074 1033346 P7Y 34551851 36035398 47227593 45622612 16951648 20314271 17600203 15721127 225000 275000 220000 80000 2750000 15000 1900000 1748311 1443457 24900000 12223884 10493877 5568750 -1248440 -37147 -2097 -1145055 113169 -4781571 -3893413 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2016, the FASB issued ASU No.&nbsp;2016-09, &#x201C;</font><font style="display:inline;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">&#x201D; (&#x201C;ASU 2016-09&#x201D;). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September&nbsp;1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In February&nbsp;2016, the FASB issued ASU No.&nbsp;2016-02, &#x201C;</font><font style="display:inline;font-style:italic;">Leases (Topic 842)</font><font style="display:inline;">&#x201D; (&#x201C;ASU 2016-02&#x201D;). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September&nbsp;1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In November&nbsp;2015, the FASB issued ASU 2015-17, </font><font style="display:inline;font-style:italic;">Balance Sheet Classification of Deferred Taxes.</font><font style="display:inline;">&nbsp; This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.&nbsp; ASU 2015-17 is effective for annual and interim reporting periods beginning after December&nbsp;15, 2016.&nbsp; This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.&nbsp; Early application is permitted as of the beginning of the interim or annual reporting period.&nbsp; The Company adopted this standard for the annual period ending December&nbsp;31, 2015.&nbsp;&nbsp;The effect of adopting the new guidance on the balance sheet was not significant.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In September&nbsp;2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No.&nbsp;2015-16,&nbsp;</font><font style="display:inline;font-style:italic;">Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,&nbsp;</font><font style="display:inline;">or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.&nbsp;&nbsp;The new standard for an annual reporting period beginning after December&nbsp;15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December&nbsp;15, 2016.&nbsp;&nbsp;The new guidance is not expected to have significant impact on the Company&#x2019;s consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In April&nbsp;2015, the FASB issued ASU 2015-05,&nbsp;</font><font style="display:inline;font-style:italic;">Intangibles-Goodwill and Other &#x2014; Internal-Use Software; Customer&#x2019;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="display:inline;">. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#x2019;s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January&nbsp;1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In April&nbsp;2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03,&nbsp;</font><font style="display:inline;font-style:italic;">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs)</font><font style="display:inline;">, effective for fiscal years beginning after December&nbsp;15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.&nbsp;&nbsp;The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In August&nbsp;2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, Disclosure of Uncertainties About an Entity&#x2019;s Ability to Continue as a Going Concern. This standard update provides guidance around management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December&nbsp;15, 2016. The new guidance is not expected to have a significant impact on the Company&#x2019;s consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In May&nbsp;2014, the Financial Accountings Standards Board (</font><font style="display:inline;font-style:italic;">&#x201C;FASB&#x201D;</font><font style="display:inline;">) issued Accounting Standards Update No.&nbsp;2014-09, </font><font style="display:inline;font-style:italic;">Revenue from Contracts with Customers</font><font style="display:inline;">, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January&nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 613719 605690 150000 511790 258998 100000 2148000 -970941 -1002442 2375000 2375000 250000 1000000 9000000 10383177 11379212 -6299470 -4916019 9169 207100 55106 50084 49075 -83148 33607 -39402 -2159 1400000 2375000 2375000 250000 50000 1400000 350000 1000000 2850000 6653078 552024 37147 2097 0.0001 0.0001 0.0001 100000000 500000 50000000 50000000 195500 195500 782004 782004 782004 782004 200000 16666 78 78 338598 146336 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Reclassification</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 5550000 19600000 138222 18750 896543 280776 769615 405493 61297 52793 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Accounts Receivable</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.&nbsp;&nbsp;The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.&nbsp;&nbsp;Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote.&nbsp; At March&nbsp;31, 2016 and December&nbsp;31, 2015, the Company had recorded an allowance for bad debts in the amounts of $375,750 and $375,750, respectively.&nbsp;&nbsp;Accounts receivable-net at March&nbsp;31, 2016 and December&nbsp;31, 2015, amounted to $153,112 and $136,842, respectively. As of March&nbsp;31, 2016, accounts receivable related to one license accounted for approximately 41% of the Company&#x2019;s total accounts receivable, accounts receivable related to recurring royalties represented approximately 42% of total accounts receivable and the remainder of the accounts receivable is primarily related to a trade receivable associated with the terminated Uniloc merger. As of December&nbsp;31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company&#x2019;s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable. As of March&nbsp;31, 2016, accounts receivable represented 7% of revenues for the three months ended March&nbsp;31, 2016 and as of December&nbsp;31, 2015, accounts receivable represented 2% of revenues for the three months ended December&nbsp;31, 2015.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 250000000 10000000 40000000 40000000 10000000 5050000 905000 1068750 3000000 3750000 276250 1184600 980000 281000 -29277524 -33170937 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Revenue Recognition</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company recognizes revenue in accordance with ASC Topic&nbsp;605, &#x201C;Revenue Recognition&#x201D;.&nbsp;Revenue is recognized when (i)&nbsp;persuasive evidence of an arrangement exists, (ii)&nbsp;all obligations have been substantially performed, (iii)&nbsp;amounts are fixed or determinable and (iv)&nbsp;collectability of amounts is reasonably assured.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, &#x201C;Multiple-Element Arrangements&#x201D; as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 93% of its revenues for the three months ended March&nbsp;31, 2016 from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company&#x2019;s patents, with the balance comprised of recurring royalties.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s subsidiaries entered into two license agreements during the three months ended March&nbsp;31, 2016.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 4093869 2059676 14785 4000000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 2pt;"> <font style="display:inline;font-size:2pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,893,413) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,781,571) </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Denominator</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Earnings (Loss) per common share:</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,500,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,296,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,796,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total consideration paid of the following:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cash</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,400,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Promissory Note</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,000,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Common Stock</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>281,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Earn Out Liability</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,115,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,796,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12,800,000&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,700,000&nbsp; </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:10.86%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,500,000&nbsp; </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:84.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>990,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net working capital</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>37,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,030,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:11.26%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>940,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.42%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>228,000&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:12.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net purchase price</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">$</font></p> </td> <td valign="bottom" style="width:11.24%;background-color: #CCEEFF;;font-weight:bold;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,168,000&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:83.96%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 96.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2016 (Nine Months)</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51,669&nbsp; </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2017</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71,288&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2018</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>74,540&nbsp; </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2019</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>77,872&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2020</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81,336&nbsp; </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Thereafter</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:07.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27,504&nbsp; </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.42%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:00.52%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:07.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>384,209&nbsp; </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:86.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.42%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2016</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:04.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:15.92%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,440,463 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2017</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,251,025 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2018</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,691,108 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2019</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,846,570 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2020</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,121,609 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">2021 and thereafter</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:20.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,857,523 </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:20.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.36%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Total</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:04.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:15.92%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23,208,298 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:3pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:75.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:04.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:15.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Number of</font><br /><font style="display:inline;">Options</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average Exercise</font><br /><font style="display:inline;">Price</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average</font><br /><font style="display:inline;">Remaining Life</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,383,267&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.25&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.11 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,167&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.45&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.31 </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,339,100&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.22&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.93 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options Exercisable at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,122,560&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options expected to vest</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,216,541&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted average fair value of options granted during the period</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;"></font><font style="display:inline;"></font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Number of</font><br /><font style="display:inline;">Warrants</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average Exercise</font><br /><font style="display:inline;">Price</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average</font><br /><font style="display:inline;">Remaining&nbsp;Life</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.27 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.87 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.84%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.27 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.63 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Warrants exercisable at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted average fair value of warrants granted during the period</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 7564 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Concentration of Revenue and Geographic Area</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Patent license revenue from enforcement activities originates in either the United States or Germany. Revenue attributable to the United States involves US patents, revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Revenues from two licenses accounted for approximately 93% of the Company&#x2019;s operating revenues for the three months ended March&nbsp;31, 2016 and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended March&nbsp;31, 2015 as set forth below.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td colspan="6" valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:48.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:22.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:21.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,900,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92% </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,750,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>275,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sarif Biomedical, LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>225,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TLIF, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000&nbsp; </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2% </td> </tr> <tr> <td colspan="4" valign="top" style="width:35.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="6" valign="top" style="width:36.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87% </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The remainder of the revenue is attributable to running royalties in the Company&#x2019;s Medtech portfolio.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 685753 550436 3465 550436 0 281000 25000 10000000 44167 20000 160000 80000 290000 40000 290000 60000 100000 680000 30000 160000 25000 20000 20000 70000 70000 280000 80000 70000 385000 3383267 3339100 4.25 4.22 P5Y P5Y P10Y P10Y P5Y P10Y P5Y P10Y P10Y P5Y P10Y P5Y P5Y P5Y P10Y P10Y P10Y P10Y 6.45 3.295 4.165 4.165 4.165 5.05 5.62 7.445 6.40 6.40 6.40 6.40 6.80 7.37 6.61 6.76 6.76 6.76 8.99 10.14 2.03 1.86 1.86 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Stock-based Compensation</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the &#x201C;measurement date.&#x201D; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest</font><font style="display:inline;">, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March&nbsp;31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company&#x2019;s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.</font> </p> <p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 4.90 5.62 2.23 1.71 1.61 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The unaudited consolidated&nbsp;financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (&#x201C;US GAAP&#x201D;) and present the consolidated financial statements of the Company&nbsp;and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company&#x2019;s consolidated financial position as of March&nbsp;31, 2016, and the results of operations and cash flows for the three months ended March&nbsp;31, 2016 have been included. The results of operations for the three months ended March&nbsp;31, 2016 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December&nbsp;31, 2015, which are contained in Form&nbsp;10-K as filed with the Securities and Exchange Commission (&#x201C;SEC&#x201D;) on March&nbsp;30, 2016. The consolidated balance sheet as of December&nbsp;31, 2015 was derived from those financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Cash</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.&nbsp;&nbsp;The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company&#x2019;s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;). As of March&nbsp;31, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Use of Estimates and Assumptions</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to,&nbsp;estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Accounts Receivable</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.&nbsp;&nbsp;The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.&nbsp;&nbsp;Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote.&nbsp; At March&nbsp;31, 2016 and December&nbsp;31, 2015, the Company had recorded an allowance for bad debts in the amounts of $375,750 and $375,750, respectively.&nbsp;&nbsp;Accounts receivable-net at March&nbsp;31, 2016 and December&nbsp;31, 2015, amounted to $153,112 and $136,842, respectively. As of March&nbsp;31, 2016, accounts receivable related to one license accounted for approximately 41% of the Company&#x2019;s total accounts receivable, accounts receivable related to recurring royalties represented approximately 42% of total accounts receivable and the remainder of the accounts receivable is primarily related to a trade receivable associated with the terminated Uniloc merger. As of December&nbsp;31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company&#x2019;s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable. As of March&nbsp;31, 2016, accounts receivable represented 7% of revenues for the three months ended March&nbsp;31, 2016 and as of December&nbsp;31, 2015, accounts receivable represented 2% of revenues for the three months ended December&nbsp;31, 2015.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Concentration of Revenue and Geographic Area</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Patent license revenue from enforcement activities originates in either the United States or Germany. Revenue attributable to the United States involves US patents, revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Revenues from two licenses accounted for approximately 93% of the Company&#x2019;s operating revenues for the three months ended March&nbsp;31, 2016 and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended March&nbsp;31, 2015 as set forth below.</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td colspan="6" valign="bottom" style="width:49.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="7" valign="bottom" style="width:48.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months Ended March&nbsp;31, 2015</font></p> </td> </tr> <tr> <td valign="bottom" style="width:22.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:21.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Licensor</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">License</font><br /><font style="display:inline;">Amount</font></p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 2.6pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Revenue</font></p> </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,900,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>92% </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,750,000&nbsp; </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:10.88%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Signal IP,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>275,000&nbsp; </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Sarif Biomedical, LLC</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>225,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6% </td> </tr> <tr> <td valign="top" style="width:22.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">TLIF, LLC</font></p> </td> <td valign="top" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220,000&nbsp; </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5% </td> </tr> <tr> <td valign="top" style="width:22.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:02.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:21.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 3.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Vantage Point Technology,&nbsp;Inc.</font></p> </td> <td valign="top" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:01.12%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="top" style="width:00.80%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:10.08%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>80,000&nbsp; </td> <td valign="bottom" style="width:01.50%;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;background-color: #CCEEFF;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2% </td> </tr> <tr> <td colspan="4" valign="top" style="width:35.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:01.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="top" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>93% </td> <td valign="top" style="width:02.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="6" valign="top" style="width:36.50%;padding:0pt 0pt 0pt 0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">% of Total Revenues</font></p> </td> <td valign="bottom" style="width:12.00%;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87% </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The remainder of the revenue is attributable to running royalties in the Company&#x2019;s Medtech portfolio.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Revenue Recognition</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company recognizes revenue in accordance with ASC Topic&nbsp;605, &#x201C;Revenue Recognition&#x201D;.&nbsp;Revenue is recognized when (i)&nbsp;persuasive evidence of an arrangement exists, (ii)&nbsp;all obligations have been substantially performed, (iii)&nbsp;amounts are fixed or determinable and (iv)&nbsp;collectability of amounts is reasonably assured.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, &#x201C;Multiple-Element Arrangements&#x201D; as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 93% of its revenues for the three months ended March&nbsp;31, 2016 from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company&#x2019;s patents, with the balance comprised of recurring royalties.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s subsidiaries entered into two license agreements during the three months ended March&nbsp;31, 2016.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Cost of Revenue</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cost of revenues mainly includes expenses incurred in connection with the Company&#x2019;s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses.&nbsp;Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Prepaid Expenses, Bonds Posted and Other Current Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses and other current assets of $146,336 and $338,598 at March&nbsp;31, 2016 and December&nbsp;31, 2015, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In addition, the Company had outstanding litigation bonds in the amount of $1,443,457 and $1,748,311 at March&nbsp;31, 2016 and December&nbsp;31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to some of the Company&#x2019;s patents in German courts. The difference in the balance of the litigation bonds at March&nbsp;31, 2016 compared to December&nbsp;31, 2015 is attributable to $55,106 in currency translation impact and the return of $359,960 in bonds related to the litigation against Schrader and TRW, which were resolved in the fourth quarter of 2015.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Fair Value of Financial Instruments</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company adopted FASB ASC 820, &#x201C;Fair Value Measurements and Disclosures&#x201D; (&#x201C;ASC 820&#x201D;), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC&nbsp;820 did not have an impact on the Company&#x2019;s financial position or operating results, but did expand certain disclosures. ASC&nbsp;820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC&nbsp;820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;1:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Observable inputs such as quoted market prices in active markets for identical assets or liabilities</font></p> </td> </tr> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;2:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Observable market-based inputs or unobservable inputs that are corroborated by market data</font></p> </td> </tr> <tr> <td valign="top" style="width:12.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 21.6pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level&nbsp;3:</font></p> </td> <td valign="top" style="width:87.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Unobservable inputs for which there is little or no market data, which require the use of the reporting entity&#x2019;s own assumptions.</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of March&nbsp;31, 2016, the Company determined that there was no change to the Clouding IP earn out liability or the carrying value of the Clouding IP intangible assets.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of March&nbsp;31, 2016 and December&nbsp;31, 2015, the Company had outstanding bonds in the amount of $1,443,457 and $1,748,311, respectively. The Company adjusted the value as of March&nbsp;31, 2016 of the bonds to reflect changes to the exchange rate between the Euro and the US Dollar.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Accounting for Acquisitions</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.&nbsp;&nbsp;With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 &#x2014; Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.&nbsp;&nbsp;The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Income Taxes</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounts for income taxes pursuant to the provision of ASC 740-10, &#x201C;Accounting for Income Taxes&#x201D; which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.&nbsp;The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2015 tax returns. After review of the 2015 financial statements and the results of operations through March&nbsp;31, 2016, the Company has recorded a deferred tax asset in the amount of $14,385,393, from which the Company expects to realize benefits in the future, and a deferred tax liability of $964,998.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Basic and Diluted Net Earnings (Loss) per Share</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (&#x201C;ASC 260&#x201D;). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,339,100 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at March&nbsp;31, 2016, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company&#x2019;s net loss.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following table sets forth the computation of basic and diluted loss per share:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the Three Months</font><br /><font style="display:inline;">Ended March&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 2pt;"> <font style="display:inline;font-size:2pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net loss</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,893,413) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,781,571) </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Denominator</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted Average Common Shares - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,967,141 </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13,868,811&nbsp; </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Earnings (Loss) per common share:</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:19.58%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3.6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:00.98%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Basic</font></p> </td> <td valign="bottom" style="width:02.34%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:56.64%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20.2pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Income (Loss) - Diluted</font></p> </td> <td valign="bottom" style="width:02.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:17.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3.6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.26) </td> <td valign="bottom" style="width:01.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 7.2pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">$</font></p> </td> <td valign="bottom" style="width:15.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.34) </td> <td valign="bottom" style="width:00.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Intangible Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March&nbsp;31, 2016 in the amount of $373,195 associated with the end of life of two of the Company&#x2019;s portfolios, compared to no impairment charge during the three months ended March&nbsp;31, 2015.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Goodwill</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, &#x201C;Intangibles - Goodwill and Others&#x201D;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 1.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant underperformance relative to expected historical or projected future operating results;</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 2.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant changes in the manner of use of the acquired assets or the strategy for the overall business;</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 3.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant negative industry or economic trends; and</font></p></td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:21pt;"><p style="width:21pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 19.00pt; display: inline;"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> 4.</font> </p> </td><td style="width:2pt;"><p style="width:2pt;width:2pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"> <font style="display:inline;color:#000000;">Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.</font></p></td></tr></table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company&#x2019;s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit&#x2019;s goodwill and if the carrying value of the reporting unit&#x2019;s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September&nbsp;30.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended March&nbsp;31, 2016 and March&nbsp;31, 2015, the Company recorded no impairment charge to its goodwill.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;text-decoration:underline;">Other Intangible Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In accordance with ASC 350-30-65, &#x201C;Intangibles - Goodwill and Others&#x201D;, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1)&nbsp;significant underperformance relative to expected historical or projected future operating results; (2)&nbsp;significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3)&nbsp;significant negative industry or economic trends.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Impairment of Long-lived Assets</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 &#x201C;Property, Plant and Equipment&#x201D;.&nbsp;&nbsp;The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable.&nbsp; Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Stock-based Compensation</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the &#x201C;measurement date.&#x201D; The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest</font><font style="display:inline;">, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March&nbsp;31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company&#x2019;s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Reclassification</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2016, the FASB issued ASU No.&nbsp;2016-09, &#x201C;</font><font style="display:inline;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">&#x201D; (&#x201C;ASU 2016-09&#x201D;). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September&nbsp;1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In February&nbsp;2016, the FASB issued ASU No.&nbsp;2016-02, &#x201C;</font><font style="display:inline;font-style:italic;">Leases (Topic 842)</font><font style="display:inline;">&#x201D; (&#x201C;ASU 2016-02&#x201D;). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September&nbsp;1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In November&nbsp;2015, the FASB issued ASU 2015-17, </font><font style="display:inline;font-style:italic;">Balance Sheet Classification of Deferred Taxes.</font><font style="display:inline;">&nbsp; This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.&nbsp; ASU 2015-17 is effective for annual and interim reporting periods beginning after December&nbsp;15, 2016.&nbsp; This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.&nbsp; Early application is permitted as of the beginning of the interim or annual reporting period.&nbsp; The Company adopted this standard for the annual period ending December&nbsp;31, 2015.&nbsp;&nbsp;The effect of adopting the new guidance on the balance sheet was not significant.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In September&nbsp;2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No.&nbsp;2015-16,&nbsp;</font><font style="display:inline;font-style:italic;">Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,&nbsp;</font><font style="display:inline;">or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.&nbsp;&nbsp;The new standard for an annual reporting period beginning after December&nbsp;15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December&nbsp;15, 2016.&nbsp;&nbsp;The new guidance is not expected to have significant impact on the Company&#x2019;s consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In April&nbsp;2015, the FASB issued ASU 2015-05,&nbsp;</font><font style="display:inline;font-style:italic;">Intangibles-Goodwill and Other &#x2014; Internal-Use Software; Customer&#x2019;s Accounting for Fees Paid in a Cloud Computing Arrangement</font><font style="display:inline;">. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer&#x2019;s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January&nbsp;1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In April&nbsp;2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03,&nbsp;</font><font style="display:inline;font-style:italic;">Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs)</font><font style="display:inline;">, effective for fiscal years beginning after December&nbsp;15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.&nbsp;&nbsp;The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In August&nbsp;2014, the FASB issued Accounting Standards Update No.&nbsp;2014-15, Disclosure of Uncertainties About an Entity&#x2019;s Ability to Continue as a Going Concern. This standard update provides guidance around management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December&nbsp;15, 2016. The new guidance is not expected to have a significant impact on the Company&#x2019;s consolidated financial statements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In May&nbsp;2014, the Financial Accountings Standards Board (</font><font style="display:inline;font-style:italic;">&#x201C;FASB&#x201D;</font><font style="display:inline;">) issued Accounting Standards Update No.&nbsp;2014-09, </font><font style="display:inline;font-style:italic;">Revenue from Contracts with Customers</font><font style="display:inline;">, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January&nbsp;1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 2807380 164020 12675742 9587214 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 5 - STOCKHOLDERS&#x2019; EQUITY</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On December&nbsp;7, 2011, the Company increased its authorized capital to 200,000,000 shares of Common Stock from 75,000,000 shares, changed the par value to $0.0001 per share from $.001 per share, and authorized 100,000,000 shares of preferred stock, par value $0.0001 per share.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;24, 2013, the reverse stock split ratio of one (1)&nbsp;for thirteen (13) basis was approved by the Board of Directors. On July&nbsp;18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company&#x2019;s issued and outstanding Common Stock, par value $0.0001 per share on a one (1)&nbsp;for thirteen (13) basis.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On November&nbsp;19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company&#x2019;s Common Stock as of the close of business of the record date of December&nbsp;15, 2014 shall receive one additional share of Common Stock at the close of business on December&nbsp;22, 2014 for each share of Common Stock held by such holders.&nbsp;&nbsp;All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split and stock dividend.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Series&nbsp;B Convertible Preferred Stock</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;1, 2014, the Company filed with the Secretary of State of Nevada a Certificate of Designations of Series&nbsp;B Convertible Preferred Stock (the &#x201C;Series&nbsp;B Certificate of Designations&#x201D;)&nbsp;authorizing 500,000 shares of Series&nbsp;B Convertible Preferred Stock and establishing the designations, preferences, and other rights of the Series&nbsp;B Convertible Preferred Stock. The Series&nbsp;B Certificate of Designations became effective upon filing.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;2, 2014, the Company&nbsp;issued an aggregate of 782,000 shares of Series&nbsp;B Convertible Preferred Stock valued at $2,807,380 to acquire IP Liquidity Ventures, LLC, Dynamic Advances, LLC and Sarif Biomedical, LLC. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section&nbsp;4(a)(2)&nbsp;thereof, as a transaction by an issuer not involving a public offering.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;17, 2014, </font><font style="display:inline;">the Company entered into a consulting agreement (the &#x201C;GRQ Consulting Agreement&#x201D;) with GRQ Consultants,&nbsp;Inc. (&#x201C;GRQ&#x201D;), pursuant to which GRQ shall provide certain consulting services including, but not limited to, advertising, marketing, business development, strategic and business planning, channel partner development and other functions intended to advance the business of the Company.&nbsp;&nbsp;As consideration, GRQ was entitled to 200,000 shares of the Company&#x2019;s Series&nbsp;B Convertible Preferred Stock, 50% of which vested upon execution of the GRQ Consulting Agreement, and 50% of which shall vest in six (6)&nbsp;equal monthly installments of commencing on October&nbsp;17, 2014.&nbsp;&nbsp;The first tranche of 100,000 shares of Series&nbsp;B Convertible Preferred Stock was issued to GRQ on October&nbsp;6, 2014. In addition, the GRQ Consulting Agreement allows for GRQ to receive additional shares of Series&nbsp;B Convertible Preferred Stock upon the achievement of certain performance benchmarks. All shares of Series&nbsp;B Convertible Preferred Stock issuable to GRQ shall be pursuant to the 2014 Plan (as defined below) and shall be subject to shareholder approval of the 2014 Plan on or prior to September&nbsp;16, 2015; the shareholders approved the 2014 Plan on July 31, 2015. The GRQ Consulting Agreement contains an acknowledgement that the conversion of the preferred stock into shares of the Company&#x2019;s common stock is precluded by the equity blockers set forth in the certificate of designation and in Section&nbsp;17 of the 2014 Plan to ensure compliance with NASDAQ Listing Rule&nbsp;5635(d).</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Common Stock</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;24, 2013, the reverse stock split ratio of one (1)&nbsp;for thirteen (13) basis was approved by the Board of Directors. On July&nbsp;18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company&#x2019;s issued and outstanding </font><font style="display:inline;">Common Stock</font><font style="display:inline;">, par value $0.0001 per share on a one (1)&nbsp;for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On April&nbsp;22, 2014, the Company issued 300,000 shares of restricted Common Stock to TT IP LLC pursuant to the acquisition of patents on November&nbsp;13, 2013.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;2, 2014, the Company issued 48,078 shares of unrestricted </font><font style="display:inline;">Common Stock</font><font style="display:inline;"> to an investor in the May&nbsp;2013 PIPE, pursuant to the exercise of a warrant received in the May&nbsp;2013 PIPE investment.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;30, 2014, the Company issued 200,000 shares of restricted Common Stock pursuant to the acquisition of Selene Communications Technologies, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the fair market value on the date of grant at $4.90 per share or $980,000.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On July&nbsp;18, 2014, the Company issues a total of 26,722 shares of Common Stock pursuant to the exercise of stock options held by a former member of the Company&#x2019;s Board of Directors and the Company&#x2019;s former Chief Financial Officer.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;16, 2014, the Company issued to two of its independent board members, in lieu of cash compensation, 6,178 shares of </font><font style="display:inline;">restricted Common Stock</font><font style="display:inline;">.&nbsp;&nbsp;The shares shall vest quarterly over twelve (12) months commencing on the date of grant.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On </font><font style="display:inline;">September&nbsp;30, 2014, the Company issued 50,000 shares of restricted Common Stock pursuant to the acquisition of the assets of Clouding IP, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $5.62 per share or $281,000.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended September&nbsp;30, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 84,652 shares of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On November&nbsp;19, 2014, the Board of Directors of the Company declared a stock dividend (&#x201C;Dividend&#x201D;) pursuant to which holders of the Company&#x2019;s Common Stock as of the close of business of the record date of December&nbsp;15, 2014 shall receive one additional share of Common Stock at the close of business on December&nbsp;22, 2014 for each share of Common Stock held by such holders.&nbsp;&nbsp;Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended December&nbsp;31, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 29,230 shares of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On January&nbsp;29, 2015, the Company issued 134,409 shares of the Company&#x2019;s Common Stock to DBD Credit Funding, LLC (&#x201C;DBD&#x201D;), an affiliate of Fortress Credit Corp. (&#x201C;Fortress&#x201D;), pursuant to the Fortress transaction as set forth in Note 6.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March&nbsp;13, 2015, the Company settled a dispute with a former consultant whereby the Company issued the consultant 60,000 shares of Common Stock for a full release of all claims.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended March&nbsp;31, 2015, certain holders of warrants exercised their warrants to purchase, in cash, 5,000 shares of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended June&nbsp;30, 2015, certain holders of options exercised their options to purchase, on a net exercise basis, 33,968 (net) shares of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In a series of transactions, the Series&nbsp;B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into shares of the Company&#x2019;s Common Stock, with 183,330 shares of Series&nbsp;B Convertible Preferred Stock converted into Common Stock prior to September&nbsp;30, 2015.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;21, 2015, the Company issued 150,000 shares of the Company&#x2019;s Common Stock to Alex Partners, LLC and Del Mar Consulting Group,&nbsp;Inc., pursuant to a services agreement entered into on September&nbsp;21, 2015. </font><font style="display:inline;">In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $2.23 per share or $334,500. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section&nbsp;4(a)(2)&nbsp;thereof, as a transaction by an issuer not involving a public offering.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;20, 2015, the remaining 16,666 shares of Series&nbsp;B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into 16,666 shares of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On November&nbsp;4, 2015, the Company issued 300,000 shares of the Company&#x2019;s Common Stock to Dominion Harbor Group LLC (&#x201C;Dominion&#x201D;), pursuant to a settlement agreement entered into with Dominion on October&nbsp;30, 2015.&nbsp; </font><font style="display:inline;">In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.71 per share or $513,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section&nbsp;4(a)(2)&nbsp;thereof, as a transaction by an issuer not involving a public offering.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On December&nbsp;9, 2015, the Company entered into an agreement with Melechdavid,&nbsp;Inc. (&#x201C;Melechdavid&#x201D;), </font><font style="display:inline;">pursuant to which the Company agreed to issue 100,000 shares of the Company&#x2019;s Common Stock. </font><font style="display:inline;">In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.61 per share or $161,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section&nbsp;4(a)(2)&nbsp;thereof, as a transaction by an issuer not involving a public offering.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Common Stock Warrants</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;1, 2014, the Company issued warrants to purchase 511,790 shares of Common Stock, at a price of $3.75 per share of Common Stock, pursuant to the Private Placement described in detail below. The Company reviewed the issuance of warrants, done in conjunction with the financing closed on May&nbsp;1, 2014, and determined that pursuant to ASC 480 and ASC 815, the warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In conjunction with the issuance of $5,550,000 in convertible debt on October&nbsp;16, 2014, the Company&nbsp;issued two-year Warrants to purchase 258,998 shares of the Company&#x2019;s Common Stock, par value $0.0001 per share pursuant to a securities purchase agreement. The warrants were valued at $164,020 and were recorded as a discount to the fair value of the convertible notes. The Warrants are initially convertible into shares of the Company&#x2019;s Common Stock at an exercise price of $8.25 per share. The conversion and exercise prices are subject to adjustment in the event of certain events, including stock splits and dividends. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that there was no beneficial conversion feature and that the conversion feature should not be bifurcated.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On January&nbsp;29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement (&#x201C;Fortress Purchase Securities Agreement&#x201D;) with DBD, an affiliate of Fortress, under which the Company issued a five-year warrant (&#x201C;Fortress Warrant&#x201D;) to purchase 100,000 shares of the Company&#x2019;s Common Stock exercisable at $7.44 per share, subject to adjustment.&nbsp; </font><font style="display:inline;">The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no beneficial conversion feature and that the convertible notes and warrants should not be bifurcated.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">During the year ended December&nbsp;31, 2015, warrants to purchase 5,000 shares of Common Stock were exercised and no warrants to purchase shares of Common Stock were forfeited.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">During the three months ended March&nbsp;31, 2015, the Company recorded stock based compensation expense of $3,465 in connection with the vested warrants associated with one warrant-based compensatory grant, compared to no compensation expenses for the three months ended March&nbsp;31, 2016 associated with this warrant. </font><font style="display:inline;">The warrant was valued at the time of grant on January&nbsp;26, 2012, based on the Black-Scholes model, using the strike and market prices of $3.25 per share, the term of 10 years, volatility of 191% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.96%. </font><font style="display:inline;">At December&nbsp;31, 2015, there was a total of $0 of unrecognized compensation expense related to&nbsp;future recognition of warrant-based compensation arrangements.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">A summary of the status of the Company&#x2019;s outstanding stock warrants at March&nbsp;31, 2016 is as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Number of</font><br /><font style="display:inline;">Warrants</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average Exercise</font><br /><font style="display:inline;">Price</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average</font><br /><font style="display:inline;">Remaining&nbsp;Life</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.27 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.87 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.84%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.27 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.63 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Warrants exercisable at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:6pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,021,308 </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted average fair value of warrants granted during the period</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:03.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:10.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 6pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Warrant Amendment Letter</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On April&nbsp;20, 2014, the Company sent a letter (the &#x201C;Warrant Amendment Letter&#x201D;) to all the holders of the warrants which were granted in connection with the sale of units pursuant to a securities purchase agreements which occurred between May&nbsp;2013 and August&nbsp;2013. The Warrant Amendment Letter offered to reduce the exercise price of the warrants from $6.50 per share to $5.75 per share, if the holders of the warrants accepted the Company&#x2019;s offer to exercise the warrants in full for cash by April&nbsp;22, 2014 (the &#x201C;Expiration Date&#x201D;).&nbsp;&nbsp;The Company subsequently extended the Expiration Date to April&nbsp;24, 2014. On April&nbsp;24, 2014, one holder of warrants, who is an accredited investor, accepted the Company&#x2019;s offer and thereby exercised his warrants, for gross proceeds to the Company of approximately $138,222. After analyzing the circumstances relative to the Warrant Amendment Letter &#x2013; the extremely short period of time to exercise pursuant to the Amendment Letter, the relatively small change in the exercise price and the limited response to the Amendment Letter &#x2013; the Company deemed that the change was not a significant modification of the terms of the warrant and did not assess a new fair value and consequently did not make an entry for any adjustment in the value.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March&nbsp;11, 2016, the Company entered into an agreement with the remaining investor in the Company&#x2019;s convertible debt issued on October&nbsp;9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 23,334 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $4.125 to the lower of 1) $2.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company&#x2019;s Common Stock.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Common Stock Options</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On April&nbsp;15, 2014, the Company issued a new board member a five (5)&nbsp;year option to purchase an aggregate of 20,000 shares of the Company&#x2019;s Common Stock with an exercise price of $3.295 per share, subject to adjustment, which shall vest in twelve (12) monthly installments commencing on the date of grant. The option was valued based on the Black-Scholes model, using the strike and market prices of $3.295 per share, life of three years, volatility of 51% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 0.84%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;14, 2014, the Company issued existing employees, ten (10)&nbsp;year options to purchase an aggregate of 80,000 shares of the Company&#x2019;s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3)&nbsp;annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;14, 2014, the Company issued to consultants, five (5)&nbsp;year options to purchase an aggregate of 160,000 shares of the Company&#x2019;s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3)&nbsp;annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 3.5 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.00%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On May&nbsp;15, 2014, the Company entered into an executive employment agreement with Francis Knuettel II (&#x201C;Knuettel Agreement&#x201D;) pursuant to which Mr.&nbsp;Knuettel would serve as the Company&#x2019;s Chief Financial Officer. As part of the consideration, the Company agreed to grant Mr.&nbsp;Knuettel a ten (10)&nbsp;year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $4.165 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Knuettel Agreement. </font><font style="display:inline;">The option was valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate</font><font style="display:inline;">&nbsp;</font><font style="display:inline;">as published by the Federal Reserve of 1.97%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On June&nbsp;15, 2014, the Company issued to a consultant a five (5)&nbsp;year stock option to purchase an aggregate of 40,000 shares of the Company&#x2019;s Common Stock with an exercise price of $5.05 per share, subject to adjustment, which shall vest in twenty-four (24) each monthly installments on each monthly anniversary date of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $5.05 per share, life of 3.25 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.05%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On August&nbsp;29, 2014, the Company entered into an executive employment agreement with Daniel Gelbtuch (&#x201C;Gelbtuch Agreement&#x201D;) pursuant to which Mr.&nbsp;Gelbtuch would serve as the Company&#x2019;s Chief Marketing Officer. As part of the consideration, the Company agreed to grant Mr.&nbsp;Gelbtuch ten (10)&nbsp;year stock options to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $5.62 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Gelbtuch Agreement. Mr.&nbsp;Gelbtuch&#x2019;s employment with the Company was terminated as of January&nbsp;20, 2015 and the vested shares at that time remained available for Mr.&nbsp;Gelbtuch to exercise until January 20, 2016.</font><font style="display:inline;"> &nbsp;The option was valued based on the Black-Scholes model, using the strike and market prices of $5.62 per share, life of 6.5 years, volatility of 62% based on the average volatility of comparable companies over the prior 10-year period and a discount rate as published by the Federal Reserve of 1.95%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;16, 2014, the Company issued its independent board members five (5)&nbsp;year options to purchase an aggregate of 60,000 shares of the Company&#x2019;s Common Stock with an exercise price of $7.445 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.445 per share, life of three years, volatility of 49% based on the average volatility of comparable companies over the prior 5-year period and a discount rate as published by the Federal Reserve of 1.04%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;31, 2014, the Company entered into an executive employment agreement with Enrique Sanchez (&#x201C;Sanchez Agreement&#x201D;) pursuant to which Mr.&nbsp;Sanchez would serve as the Company&#x2019;s Senior Vice President of Licensing. As part of the consideration, the Company agreed to grant Mr.&nbsp;Sanchez ten (10)&nbsp;year stock options to purchase an aggregate of 160,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Sanchez Agreement. </font><font style="display:inline;">The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;31, 2014, the Company entered into an executive employment agreement with Umesh Jani (&#x201C;Jani Agreement&#x201D;) pursuant to which Mr.&nbsp;Jani would serve as the Company&#x2019;s Chief Technology Officer and SVP of Licensing. As part of the consideration, the Company agreed to grant Mr.&nbsp;Jani ten (10)&nbsp;year stock options to purchase an aggregate of 100,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Jani Agreement. </font><font style="display:inline;">The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;31, 2014, the Company issued existing employees, ten (10)&nbsp;year options to purchase an aggregate of 680,000 shares of the Company&#x2019;s Common Stock with an exercise price of $6.40 per share, subject to adjustment, </font><font style="display:inline;">which shall vest in twenty-four (24) equal installments on each monthly anniversary</font><font style="display:inline;">. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;31, 2014, the Company issued to a consultant, a five (5)&nbsp;year options to purchase an aggregate of 30,000 shares of the Company&#x2019;s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall </font><font style="display:inline;">vest in twenty-four (24) equal installments on each monthly anniversary</font><font style="display:inline;"> of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 3.25 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.03%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On February&nbsp;5, 2015 the Company issued to a consultant, a five (5)&nbsp;year options to purchase an aggregate of 25,000 shares of the Company&#x2019;s Common Stock with an exercise price of $6.80 per share, subject to adjustment, which shall </font><font style="display:inline;">vest in twenty-four (24) equal installments on each monthly anniversary</font><font style="display:inline;"> of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.80 per share, an expected term of 3.25 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March&nbsp;6, 2015 the Company issued a new board member a five (5)&nbsp;year options to purchase an aggregate of 20,000 shares of the Company&#x2019;s Common Stock with an exercise price of $7.37 per share, subject to adjustment, which shall </font><font style="display:inline;">vest in twelve (12) equal installments on each monthly anniversary</font><font style="display:inline;"> of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.37 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.16%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March&nbsp;18, 2015 the Company issued a new board member a five (5)&nbsp;year options to purchase an aggregate of 20,000 shares of the Company&#x2019;s Common Stock with an exercise price of $6.61 per share, subject to adjustment, which shall </font><font style="display:inline;">vest in twelve (12) equal installments on each monthly anniversary</font><font style="display:inline;"> of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.61 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On April&nbsp;7, 2015 (the &#x201C;Effective Date&#x201D;), the Company entered into a consulting agreement (the &#x201C;Consulting Agreement&#x201D;) with Richard Chernicoff, a member of the Company&#x2019;s Board of Directors, pursuant to which Mr.&nbsp;Chernicoff shall provide certain services to the Company, including serving as the interim General Counsel and interim General Manager of commercial product commercialization development. Pursuant to the terms of the Consulting Agreement, Mr.&nbsp;Chernicoff shall receive a monthly retainer of $27,000 and a ten-year stock option to purchase 280,000 shares of the Company&#x2019;s Common Stock pursuant to the Company&#x2019;s 2014 Plan. The stock options shall have an exercise price of $6.76 per share, the closing price of the Company&#x2019;s common stock on the date immediately prior to the Board of Directors approval of such stock options and the options shall vest as follows: 25% of the option shall vest on the 12 month anniversary of the Effective Date and thereafter 2.083% on the 21st day of each succeeding calendar month for the following twelve months, provided Mr.&nbsp;Chernicoff continues to provide services (in addition to as a member of the Company&#x2019;s Board of Directors) at the time of vesting. The option shall be subject in all respects to the terms of the 2014 Plan. Notwithstanding anything herein to the contrary, the remainder of the option shall be subject to the following as an additional condition of vesting: (A)&nbsp;options to purchase 70,000 shares of the Company&#x2019;s Common Stock under the option shall not vest at all unless the price of the Company&#x2019;s common stock while Mr.&nbsp;Chernicoff continues as an officer and/or director reaches $8.99 and (B)&nbsp;options to purchase 70,000 shares of the Company&#x2019;s Common Stock under the option shall not vest at all unless the price of the Company&#x2019;s common stock while Mr.&nbsp;Chernicoff continues as an officer and/or director reaches $10.14. For valuation purposes, </font><font style="display:inline;">the options were divided into two parts &#x2013; the time-based vesting component and the performance-based vesting component. The time-based vesting component was valued based on the Black-Scholes model, using the strike and market prices of $6.76 per share, an expected term of 6.25 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.53%. The performance-based vesting component was valued based on the Monte Carlo Simulation model, using the strike and market prices of $6.76 per share, an expected term of 10.0 years, volatility of 61% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.89%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On September&nbsp;16, 2015, the Company issued its independent board members ten-year options to purchase an aggregate of 80,000 shares of the Company&#x2019;s Common Stock with an exercise price of $2.03 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.03 per share, an expected term of 5.5 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;14, 2015, the Company issued certain of its employees ten-year options to purchase an aggregate of 385,000 shares of the Company&#x2019;s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On October&nbsp;14, 2015, the Company issued certain of its consultants ten (10)&nbsp;year options to purchase an aggregate of 70,000 shares of the Company&#x2019;s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">For the three months ended March&nbsp;31, 2016 the Company recorded option-based compensation expenses of $550,436. A summary of the stock options as of March&nbsp;31, 2016 is as follows:</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Number of</font><br /><font style="display:inline;">Options</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average Exercise</font><br /><font style="display:inline;">Price</font></p> </td> <td valign="bottom" style="width:02.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted</font><br /><font style="display:inline;">Average</font><br /><font style="display:inline;">Remaining Life</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at December&nbsp;31, 2015</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,383,267&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.25&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.11 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Granted</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Cancelled</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Forfeited</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,167&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.45&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.31 </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Exercised</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 2.9pt 0pt 0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Balance at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,339,100&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.22&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:2.9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.93 </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options Exercisable at March&nbsp;31, 2016</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,122,560&nbsp; </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Options expected to vest</font></p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,216,541&nbsp; </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:14.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Weighted average fair value of options granted during the period</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:05.16%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;&nbsp;$</font></p> </td> <td valign="bottom" style="width:08.84%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">-&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:52.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:05.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.50%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:13.00%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> </tr> </table></div> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Stock options outstanding at March&nbsp;31, 2016 as disclosed in the above table have approximately $59,150 in intrinsic value at March&nbsp;31, 2016.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 3-for-2 one-for-fifteen one-for-five one (1) for thirteen (13) one (1) for thirteen (13) 48078 134409 134409 1626924 782000 48078 60000 150000 300000 100000 300000 200000 6178 50000 100000 84652 26722 29230 33968 980000 281000 818000 334500 513000 161000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">NOTE 7 &#x2013; SUBSEQUENT EVENTS</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On April&nbsp;18, 2016, a wholly-owned subsidiary of the Company entered into a settlement agreement under which the Company agreed to dismiss with prejudice certain pending litigation. Under the terms of the settlement the Company will book revenue on the amount of $24.9 million. A portion of the proceeds of the settlement will be paid to the original patent owner as well as contingent fees to counsel. In connection with the settlement, the parties have agreed to keep the additional terms of the settlement confidential. The Company believes that other voice recognition services also infringe patents involved in the settled action.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-weight:bold;">Use of Estimates and Assumptions</font> </p> <p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to,&nbsp;estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.</font> </p></div><div style="margin-left:0%;margin-right:0%;"> <p><font size="1"> </font></p></div><div style="margin-left:0%;margin-right:0%;"></div> </div> 13868811 14967141 13868811 14967141 13868811 14967141 EX-101.SCH 8 mara-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - ACQUISITIONS (Details4) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - ACQUISITIONS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - ACQUISITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Accounts Receivable, Concentration of Revenue and Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - ACQUISITIONS - CyberFone Systems, LLC (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical 2 (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - ACQUISITIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - INTANGIBLE ASSETS - Future amortization of current intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - INTANGIBLE ASSETS - Intangible Asset Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - INTANGIBLE ASSETS - Patent portfolios (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - STOCKHOLDERS' EQUITY Common Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 40505 - Disclosure - STOCKHOLDERS' EQUITY - Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mara-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 mara-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 mara-20160331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EX-101.PRE 12 mara-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT v3.4.0.3
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2016
May. 06, 2016
Document And Entity Information    
Entity Registrant Name Marathon Patent Group, Inc.  
Entity Central Index Key 0001507605  
Document Type 10-Q  
Document Period End Date Mar. 31, 2016  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   14,967,141
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2016  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash $ 1,420,390 $ 2,555,151
Accounts receivable - net of allowance for bad debt of $375,750 and $375,750 for March 31, 2016 and December 31, 2015 153,112 136,842
Bonds posted with courts 1,443,457 1,748,311
Prepaid expenses and other current assets, net of discounts of $3,414 and $3,414 for March 31, 2016 and December 31, 2015 146,336 338,598
Total current assets 3,163,295 4,778,902
Other assets:    
Property and equipment, net of accumulated depreciation of $77,653 and $67,052 for March 31, 2016 and December 31, 2015 52,793 61,297
Intangible assets, net of accumulated amortization of $16,423,203 and $15,557,353 for March 31, 2016 and December 31, 2015 23,208,298 25,457,639
Deferred tax assets 14,385,393 12,437,741
Other non current assets, net of discounts of $3,900 and $4,831 and $0 for March 31, 2016 and December 31, 2015 207,100 9,169
Goodwill 4,605,733 4,482,845
Total other assets 42,459,317 42,448,691
Total Assets 45,622,612 47,227,593
Current liabilities:    
Accounts payable and accrued expenses 8,832,010 6,534,825
Clouding IP earn out - current portion 103,049 33,646
Notes payable, net of discounts of $754,421 and $730,945 for March 31, 2016 and December 31, 2015 11,379,212 10,383,177
Total current liabilities 20,314,271 16,951,648
Long-term liabilities    
Notes payable, net of discount of $1,224,817 and $1,425,167 for March 31, 2016 and December 31, 2015 10,493,877 12,223,884
Clouding IP earn out 3,213,177 3,281,238
Deferred tax liability 964,998 1,044,997
Revenue share liability 1,000,000 1,000,000
Other long term liability 49,075 50,084
Total long-term liabilities 15,721,127 17,600,203
Total liabilities 36,035,398 34,551,851
Stockholders' Equity:    
Preferred stock Series B, $.0001 par value, 50,000,000 shares authorized: 782,004 and 782,004 issued and outstanding at March 31, 2016 and December 31, 2015 78 78
Common stock, $.0001 par value; 200,000,000 shares authorized; 14,967,141 and 14,867,141 at March 31, 2016 and December 31, 2015 1,497 1,487
Additional paid-in capital 43,774,961 43,217,513
Accumulated other comprehensive (loss) (1,018,385) (1,265,812)
Accumulated deficit (33,170,937) (29,277,524)
Total Marathon Patent Group stockholders' equity 9,587,214 12,675,742
Total liabilities and stockholders' equity $ 45,622,612 $ 47,227,593
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Mar. 31, 2016
Dec. 31, 2015
Allowance for bad debt $ 375,750 $ 375,750
Discounts on prepaid expenses and other current assets 3,414 3,414
Accumulated depreciation of property and equipment 77,653 67,052
Accumulated amortization of Intangible assets 16,423,203 15,557,353
Discount on other noncurrent assets 3,900 4,831
Discount on notes payable 754,421 730,945
Discount on notes payable $ 1,224,817 $ 1,425,167
Stockholders' Equity:    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued 14,967,141 14,867,141
Common stock, shares outstanding 14,967,141 14,867,141
Series B preferred stock    
Stockholders' Equity:    
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 50,000,000 50,000,000
Preferred stock, shares issued 782,004 782,004
Preferred stock, shares outstanding 782,004 782,004
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME    
Revenues $ 2,059,676 $ 4,093,869
Expenses    
Cost of revenues 2,639,976 4,328,165
Amortization of patents and website 2,025,899 2,598,461
Compensation and related taxes 1,033,346 1,581,074
Consulting fees 280,776 896,543
Professional fees 405,493 769,615
General and administrative 217,010 219,481
Patent Impairment 373,195 0
Total operating expenses 6,975,695 10,393,339
Operating loss (4,916,019) (6,299,470)
Other income (expenses)    
Other income (expense) (2,159) (39,402)
Foreign exchange gain (loss) 6,978  
Change in fair value adjustment of Clouding IP earn out (1,342)  
Interest income 931 2
Interest expense (1,006,850) (931,541)
Total other income (expenses) (1,002,442) (970,941)
Loss before benefit for income taxes (5,918,461) (7,270,411)
Income tax benefit 2,025,048 2,488,840
Net loss $ (3,893,413) $ (4,781,571)
Loss per common share, basic and diluted:    
Loss per common share, basic and diluted: $ (0.26) $ (0.34)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and Diluted 14,967,141 13,868,811
Other comprehensive income (loss)    
Foreign currency translation adjustments $ 247,427 $ (950,239)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Net loss $ (3,893,413) $ (4,781,571)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 1,652 1,869
Amortization of patents and website 2,025,899 2,598,461
Deferred tax asset (1,934,419) (2,335,116)
Deferred tax liability (76,463) (161,984)
Impairment of intangible assets 373,195  
Stock based compensation 550,436 685,753
Stock issued for services   750,334
Non-cash interest, discount, and financing costs 605,690 613,719
Change in fair value of Clouding earnout 1,342  
Other non-cash adjustments (33,607) 83,148
Changes in operating assets and liabilities    
Accounts receivable (15,275) (546,101)
Bonds posted with courts 359,960  
Prepaid expenses and other current assets 192,352 26,248
Other non-current assets 2,069  
Accounts payable and accrued expenses 1,953,751 1,920,185
Net cash provided by (used in) operating activities 113,169 (1,145,055)
Cash flows from investing activities:    
Purchase of property, equipment and other intangible assets (2,097) (37,147)
Net cash used in investing activities (2,097) (37,147)
Cash flows from financing activities:    
Payment on convertible debt   (5,050,000)
Cash received upon issuance of note payable, net of $400,000 loan fee   19,600,000
Cash received upon exercise of warrant   18,750
Payments of notes payable to vendors (63,840)  
Net cash provided by (used in) financing activities (1,248,440) 5,568,750
Effect of exchange rate changes on cash 2,607 8,852
Net increase (decrease) in cash (1,134,761) 4,395,400
Cash at beginning of period 2,555,151 5,082,569
Cash at end of period 1,420,390 9,477,969
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Cash paid for: Interest expense 401,159 317,821
Cash paid for: Taxes paid 7,999 8,260
Cash paid for: Loan fees   400,000
Cash invested in 3D Nano 115,000  
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES    
Common stock issued in conjunction with note payable   1,000,000
Warrant issued in conjunction with note payable   318,679
Revenue share liability incurred in conjunction with note payable   1,000,000
Convertible debt warrant repricing 6,425  
Fortress    
Cash flows from financing activities:    
Payment of note payable $ (1,184,600)  
Medtech And Orthophoenix    
Cash flows from financing activities:    
Payment of note payable   (3,000,000)
Orthophoenix LLC    
Cash flows from financing activities:    
Payment of note payable   (3,750,000)
Sarif    
Cash flows from financing activities:    
Payment of note payable   (276,250)
IP Liquidity    
Cash flows from financing activities:    
Payment of note payable   (1,068,750)
Dynamic Advances    
Cash flows from financing activities:    
Payment of note payable   $ (905,000)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
ORGANIZATION AND DESCRIPTION OF BUSINESS
3 Months Ended
Mar. 31, 2016
ORGANIZATION AND DESCRIPTION OF BUSINESS  
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Our business is to acquire patents and patent rights and to monetize the value of those assets to generate revenue and profit for the Company.  We acquire patents and patent rights from their owners, who range from individual inventors to Fortune 500 companies.  Part of our acquisition strategy is to acquire or invest in patents and patent rights that cover a wide-range of subject matter, which allows us to achieve the benefits of a growing diversified portfolio of assets.  Generally, the patents and patent rights that we acquire are characterized by having large identifiable companies who are or have been using technology that infringes our patents and patent rights.  We generally monetize our portfolio of patents and patent rights by entering into license discussions, and if that is unsuccessful, initiating enforcement activities against any infringing parties with the objective of entering into a standard form of comprehensive settlement and license agreement that may include the granting of non-exclusive retroactive and future rights to use the patented technology, a covenant not to sue, a release of the party from certain claims, the dismissal of any pending litigation and other terms that are appropriate in the circumstances.  Our strategy has been developed with the expectation that it will result in a long-term, diversified revenue stream for the Company.

 

Marathon Patent Group, Inc. (the “Company”) was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, we changed our name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, we discontinued our minerals business and began to invest in real estate properties in Southern California. In October 2012, we discontinued our real estate business when our CEO joined the firm and we commenced our current business, at which time the Company’s name was changed to Marathon Patent Group, Inc.

 

On December 7, 2011, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada in order to change its name to “American Strategic Minerals Corporation” from “Verve Ventures, Inc.”, and increase the Company’s authorized capital to 200,000,000 shares of common stock, par value $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. During June 2012, the Company decided to discontinue its exploration and potential development of uranium and vanadium minerals business.

 

On August 1, 2012, the shareholders holding a majority of the Company’s voting capital voted in favor of (i) changing the name of the Company to “Fidelity Property Group, Inc.” and (ii) the adoption the 2012 Equity Incentive Plan and reserving 10,000,000 shares of common stock for issuance thereunder (the “2012 Plan”).  The board of directors of the Company (the “Board of Directors”) approved the name change and the adoption of the 2012 Plan on August 1, 2012. The Company did not file an amendment to its Articles of Incorporation with the Secretary of State of Nevada and subsequently abandoned the decision to adopt the “Fidelity Property Group, Inc.” name and discontinue its real estate business.

 

On October 1, 2012, the shareholders holding a majority of the Company’s voting capital had voted and authorized the Company to (i) change the name of the Company to Marathon Patent Group, Inc. (the “Name Change”) and (ii) effectuate a reverse stock split of the Company’s common stock by a ratio of 3-for-2 (the “Reverse Split”) within one year from the date of approval of the stockholders of the Company.  The Board of Directors approved the Name Change and the Reverse Split on October 1, 2012. The Board of Directors determined the name “Marathon Patent Group, Inc.” better reflected the long-term strategy in exploring other opportunities and the identity of the Company going forward. On February 15, 2013, the Company filed the Certificate of Amendment with the Secretary of State of the State of Nevada in order to effectuate the Name Change. On May 31, 2013, shareholders of record holding a majority of the outstanding voting capital of the Company approved a reverse stock split of the Company’s issued and outstanding common stock by a ratio of not less than one-for-five and not more than one-for-fifteen at any time prior to April 30, 2014, with such ratio to be determined by the Company’s Board of Directors, in its sole discretion. On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

 

On September 16, 2014, the Board of Directors of the Company approved and adopted, subject to shareholder approval on or prior to September 16, 2015, the Company’s 2014 Equity Incentive Plan. The Company’s 2014 Equity Incentive Plan was approved by the shareholders of the Company at the annual meeting held on July 31, 2015.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 received one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders. Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company’s consolidated financial position as of March 31, 2016, and the results of operations and cash flows for the three months ended March 31, 2016 have been included. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December 31, 2015, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2016. The consolidated balance sheet as of December 31, 2015 was derived from those financial statements.

 

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of March 31, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

 

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

 

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote.  At March 31, 2016 and December 31, 2015, the Company had recorded an allowance for bad debts in the amounts of $375,750 and $375,750, respectively.  Accounts receivable-net at March 31, 2016 and December 31, 2015, amounted to $153,112 and $136,842, respectively. As of March 31, 2016, accounts receivable related to one license accounted for approximately 41% of the Company’s total accounts receivable, accounts receivable related to recurring royalties represented approximately 42% of total accounts receivable and the remainder of the accounts receivable is primarily related to a trade receivable associated with the terminated Uniloc merger. As of December 31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company’s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable. As of March 31, 2016, accounts receivable represented 7% of revenues for the three months ended March 31, 2016 and as of December 31, 2015, accounts receivable represented 2% of revenues for the three months ended December 31, 2015.

 

Concentration of Revenue and Geographic Area

 

Patent license revenue from enforcement activities originates in either the United States or Germany. Revenue attributable to the United States involves US patents, revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.

 

Revenues from two licenses accounted for approximately 93% of the Company’s operating revenues for the three months ended March 31, 2016 and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended March 31, 2015 as set forth below.

 

For the Three Months Ended March 31, 2016

 

For the Three Months Ended March 31, 2015

Licensor

 

License
Amount

 

% of Revenue

 

Licensor

 

License
Amount

 

% of Revenue

Signal IP, Inc.

 

$

1,900,000 

 

92%

 

Vantage Point Technology, Inc.

 

$

 

2,750,000 

 

67%

Signal IP, Inc.

 

$

15,000 

 

1%

 

Signal IP, Inc.

 

$

 

275,000 

 

7%

 

 

 

 

 

 

Sarif Biomedical, LLC

 

$

 

225,000 

 

6%

 

 

 

 

 

 

TLIF, LLC

 

$

 

220,000 

 

5%

 

 

 

 

 

 

Vantage Point Technology, Inc.

 

$

 

80,000 

 

2%

% of Total Revenues

 

93%

 

% of Total Revenues

87%

 

The remainder of the revenue is attributable to running royalties in the Company’s Medtech portfolio.

 

While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

 

The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 93% of its revenues for the three months ended March 31, 2016 from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties.

 

The Company’s subsidiaries entered into two license agreements during the three months ended March 31, 2016.

 

Cost of Revenue

 

Cost of revenues mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.

 

Prepaid Expenses, Bonds Posted and Other Current Assets

 

Prepaid expenses and other current assets of $146,336 and $338,598 at March 31, 2016 and December 31, 2015, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

In addition, the Company had outstanding litigation bonds in the amount of $1,443,457 and $1,748,311 at March 31, 2016 and December 31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to some of the Company’s patents in German courts. The difference in the balance of the litigation bonds at March 31, 2016 compared to December 31, 2015 is attributable to $55,106 in currency translation impact and the return of $359,960 in bonds related to the litigation against Schrader and TRW, which were resolved in the fourth quarter of 2015.

 

Fair Value of Financial Instruments

 

The Company adopted FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of March 31, 2016, the Company determined that there was no change to the Clouding IP earn out liability or the carrying value of the Clouding IP intangible assets.

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of March 31, 2016 and December 31, 2015, the Company had outstanding bonds in the amount of $1,443,457 and $1,748,311, respectively. The Company adjusted the value as of March 31, 2016 of the bonds to reflect changes to the exchange rate between the Euro and the US Dollar.

 

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.  With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.  The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

 

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2015 tax returns. After review of the 2015 financial statements and the results of operations through March 31, 2016, the Company has recorded a deferred tax asset in the amount of $14,385,393, from which the Company expects to realize benefits in the future, and a deferred tax liability of $964,998.

 

The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.

 

Basic and Diluted Net Earnings (Loss) per Share

 

Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,339,100 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at March 31, 2016, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

 

 

For the Three Months
Ended March 31, 2016

 

For the Three Months
Ended March 31, 2015

 

 

 

 

 

 

 

Net loss

 

(3,893,413)

 

(4,781,571)

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

Weighted Average Common Shares - Basic

 

14,967,141

 

13,868,811 

 

Weighted Average Common Shares - Diluted

 

14,967,141

 

13,868,811 

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

Income (Loss) - Basic

 

$

(0.26)

 

$

(0.34)

 

Income (Loss) - Diluted

 

$

(0.26)

 

$

(0.34)

 

 

Intangible Assets

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

 

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

 

1.

Significant underperformance relative to expected historical or projected future operating results;

2.

Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.

Significant negative industry or economic trends; and

4.

Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three months ended March 31, 2016 and March 31, 2015, the Company recorded no impairment charge to its goodwill.

 

Other Intangible Assets

 

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

 

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”.  The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

 

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March 31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Reclassification

 

Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.

 

Recent Accounting Pronouncements

 

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

 

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

 

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

 

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

 

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS
3 Months Ended
Mar. 31, 2016
ACQUISITIONS  
ACQUISITIONS

NOTE 3 — ACQUISITIONS

 

Dynamic Advances, IP Liquidity and Sarif Biomedical

 

On May 2, 2014, the Company completed the acquisition of certain ownership rights (the “Acquired Intellectual Property”) from TechDev, Granicus IP, LLC (“Granicus”) and SFF pursuant to the terms of three purchase agreements between: (i) the Company, TechDev, SFF and DA Acquisition LLC, a newly formed Texas limited liability company and wholly-owned subsidiary of the Company; (ii) the Company, Granicus, SFF and IP Liquidity Ventures Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company; and (iii) the Company, TechDev,  SFF and Sarif Biomedical Acquisition LLC, a newly formed Delaware limited liability company and wholly-owned subsidiary of the Company (the “DA Agreement,” the “IP Liquidity Agreement” and the “Sarif Agreement,” respectively and the collective transactions, the “Acquisitions”).

 

Dynamic Advances

 

Pursuant to the DA Agreement, the Company acquired 100% of the limited liability company membership interests of Dynamic Advances, LLC, a Texas limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock.  Under the terms of the DA Agreement, TechDev and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Dynamic Advances, LLC holds exclusive license to monetize certain patents owned by a third party.

 

On May 2, 2014, the Company issued TechDev and SFF a promissory note in order to evidence the second cash payment due under the terms of the DA Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the DA Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock, that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for Dynamic Advances, including capitalized costs associated with the purchase, was $6,653,078.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

IP Liquidity

 

Pursuant to the IP Liquidity Agreement, the Company acquired 100% of the limited liability company membership interests of IP Liquidity Ventures, LLC, a Delaware limited liability company, in consideration for: (i) two cash payments of $2,375,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $2,850,000 if not made on or before June 30, 2014; and (ii) 195,500 shares of the Company’s Series B Convertible Preferred Stock.  Under the terms of the IP Liquidity Agreement, Granicus and SFF are entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below.  IP Liquidity Ventures, LLC holds contract rights to the proceeds from the monetization of certain patents owned by a number of third parties.

 

On May 2, 2014, the Company issued Granicus and SFF a promissory note in order to evidence the second cash payment due under the terms of the IP Liquidity Agreement in the amount of $2,375,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $2,850,000 if the Company’s payment pursuant to the terms of the IP Liquidity Agreement were not made on or before June 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, Granicus and SFF extended the maturity to March 31, 2015 in return for a payment of $249,375, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on April 1, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for IP Liquidity the promissory note balance of $2,850,000.  Further, the Company had the Series B Convertible Preferred Stock valued by a third party firm that determined, based on the rights and privileges of the Series B Convertible Preferred Stock that it was on par with the value of the Company’s Common Stock. The total amount of consideration paid by the Company for IP Liquidity, including capitalized costs associated with the purchase, was $6,653,078.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets.  Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

Sarif Biomedical

 

Pursuant to the Sarif Agreement, the Company acquired 100% of the limited liability company membership interests of Sarif Biomedical, LLC, a Delaware limited liability company, in consideration for two cash payments of $250,000, one payment due at closing and the other payment due on or before September 30, 2014, with such second payment being subject to increase to $300,000 if not made on or before June 30, 2014.  Under the terms of the Sarif Agreement, TechDev is entitled to possible future payments for a maximum consideration of $250,000,000 pursuant to the Pay Proceeds Agreement described below. Sarif Biomedical, LLC holds ownership rights to certain patents.

 

On May 2, 2014, the Company issued TechDev a promissory note in order to evidence the second cash payment due under the terms of the Sarif Agreement in the amount of $250,000 due on or before September 30, 2014, with such amount due under the terms of the promissory note being subject to increase to $300,000 if the Company’s payment pursuant to the terms of the Sarif Agreement were not made on or before September 30, 2014. The promissory note matured on September 30, 2014; effective September 30, 2014, TechDev extended the maturity to March 31, 2015 in return for a payment of $26,250, payable within thirty days. The payment for this extension of the maturity date was made on October 10, 2014 and the promissory note was repaid on February 24, 2015. The promissory note did not otherwise include any interest payable by the Company. Since the Company did not make the payment on the promissory note prior to June 30, 2014, the Company included in the consideration paid for Dynamic Advances the higher principal amount of the promissory note. The total amount of consideration paid by the Company for Sarif Biomedical, including capitalized costs associated with the purchase, was $552,024.

 

After evaluating the facts and circumstances of the purchase, the Company determined that this was an asset purchase. In coming to its conclusion, the Company reviewed the status of the assets, the historical activity and the absence of any employees, licenses, revenues, and any other assets other than the IP Assets. Further, as there were no assumed licensees or historical revenues, the Company was not certain that it would be able to obtain access to customers pursuant to AC 805-10-55-7.

 

Dynamic Advances, IP Liquidity and Sarif Biomedical

 

Pursuant to the Pay Proceeds Agreement, the Company may pay the sellers a percentage of the net recoveries (gross revenues minus certain defined expenses) that the Company makes with respect to the assets held by the entities that the Company acquired pursuant to the DA Agreement, the IP Liquidity Agreement and the Sarif Agreement (the “IP Assets”).  Under the terms of the Pay Proceeds Agreement, if the Company recovers $10,000,000 or less with regard to the IP Assets, then nothing is due to the sellers; if the Company recovers between $10,000,000 and $40,000,000 with regard to the IP Assets, then the Company shall pay 40% of the net proceeds of such recoveries to the sellers; and if the Company recovers over $40,000,000 with regard to the IP Assets, the Company shall pay 50% of the net proceeds of such recoveries to the sellers.  In no event will the total payments made by the Company under the Pay Proceeds Agreement exceed $250,000,000.

 

Pursuant to a Registration Rights Agreement with the sellers (the “Acquisition Registration Rights Agreement”), the Company agreed to file a “resale” registration statement with the SEC covering at least 10% of the registrable shares of the Company’s Series B Convertible Preferred Stock issued to the sellers under the terms of the DA Agreement and the IP Liquidity Agreement, at any time on or after November 2, 2014 upon receipt of a written demand from the sellers which describes the amount and type of securities to be included in the registration and the intended method of distribution thereof.  The Company shall not be required to file more than three such registration statements not more than 60 days after the receipt of each such written demand from the sellers.

 

TechDev and Mr. Erich Spangenberg (the founder of IP Nav) and his spouse Audrey Spangenberg have jointly filed a Schedule 13G and are deemed to be affiliates of the Company.

 

Selene Communication Technologies

 

On June 17, 2014, Selene Communication Technologies Acquisition LLC (“Acquisition LLC”), a Delaware limited liability company and newly formed wholly owned subsidiary of the Company, entered into a merger agreement with Selene Communication Technologies, LLC (“Selene”).

 

Selene owns a patent portfolio consisting of three United States patents in the field of search and network intrusion that relate to tools for intelligent searches applied to data management systems as well as global information networks such as the internet. IP Nav will continue to support and manage the portfolio of patents and retain a contingent participation interest in all recoveries.  IP Nav provides patent monetization and support services under an existing agreement with Selene.

 

Pursuant to the terms of the Selene Interests Sale Agreement, Selene merged with and into Acquisition LLC with Selene surviving the merger as the wholly owned subsidiary of the Company.  The Company (i) issued 100,000 shares of common stock to the Selene Sellers and (ii) paid the Selene Sellers $50,000 cash.  The Company valued these common shares at the fair market value on the date of grant at $9.80 per share or $980,000. The transaction resulted in a business combination and caused Selene to become a wholly-owned subsidiary of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations” in which the Company is the acquirer for accounting purposes and Selene is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

990,000 

 

Net working capital

 

37,000 

 

Goodwill

 

3,000 

 

 

 

 

 

Net purchase price

 

$

1,030,000 

 

 

 

 

 

 

 

Clouding Corp.

 

On August 29, 2014, the Company entered into a patent purchase agreement (the “Clouding Agreement”) between Clouding Corp., a Delaware corporation and a wholly-owned subsidiary of the Company (“Clouding”) and Clouding IP, LLC, a Delaware limited liability company (“Clouding IP”), pursuant to which Clouding acquired a portfolio of patents from Clouding IP. Clouding owns patents related to network and data management technology.

 

The Company paid Clouding IP (i) $1.4 million in cash, (ii) $1.0 million in the form of a promissory note issued by the Company that would have matured on October 31, 2014, (iii) 25,000 shares of its restricted common stock valued at $281,000 and (iv) fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses) in excess of $4.0 million in net revenues that the Company makes with respect to the patents purchased from Clouding IP. The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $11.24 per share or $281,000 and the promissory note was paid in full prior to October 31, 2014. The revenue share under item (iv) above was booked as an earn out liability on the balance sheet in accordance with the appraisal of the consideration and intangible value. The Company booked a payable to the sellers pursuant to the earn out liability in the amount of $2,148,000 at September 30, 2014, based on license agreements entered into during the quarter. No further amount is owed until the Company generates additional revenue, if any, from the Clouding patents.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

14,500,000 

 

Goodwill

 

1,296,000 

 

 

 

 

 

Net purchase price

 

$

15,796,000 

 

 

 

 

 

 

 

Total consideration paid of the following:

 

Cash

 

$

1,400,000 

 

Promissory Note

 

1,000,000 

 

Common Stock

 

281,000 

 

Earn Out Liability

 

13,115,000 

 

 

 

 

 

Net purchase price

 

$

15,796,000 

 

 

 

 

 

 

 

Historical financial statements of Clouding IP and the pro forma condensed combined consolidated financial statements (both carve-out of certain operations of Clouding IP) can be found on the Form 8-K/A filed with the SEC on November 12, 2014.  The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

 

TLI Communications LLC

 

On September 19, 2014, TLI Acquisition Corp (“TLIA”), a Virginia corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the membership interests of TLI Communications LLC (“TLIC”), a Delaware limited liability company. TLIC owns a patent in the telecommunications field.

 

Pursuant to the terms of the TLIC Interests Sale Agreement, TLIC merged with and into TLIA with TLIC surviving the merger as the wholly-owned subsidiary of the Company.  The Company (i) agreed to issue 60,000 shares of Common Stock to the sellers of TLIC (“TLIC Sellers”), (ii) paid the TLIC Sellers $350,000 cash and (iii) agreed to pay the TLIC Sellers a fifty percent (50%) of the net recoveries (gross revenues minus certain defined expenses and the cash portion of the acquisition consideration) that the Company makes with respect to the patent purchased pursuant to the acquisition of TLIC.  The Company valued the Common Stock at the fair market value on the date of the Interests Sale Agreement at $13.63 per share or $818,000. The cash portion of the consideration was outstanding at September 30, 2014 and was subsequently paid in October 2014. The transaction resulted in a business combination and caused TIC to become a wholly-owned subsidiary of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

940,000 

 

Goodwill

 

228,000 

 

 

 

 

 

Net purchase price

 

$

1,168,000 

 

 

 

 

 

 

 

Medtech Entities

 

On October 13, 2014, Medtech Group Acquisition Corp (“Medtech Corp.”), a Texas corporation and newly formed wholly-owned subsidiary of the Company, entered into an interest sale agreement to purchase 100% of the equity or membership interests of OrthoPhoenix, LLC (“OrthoPhoenix”), a Delaware limited liability company, TLIF, LLC (“TLIF”) and MedTech Development Deutschland GmbH (“MedTech GmbH” and along with OrthoPhoenix and TLIF, the “Medtech Entities”) from MedTech Development, LLC (“MedTech Development”). The Medtech Entities own patents in the medical technology field.

 

Pursuant to the terms of the Interest Sale Agreement between MedTech Development, Medtech Corp. and the Medtech Entities, the Company (i) paid MedTech Development $1,000,000 cash and (ii) issue a Promissory Note to MedTech Development in the amount of $9,000,000 and (iii) assumed existing debt payable to Medtronics, Inc.  The assumed debt payable to Medtronics was renegotiated, as a result of which, the outstanding amount was $6.25 million prior to any repayment by the Company. The debt was due in installments through July 20, 2015; in the event that the Company paid the total amount due by June 30, 2015, the Company would receive a reduction in the remaining principal owed by the Company in the amount of $750,000. The transaction resulted in a business combination and caused the Medtech Entities to become wholly-owned subsidiaries of the Company.

 

The Company accounted for the acquisition as a business combination in accordance with ASC 805 “Business Combinations”. The Company is the acquirer for accounting purposes and TLIC is the acquired company.  The Company engaged a third party valuation firm to determine the fair value of the assets purchases, and the net purchase price paid by the Company was subsequently allocated to assets acquired and liabilities assumed on the records of the Company as follows:

 

Intangible assets

 

$

12,800,000 

 

Goodwill

 

2,700,000 

 

 

 

 

 

Net purchase price

 

$

15,500,000 

 

 

 

 

 

 

 

Historical financial statements of the Medtech Entities and the pro forma condensed combined consolidated financial statements can be found on the Form 8-K/A filed with the SEC on December 24, 2014. The unaudited pro forma condensed combined consolidated financial statements are not necessarily indicative of the results that actually would have been attained if the merger had been in effect on the dates indicated or which may be attained in the future. Such statements should be read in conjunction with the historical financial statements of the Company.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS
3 Months Ended
Mar. 31, 2016
INTANGIBLE ASSETS  
INTANGIBLE ASSETS

NOTE 4 – INTANGIBLE ASSETS

 

Intangible assets of the Company, including adjustments for currency translation adjustments, consisted of the following:

 

 

 

March 31, 2016

 

December 31, 2015

 

 

 

 

 

 

 

Intangible Assets

 

  $

39,631,501

 

  $

41,014,992

 

Accumulated Amortization & Impairment

 

(16,423,203)

 

(15,557,353)

 

 

 

 

 

 

 

 

Intangible assets, net

 

  $

23,208,298

 

  $

25,457,639

 

 

 

 

 

 

 

 

 

 

Other than the Company’s website as set forth in the table above, intangible assets are comprised of patents with estimated useful lives between approximately 1 to 15 years. The website was determined to have an estimated useful life of 3 years. Once placed in service, the Company will amortize the costs of intangible assets over their estimated useful lives on a straight-line basis.  Costs incurred to acquire patents, including legal costs, are also capitalized as long-lived assets and amortized on a straight-line basis with the associated patent. Amortization of patents is included in operating expenses as reflected in the accompanying consolidated statements of operations. The Company recorded an impairment charge to its long-lived assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

 

Patent and website amortization expense for the three months ended March 31, 2016 and March 31, 2015 was $2,025,899 and $2,598,461, respectively, net of foreign currency translation adjustments. Future amortization of intangible assets, net of foreign currency translation adjustments is as follows:

 

2016

 

  $

5,440,463

 

2017

 

5,251,025

 

2018

 

3,691,108

 

2019

 

2,846,570

 

2020

 

2,121,609

 

2021 and thereafter

 

3,857,523

 

 

 

 

 

Total

 

  $

23,208,298

 

 

 

 

 

 

 

The Company made the following patent purchases:

 

-      In April 2013, the Company through its subsidiary, Relay IP, Inc. acquired a US patent for $350,000;

-      In April 2013, the Company acquired 10 US patents, 27 foreign patents and 1 patent pending from CyberFone Systems valued at $1,135,512;

-      In June 2013, in connection with the closing of a licensing agreement with Siemens Technology, we acquired a patent portfolio from that company valued at $1,000,000;

-      In September 2013, the Company acquired 14 US patents for a total purchase price of $1,100,000;

-      In November 2013, the Company acquired four patents for 150,000 shares of the Company’s Common Stock, which the Company valued at $718,500 based on the fair market value of the stock issued;

-      In December 2013, the Company acquired certain patents from Delphi Technologies, Inc. for $1,700,000 pursuant to a Patent Purchase Agreement entered into on October 31, 2013 and Amended on December 16, 2013;

-      In December 2013, in connection with a licensing agreement with Zhone, the Company acquired a portfolio of patents from Zhone;

-      In December 2013, in connection with a settlement and license agreement, we agreed to settle and release another defendant for past and future use of our patents, whereby the defendant agreed to assign and transfer 2 U.S. patents and rights to the Company;

-      In May 2014, we acquired ownership rights of Dynamic Advances, LLC, a Texas limited liability company, IP Liquidity Ventures, LLC, a Delaware limited liability company, and Sarif Biomedical, LLC, a Delaware limited liability company, all of which hold patent portfolios or contract rights to the revenue generated from the patent portfolios;

-      In June 2014, we acquired Selene Communication Technologies, LLC, which holds multiple patents in the search and network intrusion field;

-      In August 2014, we acquired patents from Clouding IP LLC, with such patents related to network and data management technology;

-      In September 2014, we acquired TLI Communications, which owns a single patent in the telecommunication field;

-      In October 2014, we acquired three patent portfolios from MedTech Development, LLC, which owns medical technology patents.

 

As of March 31, 2016, the Company’s patent portfolios consist of 320 U.S. and foreign patents, 11 patent applications and contract rights to seven patents. In the aggregate, the earliest date for expiration of a patent in the Company’s patent portfolio is past (the patent is expired, but patent rules allow for six year look-back for royalties), the median expiration date for patents in the Company’s portfolio is June 17, 2017, and the latest expiration date for a patent in any of the Company’s patent portfolios is July 29, 2029.  A summary of the Company’s patent portfolios is as follows:

 

Subsidiary

 

Number of
Patents

 

Earliest
Expiration
Date

 

Median
Expiration
Date

 

Latest
Expiration
Date

 

Subject Matter

Bismarck IP Inc.

 

17 

 

09/15/16

 

09/15/15

 

01/22/18

 

Communication and PBX equipment

Clouding Corp.

 

61 

 

Expired

 

10/05/21

 

03/29/29

 

Network and data management

CRFD Research, Inc.

 

 

09/17/21

 

08/11/22

 

08/19/23

 

Web page content translator

Cyberfone Systems, LLC

 

35 

 

Expired

 

01/31/17

 

06/07/20

 

Telephony and data transactions

Dynamic Advances, LLC

 

 

Expired

 

10/02/17

 

03/06/23

 

Natural language interface

E2E Processing, Inc.

 

 

04/27/20

 

11/17/23

 

07/18/24

 

Manufacturing schedules using adaptive learning

Hybrid Sequence IP, Inc.

 

 

11/14/15

 

09/09/16

 

07/17/17

 

Asynchronous communications

IP Liquidity Ventures, LLC

 

 

Expired

 

04/09/17

 

07/26/20

 

Pharmaceuticals / tire pressure systems

Loopback Technologies, Inc.

 

10 

 

Expired

 

09/25/17

 

08/27/22

 

Automotive

Medtech Group Acquisition Corp.

 

131 

 

Expired

 

06/01/18

 

07/29/29

 

Medical technology

Relay IP, Inc.

 

 

Expired

 

Expired

 

Expired

 

Multicasting

Sampo IP, LLC

 

 

03/13/18

 

03/13/18

 

11/16/23

 

Centrifugal communications

Sarif Biomedical LLC

 

 

Expired

 

Expired

 

Expired

 

Microsurgery equipment

Selene Communication Technologies, LLC

 

 

05/05/18

 

11/23/20

 

11/28/21

 

Communications

Signal IP, Inc.

 

 

03/10/14

 

12/01/15

 

08/06/22

 

Automotive

TLI Communications, LLC

 

 

06/17/17

 

06/17/17

 

06/17/17

 

Telecommunications

Vantage Point Technology, Inc.

 

31 

 

Expired

 

12/21/16

 

03/09/18

 

Computer networking and operations

 

 

 

 

Median

 

09/25/17

 

 

 

 

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY
3 Months Ended
Mar. 31, 2016
STOCKHOLDERS' EQUITY  
STOCKHOLDERS' EQUITY

NOTE 5 - STOCKHOLDERS’ EQUITY

 

On December 7, 2011, the Company increased its authorized capital to 200,000,000 shares of Common Stock from 75,000,000 shares, changed the par value to $0.0001 per share from $.001 per share, and authorized 100,000,000 shares of preferred stock, par value $0.0001 per share.

 

On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split and stock dividend.

 

Series B Convertible Preferred Stock

 

On May 1, 2014, the Company filed with the Secretary of State of Nevada a Certificate of Designations of Series B Convertible Preferred Stock (the “Series B Certificate of Designations”) authorizing 500,000 shares of Series B Convertible Preferred Stock and establishing the designations, preferences, and other rights of the Series B Convertible Preferred Stock. The Series B Certificate of Designations became effective upon filing.

 

On May 2, 2014, the Company issued an aggregate of 782,000 shares of Series B Convertible Preferred Stock valued at $2,807,380 to acquire IP Liquidity Ventures, LLC, Dynamic Advances, LLC and Sarif Biomedical, LLC. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On September 17, 2014, the Company entered into a consulting agreement (the “GRQ Consulting Agreement”) with GRQ Consultants, Inc. (“GRQ”), pursuant to which GRQ shall provide certain consulting services including, but not limited to, advertising, marketing, business development, strategic and business planning, channel partner development and other functions intended to advance the business of the Company.  As consideration, GRQ was entitled to 200,000 shares of the Company’s Series B Convertible Preferred Stock, 50% of which vested upon execution of the GRQ Consulting Agreement, and 50% of which shall vest in six (6) equal monthly installments of commencing on October 17, 2014.  The first tranche of 100,000 shares of Series B Convertible Preferred Stock was issued to GRQ on October 6, 2014. In addition, the GRQ Consulting Agreement allows for GRQ to receive additional shares of Series B Convertible Preferred Stock upon the achievement of certain performance benchmarks. All shares of Series B Convertible Preferred Stock issuable to GRQ shall be pursuant to the 2014 Plan (as defined below) and shall be subject to shareholder approval of the 2014 Plan on or prior to September 16, 2015; the shareholders approved the 2014 Plan on July 31, 2015. The GRQ Consulting Agreement contains an acknowledgement that the conversion of the preferred stock into shares of the Company’s common stock is precluded by the equity blockers set forth in the certificate of designation and in Section 17 of the 2014 Plan to ensure compliance with NASDAQ Listing Rule 5635(d).

 

Common Stock

 

On June 24, 2013, the reverse stock split ratio of one (1) for thirteen (13) basis was approved by the Board of Directors. On July 18, 2013, the Company filed a certificate of amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock, par value $0.0001 per share on a one (1) for thirteen (13) basis. All share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the reverse stock split.

 

On April 22, 2014, the Company issued 300,000 shares of restricted Common Stock to TT IP LLC pursuant to the acquisition of patents on November 13, 2013.

 

On June 2, 2014, the Company issued 48,078 shares of unrestricted Common Stock to an investor in the May 2013 PIPE, pursuant to the exercise of a warrant received in the May 2013 PIPE investment.

 

On June 30, 2014, the Company issued 200,000 shares of restricted Common Stock pursuant to the acquisition of Selene Communications Technologies, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the fair market value on the date of grant at $4.90 per share or $980,000.

 

On July 18, 2014, the Company issues a total of 26,722 shares of Common Stock pursuant to the exercise of stock options held by a former member of the Company’s Board of Directors and the Company’s former Chief Financial Officer.

 

On September 16, 2014, the Company issued to two of its independent board members, in lieu of cash compensation, 6,178 shares of restricted Common Stock.  The shares shall vest quarterly over twelve (12) months commencing on the date of grant.

 

On September 30, 2014, the Company issued 50,000 shares of restricted Common Stock pursuant to the acquisition of the assets of Clouding IP, LLC (see Note 3). In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $5.62 per share or $281,000.

 

For the three months ended September 30, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 84,652 shares of the Company’s Common Stock.

 

On November 19, 2014, the Board of Directors of the Company declared a stock dividend (“Dividend”) pursuant to which holders of the Company’s Common Stock as of the close of business of the record date of December 15, 2014 shall receive one additional share of Common Stock at the close of business on December 22, 2014 for each share of Common Stock held by such holders.  Throughout this report, all share and per share values for all periods presented in the accompanying consolidated financial statements are retroactively restated for the effect of the stock dividend.

 

For the three months ended December 31, 2014, certain holders of warrants exercised their warrants in a cashless, net exercise basis in exchange for 29,230 shares of the Company’s Common Stock.

 

On January 29, 2015, the Company issued 134,409 shares of the Company’s Common Stock to DBD Credit Funding, LLC (“DBD”), an affiliate of Fortress Credit Corp. (“Fortress”), pursuant to the Fortress transaction as set forth in Note 6.

 

On March 13, 2015, the Company settled a dispute with a former consultant whereby the Company issued the consultant 60,000 shares of Common Stock for a full release of all claims.

 

For the three months ended March 31, 2015, certain holders of warrants exercised their warrants to purchase, in cash, 5,000 shares of the Company’s Common Stock.

 

For the three months ended June 30, 2015, certain holders of options exercised their options to purchase, on a net exercise basis, 33,968 (net) shares of the Company’s Common Stock.

 

In a series of transactions, the Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into shares of the Company’s Common Stock, with 183,330 shares of Series B Convertible Preferred Stock converted into Common Stock prior to September 30, 2015.

 

On September 21, 2015, the Company issued 150,000 shares of the Company’s Common Stock to Alex Partners, LLC and Del Mar Consulting Group, Inc., pursuant to a services agreement entered into on September 21, 2015. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $2.23 per share or $334,500. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On October 20, 2015, the remaining 16,666 shares of Series B Convertible Preferred Stock associated with the GRQ Consulting Agreement was converted into 16,666 shares of the Company’s Common Stock.

 

On November 4, 2015, the Company issued 300,000 shares of the Company’s Common Stock to Dominion Harbor Group LLC (“Dominion”), pursuant to a settlement agreement entered into with Dominion on October 30, 2015.  In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.71 per share or $513,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

On December 9, 2015, the Company entered into an agreement with Melechdavid, Inc. (“Melechdavid”), pursuant to which the Company agreed to issue 100,000 shares of the Company’s Common Stock. In connection with this transaction, the Company valued the shares at the quoted market price on the date of grant at $1.61 per share or $161,000. The transaction did not involve any underwriters, underwriting discounts or commissions, or any public offering. The issuance of these securities was deemed to be exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof, as a transaction by an issuer not involving a public offering.

 

Common Stock Warrants

 

On May 1, 2014, the Company issued warrants to purchase 511,790 shares of Common Stock, at a price of $3.75 per share of Common Stock, pursuant to the Private Placement described in detail below. The Company reviewed the issuance of warrants, done in conjunction with the financing closed on May 1, 2014, and determined that pursuant to ASC 480 and ASC 815, the warrants met the requirement to be classified as equity and were booked as Additional Paid-in Capital.

 

In conjunction with the issuance of $5,550,000 in convertible debt on October 16, 2014, the Company issued two-year Warrants to purchase 258,998 shares of the Company’s Common Stock, par value $0.0001 per share pursuant to a securities purchase agreement. The warrants were valued at $164,020 and were recorded as a discount to the fair value of the convertible notes. The Warrants are initially convertible into shares of the Company’s Common Stock at an exercise price of $8.25 per share. The conversion and exercise prices are subject to adjustment in the event of certain events, including stock splits and dividends. The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that there was no beneficial conversion feature and that the conversion feature should not be bifurcated.

 

On January 29, 2015, the Company and certain of its subsidiaries entered into a series of Agreements including a Securities Purchase Agreement (“Fortress Purchase Securities Agreement”) with DBD, an affiliate of Fortress, under which the Company issued a five-year warrant (“Fortress Warrant”) to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment.  The Company reviewed the instruments in the context of ASC 480 and determined that the convertible notes should be recorded as a liability and analyzed the conversion feature and bifurcation pursuant to ASC 815 and ASC 470, respectively, to determine that the was no beneficial conversion feature and that the convertible notes and warrants should not be bifurcated.

 

During the year ended December 31, 2015, warrants to purchase 5,000 shares of Common Stock were exercised and no warrants to purchase shares of Common Stock were forfeited.

 

During the three months ended March 31, 2015, the Company recorded stock based compensation expense of $3,465 in connection with the vested warrants associated with one warrant-based compensatory grant, compared to no compensation expenses for the three months ended March 31, 2016 associated with this warrant. The warrant was valued at the time of grant on January 26, 2012, based on the Black-Scholes model, using the strike and market prices of $3.25 per share, the term of 10 years, volatility of 191% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.96%. At December 31, 2015, there was a total of $0 of unrecognized compensation expense related to future recognition of warrant-based compensation arrangements.

 

A summary of the status of the Company’s outstanding stock warrants at March 31, 2016 is as follows:

 

 

 

Number of
Warrants

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

2,021,308

 

  $

4.27

 

0.87

Granted

 

-    

 

 

-    

 

-    

Cancelled

 

-    

 

-    

 

-    

Forfeited

 

-    

 

-    

 

-    

Exercised

 

-    

 

  $

-    

 

-    

 

 

 

 

 

 

 

 

Balance at March 31, 2016

 

2,021,308

 

4.27

 

0.63

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants exercisable at March 31, 2016

 

2,021,308

 

 

 

 

Weighted average fair value of warrants granted during the period

 

 

 

  $

-    

 

 

 

 

 

 

 

 

 

 

 

Warrant Amendment Letter

 

On April 20, 2014, the Company sent a letter (the “Warrant Amendment Letter”) to all the holders of the warrants which were granted in connection with the sale of units pursuant to a securities purchase agreements which occurred between May 2013 and August 2013. The Warrant Amendment Letter offered to reduce the exercise price of the warrants from $6.50 per share to $5.75 per share, if the holders of the warrants accepted the Company’s offer to exercise the warrants in full for cash by April 22, 2014 (the “Expiration Date”).  The Company subsequently extended the Expiration Date to April 24, 2014. On April 24, 2014, one holder of warrants, who is an accredited investor, accepted the Company’s offer and thereby exercised his warrants, for gross proceeds to the Company of approximately $138,222. After analyzing the circumstances relative to the Warrant Amendment Letter – the extremely short period of time to exercise pursuant to the Amendment Letter, the relatively small change in the exercise price and the limited response to the Amendment Letter – the Company deemed that the change was not a significant modification of the terms of the warrant and did not assess a new fair value and consequently did not make an entry for any adjustment in the value.

 

On March 11, 2016, the Company entered into an agreement with the remaining investor in the Company’s convertible debt issued on October 9, 2014 to revise the strike price of their warrant, which could be exercised for the purchase of 23,334 shares of Common Stock, in exchange for permanent waiver of certain consent rights held by the holder of the convertible debt. As a result of the amendment, the strike price was reduced from $4.125 to the lower of 1) $2.00 per share or 2) the same gross per share price as the Company sells shares of its Common Stock in any future public offering of the Company’s Common Stock.

 

Common Stock Options

 

On April 15, 2014, the Company issued a new board member a five (5) year option to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $3.295 per share, subject to adjustment, which shall vest in twelve (12) monthly installments commencing on the date of grant. The option was valued based on the Black-Scholes model, using the strike and market prices of $3.295 per share, life of three years, volatility of 51% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 0.84%.

 

On May 14, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

 

On May 14, 2014, the Company issued to consultants, five (5) year options to purchase an aggregate of 160,000 shares of the Company’s Common Stock with an exercise price of $4.165 per share, subject to adjustment, which shall vest in three (3) annual installments, with 33% vesting on the first anniversary of the date of grant, 33% on the second anniversary of the date of grant and 34% on the third anniversary of the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 3.5 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.00%.

 

On May 15, 2014, the Company entered into an executive employment agreement with Francis Knuettel II (“Knuettel Agreement”) pursuant to which Mr. Knuettel would serve as the Company’s Chief Financial Officer. As part of the consideration, the Company agreed to grant Mr. Knuettel a ten (10) year stock option to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $4.165 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Knuettel Agreement. The option was valued based on the Black-Scholes model, using the strike and market prices of $4.165 per share, life of 6.5 years, volatility of 63% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.97%.

 

On June 15, 2014, the Company issued to a consultant a five (5) year stock option to purchase an aggregate of 40,000 shares of the Company’s Common Stock with an exercise price of $5.05 per share, subject to adjustment, which shall vest in twenty-four (24) each monthly installments on each monthly anniversary date of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $5.05 per share, life of 3.25 years, volatility of 50% based on the closing price of the 50 trading sessions immediately preceding the grant and a discount rate as published by the Federal Reserve of 1.05%.

 

On August 29, 2014, the Company entered into an executive employment agreement with Daniel Gelbtuch (“Gelbtuch Agreement”) pursuant to which Mr. Gelbtuch would serve as the Company’s Chief Marketing Officer. As part of the consideration, the Company agreed to grant Mr. Gelbtuch ten (10) year stock options to purchase an aggregate of 290,000 shares of Common Stock, with a strike price of $5.62 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Gelbtuch Agreement. Mr. Gelbtuch’s employment with the Company was terminated as of January 20, 2015 and the vested shares at that time remained available for Mr. Gelbtuch to exercise until January 20, 2016.  The option was valued based on the Black-Scholes model, using the strike and market prices of $5.62 per share, life of 6.5 years, volatility of 62% based on the average volatility of comparable companies over the prior 10-year period and a discount rate as published by the Federal Reserve of 1.95%.

 

On September 16, 2014, the Company issued its independent board members five (5) year options to purchase an aggregate of 60,000 shares of the Company’s Common Stock with an exercise price of $7.445 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.445 per share, life of three years, volatility of 49% based on the average volatility of comparable companies over the prior 5-year period and a discount rate as published by the Federal Reserve of 1.04%.

 

On October 31, 2014, the Company entered into an executive employment agreement with Enrique Sanchez (“Sanchez Agreement”) pursuant to which Mr. Sanchez would serve as the Company’s Senior Vice President of Licensing. As part of the consideration, the Company agreed to grant Mr. Sanchez ten (10) year stock options to purchase an aggregate of 160,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Sanchez Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company entered into an executive employment agreement with Umesh Jani (“Jani Agreement”) pursuant to which Mr. Jani would serve as the Company’s Chief Technology Officer and SVP of Licensing. As part of the consideration, the Company agreed to grant Mr. Jani ten (10) year stock options to purchase an aggregate of 100,000 shares of Common Stock, with a strike price of $6.40 per share, vesting in thirty-six (36) equal installments on each monthly anniversary of the date of the Jani Agreement. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company issued existing employees, ten (10) year options to purchase an aggregate of 680,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 5.75 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.78%.

 

On October 31, 2014, the Company issued to a consultant, a five (5) year options to purchase an aggregate of 30,000 shares of the Company’s Common Stock with an exercise price of $6.40 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.40 per share, an expected term of 3.25 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.03%.

 

On February 5, 2015 the Company issued to a consultant, a five (5) year options to purchase an aggregate of 25,000 shares of the Company’s Common Stock with an exercise price of $6.80 per share, subject to adjustment, which shall vest in twenty-four (24) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.80 per share, an expected term of 3.25 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

 

On March 6, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $7.37 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $7.37 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.16%.

 

On March 18, 2015 the Company issued a new board member a five (5) year options to purchase an aggregate of 20,000 shares of the Company’s Common Stock with an exercise price of $6.61 per share, subject to adjustment, which shall vest in twelve (12) equal installments on each monthly anniversary of the grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $6.61 per share, an expected term of 3.00 years, volatility of 41% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 0.92%.

 

On April 7, 2015 (the “Effective Date”), the Company entered into a consulting agreement (the “Consulting Agreement”) with Richard Chernicoff, a member of the Company’s Board of Directors, pursuant to which Mr. Chernicoff shall provide certain services to the Company, including serving as the interim General Counsel and interim General Manager of commercial product commercialization development. Pursuant to the terms of the Consulting Agreement, Mr. Chernicoff shall receive a monthly retainer of $27,000 and a ten-year stock option to purchase 280,000 shares of the Company’s Common Stock pursuant to the Company’s 2014 Plan. The stock options shall have an exercise price of $6.76 per share, the closing price of the Company’s common stock on the date immediately prior to the Board of Directors approval of such stock options and the options shall vest as follows: 25% of the option shall vest on the 12 month anniversary of the Effective Date and thereafter 2.083% on the 21st day of each succeeding calendar month for the following twelve months, provided Mr. Chernicoff continues to provide services (in addition to as a member of the Company’s Board of Directors) at the time of vesting. The option shall be subject in all respects to the terms of the 2014 Plan. Notwithstanding anything herein to the contrary, the remainder of the option shall be subject to the following as an additional condition of vesting: (A) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $8.99 and (B) options to purchase 70,000 shares of the Company’s Common Stock under the option shall not vest at all unless the price of the Company’s common stock while Mr. Chernicoff continues as an officer and/or director reaches $10.14. For valuation purposes, the options were divided into two parts – the time-based vesting component and the performance-based vesting component. The time-based vesting component was valued based on the Black-Scholes model, using the strike and market prices of $6.76 per share, an expected term of 6.25 years, volatility of 53% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.53%. The performance-based vesting component was valued based on the Monte Carlo Simulation model, using the strike and market prices of $6.76 per share, an expected term of 10.0 years, volatility of 61% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.89%.

 

On September 16, 2015, the Company issued its independent board members ten-year options to purchase an aggregate of 80,000 shares of the Company’s Common Stock with an exercise price of $2.03 per share, subject to adjustment, which shall vest monthly over twelve (12) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $2.03 per share, an expected term of 5.5 years, volatility of 47% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.72%.

 

On October 14, 2015, the Company issued certain of its employees ten-year options to purchase an aggregate of 385,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

 

On October 14, 2015, the Company issued certain of its consultants ten (10) year options to purchase an aggregate of 70,000 shares of the Company’s Common Stock with an exercise price of $1.86 per share, subject to adjustment, which shall vest monthly over twenty-four (24) months commencing on the date of grant. The options were valued based on the Black-Scholes model, using the strike and market prices of $1.86 per share, an expected term of 6.5 years, volatility of 49% based on the average volatility of comparable companies over the comparable prior period and a discount rate as published by the Federal Reserve of 1.57%.

 

For the three months ended March 31, 2016 the Company recorded option-based compensation expenses of $550,436. A summary of the stock options as of March 31, 2016 is as follows:

 

 

 

Number of
Options

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

3,383,267 

 

  $

4.25 

 

7.11

Granted

 

-    

 

  $

-    

 

-    

Cancelled

 

-    

 

  $

-    

 

-    

Forfeited

 

44,167 

 

  $

6.45 

 

6.31

Exercised

 

-    

 

  $

-    

 

-    

 

 

 

 

 

 

 

 

Balance at March 31, 2016

 

3,339,100 

 

  $

4.22 

 

6.93

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Exercisable at March 31, 2016

 

2,122,560 

 

 

 

 

Options expected to vest

 

1,216,541 

 

 

 

 

Weighted average fair value of options granted during the period

 

 

 

  $

-    

 

 

 

 

 

 

 

 

 

 

 

Stock options outstanding at March 31, 2016 as disclosed in the above table have approximately $59,150 in intrinsic value at March 31, 2016.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.4.0.3
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES  
COMMITMENTS AND CONTINGENCIES

 

NOTE 6 – COMMITMENTS AND CONTINGENCIES

 

Fortress Transaction

 

On January 29, 2015, the Company and certain of its subsidiaries (each a “Subsidiary”) entered into a series of Agreements including a Fortress Securities Agreement and a Subscription Agreement with DBD, an affiliate of Fortress, under which the Company sold to the purchasers: (i) $15,000,000 original principal amount of Senior Secured Notes (“Fortress Notes”), (ii) a right to receive a portion of certain proceeds from monetization net revenues received by the Company (after receipt by the Company of $15,000,000 of monetization net revenues and repayment of the Fortress Notes),  (the “Revenue Stream”), (iii) a five-year Fortress Warrant to purchase 100,000 shares of the Company’s Common Stock exercisable at $7.44 per share, subject to adjustment; and (iv) 134,409 shares of the Company’s Common Stock.  Under the Fortress Purchase Agreement, the Company has the right to require the purchasers to purchase an additional $5,000,000 of Notes (which will increase proportionately the Revenue Stream), subject to the achievement of certain milestones, and further contemplates that Fortress may, but is not obligated to, fund up to an additional $30,000,000, on equivalent economic terms.   The Company may use the proceeds to finance the monetization of its existing assets, provide further expansion capital for new acquisitions, to repay existing debt (including without limitation, the Company’s 11% convertible notes issued October 9, 2013 and for general working capital and corporate purposes.

 

Pursuant to the Purchase Agreement entered into on January 29, 2015, the Company issued to Fortress a Note in the original principal amount of $15,000,000 (the “Initial Note”). The Initial Note matures on July 29, 2018. If any additional Notes are issued pursuant to the Fortress Securities Purchase Agreement, the maturity date of such additional Fortress Notes shall be 42 months after issuance. The unpaid principal amount of the Initial Note (including any PIK Interest, as defined below) shall bear cash interest at a rate equal to LIBOR plus 9.75% per annum; provided that upon and during the continuance of an Event of Default (as defined in the Fortress Securities Purchase Agreement), the interest rate shall increase by an additional 2% per annum.  As of March 31, 2016, the twelve-month LIBOR USD rate was 1.21040%. Interest on the Initial Note shall be paid on the last business day of each calendar month (the “Interest Payment Date”), commencing January 31, 2015.  Interest shall be paid in cash except that 2.75% per annum of the interest due on each Interest Payment Date shall be paid-in-kind, by increasing the principal amount of the Notes by the amount of such interest, effective as of the applicable Interest Payment Date (“PIK Interest”).  PIK Interest shall be treated as added principal of the Initial Note for all purposes, including interest accrual and the calculation of any prepayment premium.

 

The Fortress Securities Purchase Agreement contains certain customary events of default, and also contains certain covenants including a requirement that the Company maintain minimum liquidity of $1,000,000 in unrestricted cash and cash equivalents and that the Company shall have Monetization Revenues (as defined in the Fortress Purchase Agreement) for each of the four fiscal quarters commencing December 31, 2014 of at least $15,000,000.

 

The terms of the Fortress Warrant provide that until January 29, 2020, the Fortress Warrant may be exercised for cash or on a cashless basis. Exercisability of the Fortress Warrant is limited if, upon exercise, the holder would beneficially own more than 4.99% of the Company’s Common Stock.

 

As part of the transaction, DBD entered into a lock-up agreement (the “Lock-Up Agreement”) pursuant to which the parties and certain related holders agreed until the earlier of 12 months or acceleration of an Event of Default (as defined in the Fortress Securities Purchase Agreement), that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), the Lock-Up Shares (as defined in the Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by such Holder and his/her Related Group (as such terms are defined in the Lock-Up Agreement) on the date of the Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares.  The Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.

 

In connection with the transactions described above, TechDev, Audrey Spangenberg, Erich Spangenberg, and Granicus (the “Spangenberg Holders”) entered into a lock-up agreement (the “Spangenberg Lockup”) with respect to 1,626,924 shares of Common Stock, 48,078 shares of Common Stock underlying warrants, and 782,000 shares of Common Stock underlying preferred stock, pursuant to which the Spangenberg Holders agreed that until payment in full of the Note Obligations (as defined in the Fortress Notes), which shall include but not be limited to all principal and interest on outstanding Notes pursuant to the Purchase Agreement, the Spangenberg Holders and certain related parties agreed that they will not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell, hedge, hypothecate, pledge, sell any option or contract to purchase any option or contract to sell, grant any option, right or warrant to purchase or sell (or announce any offer, sale, offer of sale, contract of sale, hedge, hypothecation, pledge, sale of any option or contract to purchase, purchase of any option or contract of sale, grant of any option, right or warrant to purchase or other sale or disposition), or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person at any time in the future), more than 5% of the Spangenberg Lockup shares (as defined in the Spangenberg Lock-Up Agreement), beneficially owned, within the meaning of Rule 13d-3 under the Exchange Act, by such Holder and his/her Related Group (as such terms are defined in the Spangenberg Lock-Up Agreement) on the date of the Spangenberg Lock-Up Agreement or thereafter acquired or (ii) enter into any swap or other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of more than 5% of the Spangenberg Lock-Up Shares, whether or not any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of any Lock-Up Shares. The Spangenberg Holders may purchase additional shares of the Company’s Common Stock during the Lock-Up Period (as defined in the Spangenberg Lock-Up Agreement) to the extent that such purchase only increases the net holding of the Holders in the Company.

 

Pursuant to the Fortress Securities Purchase Agreement, as security for the payment and performance in full of the Secured Obligations (as defined in the Fortress Securities Purchase Agreement) in favor of DBD, the Company and certain subsidiaries executed and delivered in favor of DBD a Security Agreement (“Security Agreement”) and a Patent Security Agreement (“Patent Security Agreement”), including a pledge of the Company’s interests in certain of its subsidiaries. As further set forth in the Security Agreement, repayment of the Note Obligations is secured by a first priority lien and security interest in all of the assets of the Company, subject to permitted liens on permitted indebtedness that existed as of January 29, 2015. The security interest does not include a lien on the assets held by Orthophoenix, LLC. Certain subsidiaries of the Company (excluding Orthophoenix) also executed guarantees in favor of the purchasers (each, a “Guaranty”), guaranteeing the Note Obligations.  As required by the terms of certain notes issued by the Company in October 2014 (“October Notes”), the October Note holders consented to the transactions described herein.

 

Within thirty days, the Company was required to open a cash collateral account into which all Company revenue shall be deposited and which shall be subject to a control agreement outlining the disbursement in accordance with the terms of the Fortress Securities Purchase Agreement of all proceeds. 

 

Pursuant to the Fortress Securities Purchase Agreement, the Company entered into the Fortress Patent License Agreement with DBD pursuant to which the Company agreed to grant to the Licensee certain rights, including right to license certain patents and patent applications, which licensing rights to be available solely upon an acceleration of the Note Obligations, as provided in the Fortress Securities Purchase Agreement.

 

Office Lease

 

In October 2013, the Company entered into a net-lease for its current office space in Los Angeles, California.  The lease will commence on May 1, 2014 and runs for seven years through April 30, 2021, with monthly lease payment escalating each year of the lease.  In addition, to paying a deposit of $7,564 and the monthly base lease cost, the Company is required to pay pro rata share of operating expenses and real estate taxes.  Under the terms of the lease, the Company will not be required to pay rent for the first five months but must remain in compliance with the terms of the lease to continue to maintain that benefit.  In addition, the Company has a one-time option to terminate the lease in the 42th month of the lease.  Minimum future lease payments under this lease at March 31, 2016, for the next five years and thereafter are as follows:

 

2016 (Nine Months)

 

$

51,669 

 

2017

 

 

71,288 

 

 

2018

 

 

74,540 

 

 

2019

 

 

77,872 

 

 

2020

 

 

81,336 

 

 

Thereafter

 

 

27,504 

 

 

 

 

 

 

 

 

Total

 

$

384,209 

 

 

 

 

 

 

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2016
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

NOTE 7 – SUBSEQUENT EVENTS

 

On April 18, 2016, a wholly-owned subsidiary of the Company entered into a settlement agreement under which the Company agreed to dismiss with prejudice certain pending litigation. Under the terms of the settlement the Company will book revenue on the amount of $24.9 million. A portion of the proceeds of the settlement will be paid to the original patent owner as well as contingent fees to counsel. In connection with the settlement, the parties have agreed to keep the additional terms of the settlement confidential. The Company believes that other voice recognition services also infringe patents involved in the settled action.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

 

The unaudited consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and present the consolidated financial statements of the Company and its wholly-owned subsidiaries. In the preparation of consolidated financial statements of the Company, all intercompany transactions and balances were eliminated. All adjustments (consisting of normal recurring items) necessary to present fairly the Company’s consolidated financial position as of March 31, 2016, and the results of operations and cash flows for the three months ended March 31, 2016 have been included. The results of operations for the three months ended March 31, 2016 are not necessarily indicative of the results to be expected for the full year. Other than where noted, the accounting policies and procedures employed in the preparation of these consolidated financial statements have been derived from the audited consolidated financial statements of the Company for the year ended December 31, 2015, which are contained in Form 10-K as filed with the Securities and Exchange Commission (“SEC”) on March 30, 2016. The consolidated balance sheet as of December 31, 2015 was derived from those financial statements.

Cash

Cash

 

The Company considers all highly liquid debt instruments and other short-term investments with maturity of three months or less, when purchased, to be cash equivalents.  The Company maintains cash and cash equivalent balances at one financial institution that is insured by the Federal Deposit Insurance Corporation. The Company’s accounts held at this institution, up to a limit of $250,000, are insured by the Federal Deposit Insurance Corporation (“FDIC”). As of March 31, 2016, the Company had bank balances exceeding the FDIC insurance limit. To reduce its risk associated with the failure of such financial institution, the Company evaluates at least annually the rating of the financial institution in which it holds deposits.

Use of Estimates and Assumptions

Use of Estimates and Assumptions

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include, but are not limited to, estimating the useful lives of patent assets, the assumptions used to calculate fair value of warrants and options granted, goodwill impairment, realization of long-lived assets, deferred income taxes, unrealized tax positions and business combination accounting.

Accounts Receivable

Accounts Receivable

 

The Company has a policy of reserving for questionable accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to the bad debt expense after all means of collection have been exhausted and the potential for recovery is considered remote.  At March 31, 2016 and December 31, 2015, the Company had recorded an allowance for bad debts in the amounts of $375,750 and $375,750, respectively.  Accounts receivable-net at March 31, 2016 and December 31, 2015, amounted to $153,112 and $136,842, respectively. As of March 31, 2016, accounts receivable related to one license accounted for approximately 41% of the Company’s total accounts receivable, accounts receivable related to recurring royalties represented approximately 42% of total accounts receivable and the remainder of the accounts receivable is primarily related to a trade receivable associated with the terminated Uniloc merger. As of December 31, 2015, accounts receivable related to one license accounted for approximately 54% of the Company’s total accounts receivable and accounts receivable related to recurring royalties represented 46% of total accounts receivable. As of March 31, 2016, accounts receivable represented 7% of revenues for the three months ended March 31, 2016 and as of December 31, 2015, accounts receivable represented 2% of revenues for the three months ended December 31, 2015.

Concentration of Revenue and Geographic Area

Concentration of Revenue and Geographic Area

 

Patent license revenue from enforcement activities originates in either the United States or Germany. Revenue attributable to the United States involves US patents, revenue attributable to Germany is based on the enforcement of German patents and in the event that the Company enters into a worldwide license, the revenue is allocated between the two. The Company commenced enforcement actions in France in 2015, but has not yet had any revenue attributable to this country; the Company has not initiated enforcement actions in any other countries, but is evaluating a number of countries for future action.

 

Revenues from two licenses accounted for approximately 93% of the Company’s operating revenues for the three months ended March 31, 2016 and revenue from the five largest licenses accounting for 87% of the revenue for the three months ended March 31, 2015 as set forth below.

 

For the Three Months Ended March 31, 2016

 

For the Three Months Ended March 31, 2015

Licensor

 

License
Amount

 

% of Revenue

 

Licensor

 

License
Amount

 

% of Revenue

Signal IP, Inc.

 

$

1,900,000 

 

92%

 

Vantage Point Technology, Inc.

 

$

 

2,750,000 

 

67%

Signal IP, Inc.

 

$

15,000 

 

1%

 

Signal IP, Inc.

 

$

 

275,000 

 

7%

 

 

 

 

 

 

Sarif Biomedical, LLC

 

$

 

225,000 

 

6%

 

 

 

 

 

 

TLIF, LLC

 

$

 

220,000 

 

5%

 

 

 

 

 

 

Vantage Point Technology, Inc.

 

$

 

80,000 

 

2%

% of Total Revenues

 

93%

 

% of Total Revenues

87%

 

The remainder of the revenue is attributable to running royalties in the Company’s Medtech portfolio.

 

While the Company has a growing portfolio of patents, the Company has historically received a significant portion of its revenue and expects that a significant portion of its future revenues were and will be based on one-time grants of similar non-recurring, non-exclusive, non-assignable licenses to a relatively small number of entities and their affiliates. Further, with the expected small number of firms with which the Company enters into license agreements, and the amount and timing of such license agreements, the Company also expects that its revenues may be highly variable from one period to the next.

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC Topic 605, “Revenue Recognition”. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) all obligations have been substantially performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

 

The Company considers its licensing and enforcement activities as one unit of accounting under ASC 605-25, “Multiple-Element Arrangements” as the delivered items do not have value to customers on a standalone basis, there are no undelivered elements and there is no general right of return relative to the license. Under ASC 605-25, the appropriate recognition of revenue is determined for the combined deliverables as a single unit of accounting and revenue is recognized upon delivery of the final elements, including the license for past and future use, and the release.

 

Also, due to the fact that the settlement element and license element for past and future use are the major central business, the Company does not present these two elements as different revenue streams in its statement of operations. The Company does not expect to provide licenses that do not provide some form of settlement or release. The Company derived approximately 93% of its revenues for the three months ended March 31, 2016 from the one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain of the Company’s patents, with the balance comprised of recurring royalties.

 

The Company’s subsidiaries entered into two license agreements during the three months ended March 31, 2016.

Cost of Revenue

Cost of Revenue

 

Cost of revenues mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance, royalty fees for acquired patents and other related expenses. Cost of revenues does not include patent amortization expenses, which are included as a separate line item in operating expenses and cost of revenues also does not include expenses related to product development, integration or support, as these are included in general and administrative expenses.

Prepaid Expenses, Bonds Posted and Other Current Assets

Prepaid Expenses, Bonds Posted and Other Current Assets

 

Prepaid expenses and other current assets of $146,336 and $338,598 at March 31, 2016 and December 31, 2015, respectively, consist primarily of costs paid for future services, which will occur within a year. Prepaid expenses include prepayments in cash and equity instruments for public relation services, business advisory, consulting, and prepaid insurance, which are being amortized over the terms of their respective agreements.

 

In addition, the Company had outstanding litigation bonds in the amount of $1,443,457 and $1,748,311 at March 31, 2016 and December 31, 2015, respectively. These bonds were entered into in Germany after the successful ruling by the court in first instance trials related to some of the Company’s patents in German courts. The difference in the balance of the litigation bonds at March 31, 2016 compared to December 31, 2015 is attributable to $55,106 in currency translation impact and the return of $359,960 in bonds related to the litigation against Schrader and TRW, which were resolved in the fourth quarter of 2015.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company adopted FASB ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing US GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying amounts reported in the consolidated balance sheet for cash, accounts receivable, bonds posted with courts, accounts payable, and accrued expenses, approximate their estimated fair market value based on the short-term maturity of these instruments. The carrying value of notes payable and other long-term liabilities approximates fair value as the related interest rates approximate rates currently available to the Company.

 

Clouding IP earn out liability was determined as a Level 3 liability, which requires fair assessment of fair value at each period end by using discounted cash flow as valuation technique using unobservable inputs, such as revenue and expenses forecasts, timing of proceeds, and discount rate. Based on reassessment of fair value as of March 31, 2016, the Company determined that there was no change to the Clouding IP earn out liability or the carrying value of the Clouding IP intangible assets.

 

Under certain circumstances related to litigations in Germany, the Company is either required to or may decide to enter a bond with the courts. As of March 31, 2016 and December 31, 2015, the Company had outstanding bonds in the amount of $1,443,457 and $1,748,311, respectively. The Company adjusted the value as of March 31, 2016 of the bonds to reflect changes to the exchange rate between the Euro and the US Dollar.

Accounting for Acquisitions

Accounting for Acquisitions

 

In the normal course of its business, the Company makes acquisitions of patent assets and may also make acquisitions of businesses.  With respect to each such transaction, the Company evaluates facts of the transaction and follows the guidelines prescribed in accordance with ASC 805 — Business Combinations to determine the proper accounting treatment for each such transaction and then records the transaction in accordance with the conclusions reached in such analysis.  The Company performs such analysis with respect to each material acquisition within the consolidated group of entities.

Income Taxes

Income Taxes

 

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 

The Company follows the provision of the ASC 740-10 related to Accounting for Uncertain Income Tax Position. When tax returns are filed, it is highly certain that some positions taken would be situated upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

 

Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

 

The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For a tax position considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open. The federal and state income tax returns of the Company are subject to examination by the Internal Revenue Service and state taxing authorities, generally for three years after they were filed. The Company is in the process of filing the 2015 tax returns. After review of the 2015 financial statements and the results of operations through March 31, 2016, the Company has recorded a deferred tax asset in the amount of $14,385,393, from which the Company expects to realize benefits in the future, and a deferred tax liability of $964,998.

 

The Company files U.S. and state income tax returns with varying statutes of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal and state tax authorities.

Basic and Diluted Net Earnings (Loss) per Share

Basic and Diluted Net Earnings (Loss) per Share

 

Net earnings (loss) per common share is calculated in accordance with ASC Topic 260: Earnings Per Share (“ASC 260”). Basic earnings (loss) per share is computed by dividing net earnings (loss) by the weighted average number of shares of common stock outstanding during the period. The computation of diluted net earnings (loss) per share does not include dilutive common stock equivalents in the weighted average shares outstanding, as they would be anti-dilutive. The Company has options to purchase 3,339,100 shares of common stock and warrants to purchase 2,021,308 shares of common stock outstanding at March 31, 2016, which were excluded from the computation of diluted shares outstanding, as they would have had an anti-dilutive impact on the Company’s net loss.

 

The following table sets forth the computation of basic and diluted loss per share:

 

 

 

For the Three Months
Ended March 31, 2016

 

For the Three Months
Ended March 31, 2015

 

 

 

 

 

 

 

Net loss

 

(3,893,413)

 

(4,781,571)

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

Weighted Average Common Shares - Basic

 

14,967,141

 

13,868,811 

 

Weighted Average Common Shares - Diluted

 

14,967,141

 

13,868,811 

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

Income (Loss) - Basic

 

$

(0.26)

 

$

(0.34)

 

Income (Loss) - Diluted

 

$

(0.26)

 

$

(0.34)

 

 

Intangible Assets

Intangible Assets

 

Intangible assets include patents purchased and patents acquired in lieu of cash in licensing transactions. The patents purchased are recorded based on the cost to acquire them and patents acquired in lieu of cash are recorded at their fair market value. The costs of these assets are amortized over their remaining useful lives. Useful lives of intangible assets are periodically evaluated for reasonableness and the assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may no longer be recoverable. The Company recorded an impairment charge to its intangible assets during the three months ended March 31, 2016 in the amount of $373,195 associated with the end of life of two of the Company’s portfolios, compared to no impairment charge during the three months ended March 31, 2015.

Goodwill

Goodwill

 

Goodwill is tested for impairment at the reporting unit level at least annually in accordance with ASC 350, and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following:

 

1.

Significant underperformance relative to expected historical or projected future operating results;

2.

Significant changes in the manner of use of the acquired assets or the strategy for the overall business;

3.

Significant negative industry or economic trends; and

4.

Significant reduction or exhaustion of the potential licenses of the patents which gave rise to the goodwill.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model. When conducting its annual goodwill impairment assessment, the Company initially performs a qualitative evaluation of whether it is more likely than not that goodwill is impaired. If it is determined by a qualitative evaluation that it is more likely than not that goodwill is impaired, the Company then applies a two-step impairment test. The two-step impairment test first compares the fair value of the Company’s reporting unit to its carrying or book value. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired and the Company is not required to perform further testing. If the carrying value of the reporting unit exceeds its fair value, the Company determines the implied fair value of the reporting unit’s goodwill and if the carrying value of the reporting unit’s goodwill exceeds its implied fair value, then an impairment loss equal to the difference is recorded in the consolidated statement of operations. The Company performs the annual testing for impairment of goodwill at the reporting unit level during the quarter ended September 30.

 

For the three months ended March 31, 2016 and March 31, 2015, the Company recorded no impairment charge to its goodwill.

Other Intangible Assets

Other Intangible Assets

 

In accordance with ASC 350-30-65, “Intangibles - Goodwill and Others”, the Company assesses the impairment of identifiable intangibles whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors the Company considers to be important which could trigger an impairment review include the following: (1) significant underperformance relative to expected historical or projected future operating results; (2) significant changes in the manner of use of the acquired assets or the strategy for the overall business; and (3) significant negative industry or economic trends.

 

When the Company determines that the carrying value of intangibles may not be recoverable based upon the existence of one or more of the above indicators of impairment and the carrying value of the asset cannot be recovered from projected undiscounted cash flows, the Company records an impairment charge. The Company measures any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in the current business model.

Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

The Company accounts for the impairment or disposal of long-lived assets according to the ASC 360 “Property, Plant and Equipment”.  The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of long-lived assets may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated future net undiscounted cash flows expected to be generated by the asset. When necessary, impaired assets are written down to estimated fair value based on the best information available. Estimated fair value is generally based on either appraised value or measured by discounting estimated future cash flows. Considerable management judgment is necessary to estimate discounted future cash flows. Accordingly, actual results could vary significantly from such estimates. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset.

Stock-based Compensation

Stock-based Compensation

 

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

 

Pursuant to ASC Topic 505-50, for share-based payments to consultants and other third-parties, compensation expense is determined at the “measurement date.” The expense is recognized over the vesting period of the award. Until the measurement date is reached, the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value of the award at the reporting date. As stock-based compensation expense is recognized based on awards expected to vest, forfeitures are also estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the three months ended March 31, 2016, the expected forfeiture rate was 11.0%, which resulted in an expense of $14,785 recognized in the Company’s compensation expenses. The Company will continue to re-assess the impact of forfeitures if actual forfeitures increase in future quarters.

 

Reclassification

Reclassification

 

Certain amounts in the financial statements of prior year have been reclassified to conform to the fiscal 2016 presentation, with no effect on net earnings.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2017 and we are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. ASU 2016-02 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Accordingly, the standard is effective for us on September 1, 2019 using a modified retrospective approach. We are currently evaluating the impact that the standard will have on our consolidated financial statements.

 

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes.  This update requires an entity to classify deferred tax liabilities and assets as noncurrent within a classified statement of financial position.  ASU 2015-17 is effective for annual and interim reporting periods beginning after December 15, 2016.  This update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented.  Early application is permitted as of the beginning of the interim or annual reporting period.  The Company adopted this standard for the annual period ending December 31, 2015.  The effect of adopting the new guidance on the balance sheet was not significant.

 

In September 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, or ASU 2015-16. This amendment requires the acquirer in a business combination to recognize in the reporting period in which adjustment amounts are determined, any adjustments to provisional amounts that are identified during the measurement period, calculated as if the accounting had been completed at the acquisition date. Prior to the issuance of ASU 2015-16, an acquirer was required to restate prior period financial statements as of the acquisition date for adjustments to provisional amounts.  The new standard for an annual reporting period beginning after December 15, 2017 with an earlier effective application is permitted only as of annual reporting periods beginning after December 15, 2016.  The new guidance is not expected to have significant impact on the Company’s consolidated financial statements.

 

In April 2015, the FASB issued ASU 2015-05, Intangibles-Goodwill and Other — Internal-Use Software; Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. Prior to this ASU, U.S. GAAP did not include explicit guidance about a customer’s accounting for fees paid in a cloud computing arrangement. Examples of cloud computing arrangements include software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements. This ASU provides guidance to customers about whether a cloud computing arrangement includes a software license, in which case the customer should account for such license consistent with the acquisitions of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The ASU does not change the accounting for service contracts. The new standard is effective for us on January 1, 2016 with early adoption permitted. We do not expect the adoption of ASU 2015-05 to have a significant impact on our consolidated financial statements.

 

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs (ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs), effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years and should be applied retrospectively to all periods presented. Early adoption of the new guidance is permitted for financial statements that have not been previously issued. The new guidance will require that debt issuance costs be presented in the balance sheet as a direct deduction from the related debt liability rather than as an asset, consistent with debt discounts.  The Company adopted ASU 2015-03 and as such, the debt issuance costs for Fortress note was presented in the balance sheet as direct deduction from the related debt liability.

 

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern. This standard update provides guidance around management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance is not expected to have a significant impact on the Company’s consolidated financial statements.

 

In May 2014, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers, or ASU 2014-09, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The standard will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective and shall take effective on January 1, 2017. The standard permits the use of either the retrospective or cumulative effect transition method and the early application of the standard is not permitted. The Company is presently evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures and has not yet selected a transition method.

 

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of Concentration of Revenue and Geographic Area

 

For the Three Months Ended March 31, 2016

 

For the Three Months Ended March 31, 2015

Licensor

 

License
Amount

 

% of Revenue

 

Licensor

 

License
Amount

 

% of Revenue

Signal IP, Inc.

 

$

1,900,000 

 

92%

 

Vantage Point Technology, Inc.

 

$

 

2,750,000 

 

67%

Signal IP, Inc.

 

$

15,000 

 

1%

 

Signal IP, Inc.

 

$

 

275,000 

 

7%

 

 

 

 

 

 

Sarif Biomedical, LLC

 

$

 

225,000 

 

6%

 

 

 

 

 

 

TLIF, LLC

 

$

 

220,000 

 

5%

 

 

 

 

 

 

Vantage Point Technology, Inc.

 

$

 

80,000 

 

2%

% of Total Revenues

 

93%

 

% of Total Revenues

87%

 

Schedule of computation of basic and diluted loss per share

 

 

 

For the Three Months
Ended March 31, 2016

 

For the Three Months
Ended March 31, 2015

 

 

 

 

 

 

 

Net loss

 

(3,893,413)

 

(4,781,571)

 

 

 

 

 

 

 

Denominator

 

 

 

 

 

Weighted Average Common Shares - Basic

 

14,967,141

 

13,868,811 

 

Weighted Average Common Shares - Diluted

 

14,967,141

 

13,868,811 

 

 

 

 

 

 

 

Earnings (Loss) per common share:

 

 

 

 

 

Income (Loss) - Basic

 

$

(0.26)

 

$

(0.34)

 

Income (Loss) - Diluted

 

$

(0.26)

 

$

(0.34)

 

 

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS (Tables)
3 Months Ended
Mar. 31, 2016
Selene Communication Technologies  
Net purchase price paid, assets and liabilities

 

Intangible assets

 

$

990,000 

 

Net working capital

 

37,000 

 

Goodwill

 

3,000 

 

 

 

 

 

Net purchase price

 

$

1,030,000 

 

 

 

 

 

 

 

Clouding Corp  
Net purchase price paid, assets and liabilities

 

Intangible assets

 

$

14,500,000 

 

Goodwill

 

1,296,000 

 

 

 

 

 

Net purchase price

 

$

15,796,000 

 

 

 

 

 

 

 

Total consideration paid of the following:

 

Cash

 

$

1,400,000 

 

Promissory Note

 

1,000,000 

 

Common Stock

 

281,000 

 

Earn Out Liability

 

13,115,000 

 

 

 

 

 

Net purchase price

 

$

15,796,000 

 

 

 

 

 

 

 

TLI Communications LLC  
Net purchase price paid, assets and liabilities

 

Intangible assets

 

$

940,000 

 

Goodwill

 

228,000 

 

 

 

 

 

Net purchase price

 

$

1,168,000 

 

 

 

 

 

 

 

Medtech Entities  
Net purchase price paid, assets and liabilities

 

Intangible assets

 

$

12,800,000 

 

Goodwill

 

2,700,000 

 

 

 

 

 

Net purchase price

 

$

15,500,000 

 

 

 

 

 

 

 

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS (Tables)
3 Months Ended
Mar. 31, 2016
INTANGIBLE ASSETS  
Schedule of Intangible Assets

 

 

 

March 31, 2016

 

December 31, 2015

 

 

 

 

 

 

 

Intangible Assets

 

  $

39,631,501

 

  $

41,014,992

 

Accumulated Amortization & Impairment

 

(16,423,203)

 

(15,557,353)

 

 

 

 

 

 

 

 

Intangible assets, net

 

  $

23,208,298

 

  $

25,457,639

 

 

 

 

 

 

 

 

 

 

Schedule of Amortization Expense

 

2016

 

  $

5,440,463

 

2017

 

5,251,025

 

2018

 

3,691,108

 

2019

 

2,846,570

 

2020

 

2,121,609

 

2021 and thereafter

 

3,857,523

 

 

 

 

 

Total

 

  $

23,208,298

 

 

 

 

 

 

 

Summary of the Company's patent portfolios

 

Subsidiary

 

Number of
Patents

 

Earliest
Expiration
Date

 

Median
Expiration
Date

 

Latest
Expiration
Date

 

Subject Matter

Bismarck IP Inc.

 

17 

 

09/15/16

 

09/15/15

 

01/22/18

 

Communication and PBX equipment

Clouding Corp.

 

61 

 

Expired

 

10/05/21

 

03/29/29

 

Network and data management

CRFD Research, Inc.

 

 

09/17/21

 

08/11/22

 

08/19/23

 

Web page content translator

Cyberfone Systems, LLC

 

35 

 

Expired

 

01/31/17

 

06/07/20

 

Telephony and data transactions

Dynamic Advances, LLC

 

 

Expired

 

10/02/17

 

03/06/23

 

Natural language interface

E2E Processing, Inc.

 

 

04/27/20

 

11/17/23

 

07/18/24

 

Manufacturing schedules using adaptive learning

Hybrid Sequence IP, Inc.

 

 

11/14/15

 

09/09/16

 

07/17/17

 

Asynchronous communications

IP Liquidity Ventures, LLC

 

 

Expired

 

04/09/17

 

07/26/20

 

Pharmaceuticals / tire pressure systems

Loopback Technologies, Inc.

 

10 

 

Expired

 

09/25/17

 

08/27/22

 

Automotive

Medtech Group Acquisition Corp.

 

131 

 

Expired

 

06/01/18

 

07/29/29

 

Medical technology

Relay IP, Inc.

 

 

Expired

 

Expired

 

Expired

 

Multicasting

Sampo IP, LLC

 

 

03/13/18

 

03/13/18

 

11/16/23

 

Centrifugal communications

Sarif Biomedical LLC

 

 

Expired

 

Expired

 

Expired

 

Microsurgery equipment

Selene Communication Technologies, LLC

 

 

05/05/18

 

11/23/20

 

11/28/21

 

Communications

Signal IP, Inc.

 

 

03/10/14

 

12/01/15

 

08/06/22

 

Automotive

TLI Communications, LLC

 

 

06/17/17

 

06/17/17

 

06/17/17

 

Telecommunications

Vantage Point Technology, Inc.

 

31 

 

Expired

 

12/21/16

 

03/09/18

 

Computer networking and operations

 

 

 

 

Median

 

09/25/17

 

 

 

 

 

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY (Tables)
3 Months Ended
Mar. 31, 2016
STOCKHOLDERS' EQUITY  
Status of outstanding stock warrants

 

 

 

Number of
Warrants

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

2,021,308

 

  $

4.27

 

0.87

Granted

 

-    

 

 

-    

 

-    

Cancelled

 

-    

 

-    

 

-    

Forfeited

 

-    

 

-    

 

-    

Exercised

 

-    

 

  $

-    

 

-    

 

 

 

 

 

 

 

 

Balance at March 31, 2016

 

2,021,308

 

4.27

 

0.63

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Warrants exercisable at March 31, 2016

 

2,021,308

 

 

 

 

Weighted average fair value of warrants granted during the period

 

 

 

  $

-    

 

 

 

 

 

 

 

 

 

 

 

Summary of stock options

 

 

 

Number of
Options

 

Weighted
Average Exercise
Price

 

Weighted
Average
Remaining Life

Balance at December 31, 2015

 

3,383,267 

 

  $

4.25 

 

7.11

Granted

 

-    

 

  $

-    

 

-    

Cancelled

 

-    

 

  $

-    

 

-    

Forfeited

 

44,167 

 

  $

6.45 

 

6.31

Exercised

 

-    

 

  $

-    

 

-    

 

 

 

 

 

 

 

 

Balance at March 31, 2016

 

3,339,100 

 

  $

4.22 

 

6.93

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Exercisable at March 31, 2016

 

2,122,560 

 

 

 

 

Options expected to vest

 

1,216,541 

 

 

 

 

Weighted average fair value of options granted during the period

 

 

 

  $

-    

 

 

 

 

 

 

 

 

 

 

 

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.4.0.3
COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended
Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES  
Schedule of leases

 

2016 (Nine Months)

 

$

51,669 

 

2017

 

 

71,288 

 

 

2018

 

 

74,540 

 

 

2019

 

 

77,872 

 

 

2020

 

 

81,336 

 

 

Thereafter

 

 

27,504 

 

 

 

 

 

 

 

 

Total

 

$

384,209 

 

 

 

 

 

 

 

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.4.0.3
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) - $ / shares
Jun. 24, 2013
May. 31, 2013
Oct. 01, 2012
Mar. 31, 2016
Dec. 31, 2015
Nov. 19, 2014
Jul. 18, 2013
Aug. 01, 2012
Dec. 07, 2011
Dec. 06, 2011
Common stock, shares authorized       200,000,000 200,000,000       200,000,000 75,000,000
Common stock, par value       $ 0.0001 $ 0.0001   $ 0.0001   $ 0.0001 $ 0.001
Preferred stock, shares authorized                 100,000,000  
Preferred stock, par value                 $ 0.0001  
Shares reserved for issuance under plan               10,000,000    
Reverse stock split ratio (as a percent) one (1) for thirteen (13)   3-for-2              
Reverse stock split time to effectuate     1 year              
Stock dividend ( in shares)           1        
Common Stock                    
Reverse stock split ratio (as a percent) one (1) for thirteen (13)                  
Minimum                    
Reverse stock split ratio (as a percent)   one-for-five                
Maximum                    
Reverse stock split ratio (as a percent)   one-for-fifteen                
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Accounts Receivable, Concentration of Revenue and Geographic Area (Details)
3 Months Ended
Mar. 31, 2016
USD ($)
agreement
Mar. 31, 2015
USD ($)
agreement
Dec. 31, 2015
USD ($)
agreement
Cash      
Insured by FDIC $ 250,000    
Accounts Receivable      
Allowance for bad debts 375,750   $ 375,750
Net accounts receivable $ 153,112   $ 136,842
Concentration of Revenue and Geographic Area      
Revenues from five licenses (as a percent) 93.00% 87.00%  
Percent of revenue 93.00% 87.00%  
Credit concentration risk      
Concentration of Revenue and Geographic Area      
Number of licenses | agreement 1   1
Customer concentration risk      
Concentration of Revenue and Geographic Area      
Number of licenses | agreement 2 5  
Signal IP, Inc      
Concentration of Revenue and Geographic Area      
License Amount $ 1,900,000 $ 275,000  
Percent of revenue 92.00% 7.00%  
Signal IP, Inc      
Concentration of Revenue and Geographic Area      
License Amount $ 15,000    
Percent of revenue 1.00%    
TLIF, LLC      
Concentration of Revenue and Geographic Area      
License Amount   $ 220,000  
Percent of revenue   5.00%  
Vantage Point Technology, Inc      
Concentration of Revenue and Geographic Area      
License Amount   $ 2,750,000  
Percent of revenue   67.00%  
Vantage Point Technology, Inc      
Concentration of Revenue and Geographic Area      
License Amount   $ 80,000  
Percent of revenue   2.00%  
Sarif Biomedical LLC [Member]      
Concentration of Revenue and Geographic Area      
License Amount   $ 225,000  
Percent of revenue   6.00%  
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Net Loss per Share (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Computation of basic and diluted loss per share    
Net loss $ (3,893,413) $ (4,781,571)
Denominator    
Weighted Average Common Shares - Basic (shares) 14,967,141 13,868,811
Weighted Average Common Shares -Diluted (shares) 14,967,141 13,868,811
Earnings (Loss) per common share:    
Earnings (Loss) - Basic (per share) $ (0.26) $ (0.34)
Earnings (Loss) - Diluted (per share) $ (0.26) $ (0.34)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 31, 2016
USD ($)
agreement
shares
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Collection of revenue as Accounts receivable related to two licenses 41.00%   54.00%
Collection of accounts receivable related to recurring royalties 42.00%    
Percent of total A/R associated with outstanding recurring royalties     46.00%
Concentration risk (as a percent) 93.00% 87.00%  
Percent of revenue from one-time issuance of non-recurring, non-exclusive, non-assignable licenses for certain patents 93.00%    
Number of new license agreements | agreement 2    
Prepaid expenses and other current assets $ 146,336   $ 338,598
Estimated Litigation Liability 1,443,457   1,748,311
Currency translation impact 55,106    
Bonds returned in litigation 359,960    
Bonds posted with courts $ 1,443,457   $ 1,748,311
Tax benefit 50.00%    
Deferred tax assets $ 14,385,393    
Deferred Tax Liabilities, Gross $ 964,998    
Option to purchase common stock | shares 3,339,100    
Warrants to purchase shares of common stock | shares 2,021,308    
Asset Impairment Charges $ 373,195 $ 0  
Goodwill, Impairment Loss $ 0 $ 0  
Expected Forfeiture Rate 11.00%    
Compensation expenses $ 14,785    
Accounts receivable | Credit concentration risk      
Concentration risk (as a percent) 7.00%   2.00%
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS - CyberFone Systems, LLC (Details)
3 Months Ended
Mar. 31, 2016
USD ($)
patent
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
ACQUISITIONS      
Number of patents (in patents) | patent 320    
Goodwill $ 4,605,733   $ 4,482,845
Goodwill impairment $ 0 $ 0  
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical (Details)
3 Months Ended
Apr. 01, 2015
USD ($)
May. 02, 2014
USD ($)
payment
shares
May. 02, 2013
USD ($)
payment
Mar. 31, 2016
USD ($)
Sep. 30, 2014
USD ($)
Sep. 19, 2014
Acquisitions Member            
Purchase Agreements   3        
TLI Communications LLC            
Ownership interest held (as a percent)           100.00%
Dynamic Advances            
Ownership interest held (as a percent)     100.00%      
Cash payments made (in payments) | payment     2      
Consideration paid     $ 2,375,000 $ 6,653,078    
Second payment amount after June 30, 2014     $2,850,000      
Maximum possible amount of future payments   $ 250,000,000        
Promissory note issued   2,375,000        
Promissory note amount upon late payment   $ 2,850,000        
Payment agreement to extend maturity date       $ 249,375    
Note term       30 days    
Dynamic Advances | Series B Convertible Preferred Stock            
Preferred stock, shares issued | shares   195,500        
IP Liquidity            
Ownership interest held (as a percent)   100.00%        
Cash payments made (in payments) | payment   2        
Consideration paid $ 2,850,000 $ 2,375,000        
Second payment amount after June 30, 2014       $2,850,000    
Maximum possible amount of future payments   250,000,000        
Promissory note issued   2,375,000        
Promissory note amount upon late payment   $ 2,850,000        
Payment agreement to extend maturity date         $ 249,375  
Note term         30 days  
Consideration paid, including capitalized costs       $ 6,653,078    
IP Liquidity | Series B Convertible Preferred Stock            
Preferred stock, shares issued | shares   195,500        
Sarif            
Ownership interest held (as a percent)   100.00%        
Cash payments made (in payments) | payment   2        
Consideration paid   $ 250,000   $ 552,024    
Second payment amount after June 30, 2014   $300,000        
Maximum possible amount of future payments   $ 250,000,000        
Promissory note issued   250,000        
Promissory note amount upon late payment   $ 300,000        
Payment agreement to extend maturity date         $ 26,250  
Note term         30 days  
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical 2 (Details) - Acquisitions Member
Nov. 02, 2014
May. 02, 2014
USD ($)
Pay Proceeds Agreement Member | Maximum    
Recovery amount   $ 250,000,000
Registration Rights Agreement Member | Maximum    
Registration statements required to be filed (in statements) 3  
Filing period 60 days  
$10,000,000 or less | Pay Proceeds Agreement Member | Maximum    
Recovery amount   $ 10,000,000
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member    
Net recovery proceeds due to sellers (as a percent)   40.00%
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member | Minimum    
Recovery amount   $ 10,000,000
$10,000,000 to $40,000,000 | Pay Proceeds Agreement Member | Maximum    
Recovery amount   $ 40,000,000
Over $40,000,000 | Pay Proceeds Agreement Member    
Net recovery proceeds due to sellers (as a percent)   50.00%
Over $40,000,000 | Pay Proceeds Agreement Member | Minimum    
Recovery amount   $ 40,000,000
Series B Convertible Preferred Stock | Registration Rights Agreement Member | Minimum    
Percentage of registrable shares covered in resale registration statement (as a percent) 10.00%  
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
ACQUISITIONS (Details)
1 Months Ended 3 Months Ended
Oct. 13, 2014
USD ($)
Sep. 30, 2014
USD ($)
$ / shares
Sep. 19, 2014
USD ($)
shares
Aug. 29, 2014
USD ($)
$ / shares
shares
Jun. 17, 2014
USD ($)
patent
$ / shares
shares
Sep. 30, 2014
USD ($)
$ / shares
Mar. 31, 2016
USD ($)
patent
Mar. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Aug. 31, 2014
USD ($)
Number of patents (in patents) | patent             320      
Goodwill impairment             $ 0 $ 0    
Goodwill             4,605,733   $ 4,482,845  
Earnout liability, short-term             103,049   33,646  
Earnout liability, long-term             $ 3,213,177   $ 3,281,238  
Selene Communication Technologies                    
Number of patents (in patents) | patent         3          
Common stock issued (in shares) | shares         100,000          
Consideration paid         $ 50,000          
Fair value on grant date (in dollars per share) | $ / shares         $ 9.80          
Common stock issued in acquisition         $ 980,000          
Intangible assets         990,000          
Net working capital         37,000          
Goodwill         3,000          
Net purchase price         $ 1,030,000          
Clouding Corp                    
Intangible assets                   $ 14,500,000
Goodwill                   1,296,000
Net purchase price                   $ 15,796,000
Cash       $ 1,400,000            
Promissory Note       1,000,000            
Common Stock       281,000            
Earn Out Liability       13,115,000            
Net purchase price       15,796,000            
TLI Communications LLC                    
Ownership interest held (as a percent)     100.00%              
Intangible assets     $ 940,000              
Goodwill     228,000              
Net purchase price     $ 1,168,000              
Medtech Entities                    
Ownership interest held (as a percent) 100.00%                  
Consideration paid $ 1,000,000                  
Promissory note issued 9,000,000                  
Intangible assets 12,800,000                  
Goodwill 2,700,000                  
Net purchase price 15,500,000                  
Patent purchase agreement | Clouding Corp                    
Consideration paid       1,400,000            
Promissory note issued       $ 1,000,000            
Restricted common stock issued (in shares) | shares       25,000            
Net recovery proceeds due to sellers (as a percent)       50.00%            
Fair value of restricted common stock       $ 281,000            
Net revenues       $ 4,000,000            
Interests Sale Agreement Member | Clouding Corp                    
Fair value on grant date (in dollars per share) | $ / shares       $ 11.24            
Common stock issued in acquisition       $ 281,000            
Earn out liability booked   $ 2,148,000                
Interests Sale Agreement Member | TLI Communications LLC                    
Common stock issued (in shares) | shares     60,000              
Consideration paid     $ 350,000              
Net recovery proceeds due to sellers (as a percent)     50.00%              
Fair value on grant date (in dollars per share) | $ / shares   $ 13.63       $ 13.63        
Common stock issued in acquisition           $ 818,000        
Interests Sale Agreement Member | Medtech Entities                    
Outstanding amount after renegotiation 6,250,000                  
Debt reduction available upon early repayment $ 750,000                  
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Intangible Assets $ 39,631,501   $ 41,014,992
Accumulated Amortization & Impairment (16,423,203)   (15,557,353)
Intangible assets, net 23,208,298   $ 25,457,639
Patent Impairment $ 373,195 $ 0  
Patents | Minimum      
Weighted average useful life, intangibles 1 year    
Patents | Maximum      
Weighted average useful life, intangibles 15 years    
Website      
Weighted average useful life, intangibles 3 years    
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS - Future amortization of current intangible assets (Details) - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Future amortization of intangible assets, net    
2016 $ 5,440,463  
2017 5,251,025  
2018 3,691,108  
2019 2,846,570  
2020 2,121,609  
2021 and thereafter 3,857,523  
Total 23,208,298  
Amortization expense $ 2,025,899 $ 2,598,461
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS - Intangible Asset Acquisitions (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2013
USD ($)
Nov. 30, 2013
USD ($)
shares
Sep. 30, 2013
USD ($)
Jun. 30, 2013
USD ($)
Apr. 30, 2013
USD ($)
Mar. 31, 2016
patent
Sep. 30, 2015
Number of patents | patent           320  
Relay IP              
Date of patent transaction         Apr. 01, 2013    
Patent acquired, value         $ 350,000    
Delphi Technologies, Inc              
Date of patent transaction Dec. 01, 2013            
Patent acquired, value $ 1,700,000            
CyberFone              
Date of patent transaction         Apr. 01, 2013   Apr. 01, 2013
Patent acquired, value         $ 1,135,512    
Fourteen US Patents              
Date of patent transaction     Sep. 01, 2013        
Patent acquired, value     $ 1,100,000        
Four Patents              
Date of patent transaction   Nov. 01, 2013          
Patent acquired, value   $ 718,500          
Shares issued for patent acquisition | shares   150,000          
Siemens Technology              
Date of patent transaction       Jun. 01, 2013      
Patent acquired, value       $ 1,000,000      
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.4.0.3
INTANGIBLE ASSETS - Patent portfolios (Details)
3 Months Ended
Mar. 31, 2016
item
patent
Number of patents | patent 320
Communication and PBX equipment  
Number of patents 17
Earliest Expiration Date 09/15/16
Median Expiration Date 09/15/15
Latest Expiration Date 01/22/18
Network and data management  
Number of patents 61
Earliest Expiration Date Expired
Median Expiration Date 10/05/21
Latest Expiration Date 03/29/29
Web page content translator and device-to-device transfer system [Member]  
Number of patents 5
Earliest Expiration Date 09/17/21
Median Expiration Date 08/11/22
Latest Expiration Date 08/19/23
Telephony and data transactions [Member]  
Number of patents 35
Earliest Expiration Date Expired
Median Expiration Date 01/31/17
Latest Expiration Date 06/07/20
Natural language interface [Member]  
Number of patents 4
Earliest Expiration Date Expired
Median Expiration Date 10/02/17
Latest Expiration Date 03/06/23
Manufacturing schedules using adaptive learning [Member]  
Number of patents 4
Earliest Expiration Date 04/27/20
Median Expiration Date 11/17/23
Latest Expiration Date 07/18/24
Asynchronous communications [Member]  
Number of patents 2
Earliest Expiration Date 11/14/15
Median Expiration Date 09/09/16
Latest Expiration Date 07/17/17
Pharmaceuticals / tire pressure systems [Member]  
Number of patents 3
Earliest Expiration Date Expired
Median Expiration Date 04/09/17
Latest Expiration Date 07/26/20
Automotive [Member]  
Number of patents 10
Earliest Expiration Date Expired
Median Expiration Date 09/25/17
Latest Expiration Date 08/27/22
Medical technology [Member]  
Number of patents 131
Earliest Expiration Date Expired
Median Expiration Date 06/01/18
Latest Expiration Date 07/29/29
Multicasting [Member]  
Number of patents 1
Earliest Expiration Date Expired
Median Expiration Date Expired
Latest Expiration Date Expired
Centrifugal communications [Member]  
Number of patents 3
Earliest Expiration Date 03/13/18
Median Expiration Date 03/13/18
Latest Expiration Date 11/16/23
Microsurgery equipment [Member]  
Number of patents 4
Earliest Expiration Date Expired
Median Expiration Date Expired
Latest Expiration Date Expired
Communications [Member]  
Number of patents 3
Earliest Expiration Date 05/05/18
Median Expiration Date 11/23/20
Latest Expiration Date 11/28/21
Automotive [Member]  
Number of patents 7
Earliest Expiration Date 03/10/14
Median Expiration Date 12/01/15
Latest Expiration Date 08/06/22
Telecommunications [Member]  
Number of patents 6
Earliest Expiration Date 06/17/17
Median Expiration Date 06/17/17
Latest Expiration Date 06/17/17
Computer networking and operations [Member]  
Number of patents 31
Earliest Expiration Date Expired
Median Expiration Date 12/21/16
Latest Expiration Date 03/09/18
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY Common Stock Warrants (Details) - Common Stock Warrant - $ / shares
3 Months Ended 12 Months Ended
Mar. 11, 2016
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Number of Warrants        
Granted 23,334      
Exercised       5,000
Forfeited       0
Warrants, ending balance   2,021,308 2,021,308  
Warrants Exercisable   2,021,308    
Weighted Average Exercise Price        
Weighted Average Exercise Price, Warrants Outstanding, Ending Balance   $ 4.27 $ 4.27  
Weighted Average Remaining Life        
Weighted Average Remaining Life, beginning     10 months 13 days  
Weighted Average Remaining Life, ending   7 months 17 days    
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY (Details 1) - $ / shares
3 Months Ended 12 Months Ended
Sep. 16, 2015
Mar. 31, 2016
Dec. 31, 2015
Number of Options      
Granted 80,000    
Common Stock Option      
Number of Options      
Options outstanding, beginning   3,383,267  
Forfeited   44,167  
Options outstanding, ending   3,339,100 3,383,267
Options Exercisable   2,122,560  
Options expected to vest   1,216,541  
Weighted Average Exercise Price      
Weighted average exercise price, beginning balance   $ 4.25  
Forfeited   6.45  
Weighted average exercise price, ending balance   $ 4.22 $ 4.25
Weighted Average Remaining Life      
Weighted Average Remaining Life, beginning     7 years 1 month 10 days
Forfeited   6 years 3 months 22 days  
Weighted Average Remaining Life, ending   6 years 11 months 5 days  
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY (Details Narrative)
1 Months Ended 3 Months Ended
Dec. 09, 2015
USD ($)
$ / shares
shares
Nov. 04, 2015
USD ($)
$ / shares
shares
Oct. 20, 2015
shares
Sep. 21, 2015
USD ($)
$ / shares
shares
Mar. 13, 2015
shares
Jan. 29, 2015
$ / shares
shares
Oct. 16, 2014
USD ($)
$ / shares
shares
Oct. 06, 2014
shares
Sep. 30, 2014
USD ($)
$ / shares
shares
Sep. 16, 2014
shares
Jul. 18, 2014
shares
Jun. 30, 2014
USD ($)
$ / shares
shares
Jun. 02, 2014
shares
May. 02, 2014
USD ($)
shares
May. 01, 2014
$ / shares
shares
Apr. 24, 2014
USD ($)
Apr. 22, 2014
shares
Jun. 24, 2013
Oct. 01, 2012
Sep. 30, 2015
shares
Mar. 31, 2016
USD ($)
$ / shares
shares
Jun. 30, 2015
shares
Mar. 31, 2015
USD ($)
shares
Dec. 31, 2014
shares
Sep. 30, 2014
$ / shares
shares
Dec. 31, 2015
USD ($)
$ / shares
shares
Sep. 17, 2015
payment
Apr. 07, 2015
period
Sep. 17, 2014
shares
Apr. 20, 2014
$ / shares
Apr. 19, 2014
$ / shares
Jul. 18, 2013
$ / shares
Dec. 07, 2011
$ / shares
shares
Dec. 06, 2011
$ / shares
shares
Common stock, shares authorized                                         200,000,000         200,000,000             200,000,000 75,000,000
Common stock, par value | $ / shares                                         $ 0.0001         $ 0.0001           $ 0.0001 $ 0.0001 $ 0.001
Authorized shares of preferred stock                                                                 100,000,000  
Issuance of Convertible Debt | $             $ 5,550,000                               $ 19,600,000                      
Preferred stock, par value | $ / shares                                                                 $ 0.0001  
Reverse stock split ratio (as a percent)                                   one (1) for thirteen (13) 3-for-2                              
Proceeds from Stock Options Exercised | $                                             $ 18,750                      
Number of monthly installments | period                                                       12            
Stock compensation expense | $                                         $ 550,436                          
Common Stock                                                                    
Reverse stock split ratio (as a percent)                                   one (1) for thirteen (13)                                
Stock issued for warrants exercised (in shares)                                             5,000                      
Exercise stock options (in shares)                     26,722                     33,968   29,230 84,652                  
Common stock issued (in shares)         60,000 134,409             48,078                                          
Common Stock Warrant                                                                    
Granted                             511,790                                      
Stock compensation expense | $                                         $ 0                          
Warrants                                                                    
Value, preferred shares and warrants issued | $             $ 164,020                                                      
Warrant price | $ / shares                                                           $ 5.75 $ 6.50      
Proceeds from Stock Options Exercised | $                               $ 138,222                                    
Granted           100,000 258,998                                                      
Stock compensation expense | $                                             $ 3,465                      
Unrecognized compensation expense, warrants | $                                                   $ 0                
Warrant Exercise Price | $ / shares           $ 7.44 $ 8.25               $ 3.75                                      
Restricted Stock [Member]                                                                    
Restricted shares issued (in shares)                 50,000 6,178   200,000         300,000                                  
Shares issued, value per share | $ / shares                 $ 5.62     $ 4.90                         $ 5.62                  
Fair value of restricted issuance | $                 $ 281,000     $ 980,000                                            
Alex Partners, LLC and Del Mar Consulting Group, Inc | Common Stock                                                                    
Value of stock issued for services | $       $ 334,500                                                            
Shares issued, value per share | $ / shares       $ 2.23                                                            
Common stock issued (in shares)       150,000                                                            
Dominion Harbor Group LLC | Common Stock                                                                    
Value of stock issued for services | $   $ 513,000                                                                
Shares issued, value per share | $ / shares   $ 1.71                                                                
Common stock issued (in shares)   300,000                                                                
Melechdavid, Inc | Common Stock                                                                    
Value of stock issued for services | $ $ 161,000                                                                  
Shares issued, value per share | $ / shares $ 1.61                                                                  
Common stock issued (in shares) 100,000                                                                  
Series B preferred stock                                                                    
Authorized shares of preferred stock                             500,000           50,000,000         50,000,000                
Preferred shares issued                           782,000                                        
Value, preferred shares and warrants issued | $                           $ 2,807,380                                        
Preferred stock, par value | $ / shares                                         $ 0.0001         $ 0.0001                
Series B preferred stock | GRQ                                                                    
Preferred shares agreement     16,666                                                              
Preferred Stock converted to Common Stock     16,666                                                              
Series B preferred stock | GRQ                                                                    
Preferred shares agreement                                                         200,000          
Percent vested upon execution of the GRQ Consulting Agreement                                                         50.00%          
Percent vested after execution                                                         50.00%          
Number of monthly installments | payment                                                     (6)              
Restricted shares issued (in shares)               100,000                                                    
Preferred Stock converted to Common Stock                                       183,330                            
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY - Warrants (Details Narrative)
3 Months Ended 12 Months Ended
Mar. 11, 2016
$ / shares
shares
Mar. 10, 2016
$ / shares
Jan. 20, 2015
Oct. 31, 2014
Jan. 26, 2012
item
$ / shares
Mar. 31, 2016
USD ($)
shares
Dec. 31, 2015
shares
Mar. 31, 2015
shares
Stock compensation expense | $           $ 550,436    
Expected term     6 years 6 months 5 years 9 months        
Common Stock Warrant                
Warrants to purchase shares of common stock 23,334              
Warrants exercised             5,000  
Stock compensation expense | $           $ 0    
Strike price | $ / shares $ 2.00 $ 4.125     $ 3.25      
Expected term         10 years      
Volatility         191.00%      
Number of trading sessions | item         50      
Discount rate         1.96%      
Class of Warrant or Right, Outstanding           2,021,308   2,021,308
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
STOCKHOLDERS' EQUITY - Options (Details Narrative)
3 Months Ended
Oct. 14, 2015
installment
$ / shares
shares
Sep. 16, 2015
period
$ / shares
shares
Apr. 07, 2015
USD ($)
period
$ / shares
shares
Mar. 18, 2015
period
$ / shares
shares
Mar. 06, 2015
period
$ / shares
shares
Feb. 05, 2015
period
$ / shares
shares
Jan. 20, 2015
Oct. 31, 2014
period
$ / shares
shares
Sep. 16, 2014
period
$ / shares
shares
Aug. 29, 2014
period
$ / shares
shares
Jun. 15, 2014
period
item
$ / shares
shares
May. 15, 2014
period
$ / shares
shares
May. 14, 2014
period
item
$ / shares
shares
Apr. 15, 2014
period
$ / shares
shares
Mar. 31, 2016
USD ($)
Granted | shares   80,000                          
Number of monthly installments | period     12                        
Expected term             6 years 6 months 5 years 9 months              
Stock compensation expense | $                             $ 550,436
Stock Option                              
Granted | shares     280,000 20,000 20,000 25,000   160,000 60,000 290,000 40,000     20,000  
Option term   10 years 10 years 5 years 5 years 5 years   10 years 5 years 10 years 5 years     5 years  
Option price   $ 2.03 $ 6.76 $ 6.61 $ 7.37 $ 6.80   $ 6.40 $ 7.445 $ 5.62 $ 5.05     $ 3.295  
Percent vested upon execution of the GRQ Consulting Agreement     25.00%                        
Percent vested after execution     2.083%                        
Number of monthly installments | period   12   12 12 24     12   24     12  
Number of annual installments | period               36   36          
Expected term   5 years 6 months   3 years 3 years 3 years 3 months     3 years   3 years 3 months     3 years  
Volatility   47.00%   41.00% 41.00% 47.00% 62.00% 53.00% 49.00%   50.00%     51.00%  
Number of trading sessions | item                     50        
Discount rate   1.72%   0.92% 1.16% 0.92% 1.95% 1.78% 1.04%   1.05%     0.84%  
Monthly retainer | $     $ 27,000                        
Stock Option | Existing Employees                              
Granted | shares 385,000                       80,000    
Option term 10 years                       10 years    
Option price $ 1.86                       $ 4.165    
Number of monthly installments | installment 24                            
Number of annual installments | period                         3    
Expected term 6 years 6 months                       6 years 6 months    
Volatility 49.00%                       63.00%    
Number of trading sessions | item                         50    
Discount rate 1.57%                       1.97%    
Stock Option | Consultants                              
Granted | shares 70,000                            
Option term 10 years                            
Option price $ 1.86                            
Number of monthly installments | installment 24                            
Expected term 6 years 6 months                            
Volatility 49.00%                            
Discount rate 1.57%                            
Stock Option 2                              
Granted | shares               100,000              
Option term               10 years              
Option price               $ 6.40              
Number of annual installments | period               36         3    
Expected term               5 years 9 months              
Volatility               53.00%              
Discount rate               1.78%              
Stock Option 2 | Consultants                              
Granted | shares                         160,000    
Option term                         5 years    
Option price                         $ 4.165    
Expected term                         3 years 6 months    
Volatility                         50.00%    
Number of trading sessions | item                         50    
Discount rate                         1.00%    
Stock Option 3                              
Granted | shares               680,000       290,000      
Option term               10 years       10 years      
Option price               $ 6.40       $ 4.165      
Number of monthly installments | period               24              
Number of annual installments | period                       36      
Expected term               5 years 9 months       6 years 6 months      
Volatility               53.00%       63.00%      
Discount rate               1.78%       1.97%      
Stock Option 4                              
Granted | shares               30,000              
Option term               5 years              
Option price               $ 6.40              
Number of monthly installments | period               24              
Expected term               3 years 3 months              
Volatility               49.00%              
Discount rate               1.03%              
Time Based Shares                              
Granted | shares     70,000                        
Option price     $ 6.76                        
Expected term     6 years 3 months                        
Volatility     53.00%                        
Discount rate     1.53%                        
Time Based Shares | Minimum                              
Option price     $ 8.99                        
Performance Shares                              
Granted | shares     70,000                        
Option price     $ 6.76                        
Expected term     10 years                        
Volatility     61.00%                        
Discount rate     1.89%                        
Performance Shares | Minimum                              
Option price     $ 10.14                        
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.4.0.3
COMMITMENTS AND CONTINGENCIES (Details)
12 Months Ended
Mar. 13, 2015
shares
Jan. 31, 2015
Jan. 29, 2015
USD ($)
$ / shares
shares
Jun. 02, 2014
shares
Dec. 31, 2014
USD ($)
period
Mar. 31, 2016
Apr. 20, 2014
$ / shares
Apr. 19, 2014
$ / shares
Oct. 09, 2013
Common Stock                  
Common stock issued (in shares) | shares 60,000   134,409 48,078          
Warrants                  
Exercise price (in dollars per share) | $ / shares             $ 5.75 $ 6.50  
Fortress                  
Warrant term     5 years            
Warrant to purchase (in shares) | shares     100,000            
Exercise price (in dollars per share) | $ / shares     $ 7.44            
Common stock issued (in shares) | shares     134,409            
Additional amount     $ 5,000,000            
Minimum liquidity requirement     $ 1,000,000            
Number of fiscal quarters (in quarters) | period         4        
Fortress | Warrants                  
Percentage of ownership on common stock upon exercise of warrants     4.99%            
Spangenberg Lockup Agreement | Common Stock                  
Common stock issued (in shares) | shares     1,626,924            
Spangenberg Lockup Agreement | Warrants                  
Common stock issued (in shares) | shares     48,078            
Spangenberg Lockup Agreement | Preferred Stock                  
Common stock issued (in shares) | shares     782,000            
Minimum | Fortress                  
Monetization net revenues         $ 15,000,000        
Minimum | Spangenberg Lockup Agreement                  
Percentage of Lock-up Shares     5.00%            
Senior Secured Notes | Fortress                  
Original principal amount     $ 15,000,000            
Monetization net revenues     15,000,000            
Senior Secured Notes | Fortress | Additional Obligation Upon Milestone Achievement                  
Original principal amount     30,000,000            
Initial Note | Fortress                  
Original principal amount     $ 15,000,000            
Note term     42 months            
Interest rate paid-in-kind (as a percent)   2.75%              
Initial Note | LIBOR | Fortress                  
Interest rate     LIBOR            
Spread (as a percent)     9.75%            
Increase in interest rate (as a percent)     2.00%            
Initial Note | 12-months LIBOR | Fortress                  
Effective rate (as a percent)           1.2104%      
Convertible notes.                  
Effective rate (as a percent)                 11.00%
DBD | Fortress                  
Lock-up agreement period     12 months            
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.4.0.3
COMMITMENTS AND CONTINGENCIES (Details 2) - USD ($)
May. 01, 2014
Mar. 31, 2016
COMMITMENTS AND CONTINGENCIES    
Lease term 7 years  
Security deposit $ 7,564  
Rent payment grace period 5 months  
Lease termination option available 42th month of the lease  
Minimum future lease payments, net of rent abatement    
2016 (Nine Months)   $ 51,669
2017   71,288
2018   74,540
2019   77,872
2020   81,336
Thereafter   27,504
Total   $ 384,209
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.4.0.3
SUBSEQUENT EVENTS (Details)
$ in Millions
Apr. 18, 2016
USD ($)
Settlement agreement | Subsequent Event  
SUBSEQUENT EVENTS  
Settlement amount $ 24.9
EXCEL 51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 231 297 1 false 87 0 false 10 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://marathonpg.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://marathonpg.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://marathonpg.com/role/StatementConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://marathonpg.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncome CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://marathonpg.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 10101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://marathonpg.com/role/DisclosureOrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 6 false false R7.htm 10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 10301 - Disclosure - ACQUISITIONS Sheet http://marathonpg.com/role/DisclosureAcquisitions ACQUISITIONS Notes 8 false false R9.htm 10401 - Disclosure - INTANGIBLE ASSETS Sheet http://marathonpg.com/role/DisclosureIntangibleAssets INTANGIBLE ASSETS Notes 9 false false R10.htm 10501 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://marathonpg.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 10 false false R11.htm 10601 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://marathonpg.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 10701 - Disclosure - SUBSEQUENT EVENTS Sheet http://marathonpg.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 12 false false R13.htm 20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 13 false false R14.htm 30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPolicies 14 false false R15.htm 30303 - Disclosure - ACQUISITIONS (Tables) Sheet http://marathonpg.com/role/DisclosureAcquisitionsTables ACQUISITIONS (Tables) Tables http://marathonpg.com/role/DisclosureAcquisitions 15 false false R16.htm 30403 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsTables INTANGIBLE ASSETS (Tables) Tables http://marathonpg.com/role/DisclosureIntangibleAssets 16 false false R17.htm 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://marathonpg.com/role/DisclosureStockholdersEquity 17 false false R18.htm 30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://marathonpg.com/role/DisclosureCommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://marathonpg.com/role/DisclosureCommitmentsAndContingencies 18 false false R19.htm 40101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Sheet http://marathonpg.com/role/DisclosureOrganizationAndDescriptionOfBusinessDetails ORGANIZATION AND DESCRIPTION OF BUSINESS (Details) Details http://marathonpg.com/role/DisclosureOrganizationAndDescriptionOfBusiness 19 false false R20.htm 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Accounts Receivable, Concentration of Revenue and Geographic Area (Details) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashAccountsReceivableConcentrationOfRevenueAndGeographicAreaDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, Accounts Receivable, Concentration of Revenue and Geographic Area (Details) Details 20 false false R21.htm 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Net Loss per Share (Details) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasicAndDilutedNetLossPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Net Loss per Share (Details) Details 21 false false R22.htm 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://marathonpg.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 40301 - Disclosure - ACQUISITIONS - CyberFone Systems, LLC (Details) Sheet http://marathonpg.com/role/DisclosureAcquisitionsCyberfoneSystemsLlcDetails ACQUISITIONS - CyberFone Systems, LLC (Details) Details 23 false false R24.htm 40302 - Disclosure - ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical (Details) Sheet http://marathonpg.com/role/DisclosureAcquisitionsDynamicAdvancesIpLiquidityAndSarifBiomedicalDetails ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical (Details) Details 24 false false R25.htm 40303 - Disclosure - ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical 2 (Details) Sheet http://marathonpg.com/role/DisclosureAcquisitionsDynamicAdvancesIpLiquidityAndSarifBiomedical2Details ACQUISITIONS - Dynamic Advances, IP Liquidity and Sarif Biomedical 2 (Details) Details 25 false false R26.htm 40304 - Disclosure - ACQUISITIONS (Details) Sheet http://marathonpg.com/role/DisclosureAcquisitionsDetails ACQUISITIONS (Details) Details http://marathonpg.com/role/DisclosureAcquisitionsTables 26 false false R27.htm 40401 - Disclosure - INTANGIBLE ASSETS (Details) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsDetails INTANGIBLE ASSETS (Details) Details http://marathonpg.com/role/DisclosureIntangibleAssetsTables 27 false false R28.htm 40402 - Disclosure - INTANGIBLE ASSETS - Future amortization of current intangible assets (Details) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsFutureAmortizationOfCurrentIntangibleAssetsDetails INTANGIBLE ASSETS - Future amortization of current intangible assets (Details) Details 28 false false R29.htm 40403 - Disclosure - INTANGIBLE ASSETS - Intangible Asset Acquisitions (Details) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsIntangibleAssetAcquisitionsDetails INTANGIBLE ASSETS - Intangible Asset Acquisitions (Details) Details 29 false false R30.htm 40404 - Disclosure - INTANGIBLE ASSETS - Patent portfolios (Details) Sheet http://marathonpg.com/role/DisclosureIntangibleAssetsPatentPortfoliosDetails INTANGIBLE ASSETS - Patent portfolios (Details) Details 30 false false R31.htm 40501 - Disclosure - STOCKHOLDERS' EQUITY Common Stock Warrants (Details) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails STOCKHOLDERS' EQUITY Common Stock Warrants (Details) Details 31 false false R32.htm 40502 - Disclosure - STOCKHOLDERS' EQUITY (Details 1) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityDetails1 STOCKHOLDERS' EQUITY (Details 1) Details http://marathonpg.com/role/DisclosureStockholdersEquityTables 32 false false R33.htm 40503 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://marathonpg.com/role/DisclosureStockholdersEquityTables 33 false false R34.htm 40504 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details Narrative) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityWarrantsDetailsNarrative STOCKHOLDERS' EQUITY - Warrants (Details Narrative) Details 34 false false R35.htm 40505 - Disclosure - STOCKHOLDERS' EQUITY - Options (Details Narrative) Sheet http://marathonpg.com/role/DisclosureStockholdersEquityOptionsDetailsNarrative STOCKHOLDERS' EQUITY - Options (Details Narrative) Details 35 false false R36.htm 40601 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://marathonpg.com/role/DisclosureCommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://marathonpg.com/role/DisclosureCommitmentsAndContingenciesTables 36 false false R37.htm 40602 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details 2) Sheet http://marathonpg.com/role/DisclosureCommitmentsAndContingenciesDetails2 COMMITMENTS AND CONTINGENCIES (Details 2) Details http://marathonpg.com/role/DisclosureCommitmentsAndContingenciesTables 37 false false R38.htm 40701 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://marathonpg.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://marathonpg.com/role/DisclosureSubsequentEvents 38 false false All Reports Book All Reports mara-20160331.xml mara-20160331.xsd mara-20160331_cal.xml mara-20160331_def.xml mara-20160331_lab.xml mara-20160331_pre.xml true true ZIP 57 0001104659-16-120481-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-16-120481-xbrl.zip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end